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1. Introduction
Morphological	 characterization	 of	 the	 skin	 plays	 an	 important	 role	 in	 clinical	
dermatology	 for	 diagnosis	 and	 monitoring	 of	 treatment	 effects.	 In	 recent	 years,	
noninvasive imaging tools have been developed that reveal morphological features 
of	 the	 skin	 not	 visible	 to	 the	 naked	 eye,	which	 therefore	may	 improve	 diagnostic	
accuracy.	 Among	 novel	 noninvasive	 skin	 imaging	 tools	 (e.g.	 optical	 coherent	
tomography, high frequency ultrasound) in vivo	 reflectance	 confocal	 microscopy	
(RCM)	stands	out	because	of	the	high,	near-histological	resolution1-3. At the start of 
this thesis, there was increasing evidence for the applicability of RCM to improve 
diagnosis	of	melanocytic	skin	 lesions3-8.	Compared	to	melanocytic	skin	 lesions,	there	
was less known about the value of RCM in two other major problems in dermatology; 
nonmelanoma	 skin	 cancer	 (NMSC)	 and	 inflammatory	 skin	 diseases2,9-20. For this 
reason, these two topics will be addressed in this thesis, in which psoriasis will be 
studied	as	an	example	of	an	inflammatory	skin	disease.	
2. Psoriasis
2.1 Epidemiology
Psoriasis	 is	 a	 common	 and	 chronic	 inflammatory	 skin	 disease.	 The	 prevalence	 of	
psoriasis	 in	 Europe	 varies	 between	 0.7%	 and	 2.9%,	 with	 a	 predilection	 for	 the	
Caucasian	population21-23.	Psoriasis	can	appear	at	any	time	during	life.	However,	there	
is	a	peak	prevalence	 in	young	adults	that	gradually	 increases	among	patients	aged	 
30	to	69	years.	There	is	no	gender	predisposition24.
2.2 Clinical features
Psoriasis is a clinical heterogeneous disease with several phenotypes22. The most 
common phenotype is psoriasis vulgaris, also known as plaque psoriasis. This phenotype 
accounts	 for	 90%	 of	 all	 psoriatic	 lesions	 and	 is	 characterised	 by	 well	 delineated	
 erythematosquamous plaques (Figure 1). Lesions are usually distributed symmetrically, 
with	 a	 predilection	 for	 the	 elbows,	 knees,	 lumbosacral	 region,	 umbilicus	 and	 scalp.	
Psoriasis	may	have	a	variable	course	presenting	as	chronic,	stable	plaques	or	more	
acutely, with a rapid progression of lesions and widespread involvement25. Other 
phenotypes	of	psoriasis	 include	 guttate	psoriasis,	 flexural	 psoriasis,	 scalp	 psoriasis,	
erythroderma	and	pustular	psoriasis.	Guttate	psoriasis	is	an	acute	form	of	psoriasis,	
with	papules	distributed	over	the	whole	body.	This	phenotype	often	occurs	after	a	
streptococcal	infection	of	the	upper	respiratory	tract.	Flexural	psoriasis	is	characterized	
by sharply demarcated erythematous plaques without scaling, typically located in 
intertriginous areas including the groins and axillae26. In scalp psoriasis the clinical 
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features vary from discrete lesions to total scalp involvement with either thick plaques 
or scaly, non thickened areas22.	In	erythroderma	the	whole	body	surface	is	affected	with	
psoriasis,	 potentially	 leading	 to	 hypothermia,	 hypoalbuminaemia	 and	 high	 output	
cardiac failure. Pustular psoriasis can be either localized (palmoplantar pustulosis on 
palms and soles or pustules on distal parts of hand and feet) or present as generalized 
pustular psoriasis26,27.	Nail	changes	(e.g.	pitting,	distal	onycholysis)	and	psoriatic	arthritis	
occur	 in	 about	 85%	 and	 30%	 of	 psoriatic	 patients,	 respectively28-30. Furthermore, 
psoriasis	 is	 associated	with	multiple	 comorbidities,	 including	metabolic	 syndrome	
and cardio- vascular disease31,32.
2.3 Histopathology
Psoriasis	has	a	distinct	histological	representation.	It	is	characterized	by	parakeratosis	
(nuclei retainment of corneocytes), absence or diminished granular layer, acanthosis 
(epidermal	 thickening	 due	 to	 epidermal	 hyperproliferation),	 thinning	 of	 the	
suprapapillary plate (epidermal thickness between the stratum corneum and top of 
the	dermal	papillae)	and	elongation	of	the	dermal	papillae	(Figure	1).	The	presence	of	
micropustules	of	Kogoj	 (trafficking	of	 inflammatory	cells	 through	the	epidermis)	or	
microabcesses	 of	 Munro	 (accumulations	 of	 inflammatory	 cells	 at	 the	 stratum	
corneum)	are	highly	specific	for	psoriasis,	though	not	present	in	every	psoriatic	lesion.	
In	 the	papillary	and	reticular	dermis	 tortuous,	dilated	capillaries	and	 inflammatory	
cells can be found26,33,34.	 The	 inflammatory	 infiltrate	 mainly	 consists	 of	 T	 cells,	
neutrophils,	dendritic	cells	and	macrophages23,35.
2.4 Pathogenesis
Psoriasis	is	a	multifactorial	disease,	resulting	from	an	interplay	of	genetic	susceptibility,	
environmental	 factors,	 abnormal	 function	 of	 keratinocytes	 and	 immunological	
dysregulation23. Population	studies	reporting	that	the	incidence	of	psoriasis	 is	higher	
among	first-degree	and	 second-degree	 relatives	of	psoriatic	patients	 compared	 to	
the	general	population	support	the	view	for	a	genetic	component23,26. Genome-wide 
association	studies	have	identified	nine	chromosomal	loci	(PSORS1	through	PSORS9)	
which	 can	be	 linked	 to	psoriasis.	 The	major	 genetic	determinant	 is	 PSORS1,	which	
probably accounts for 35 to 50% of the hereditary of psoriasis22,23,36. In recent years 
several	 other	 genome-wide	 association	 studies	 have	 identified	 genes	 related	 to	 
the	adaptive	immunity,	innate	immunity	and	skin	barrier	function37-39. Most	genetic	
data	 support	 an	 immune-based	 pathogenesis.	 The	 association	 of	 psoriasis	 with	
copynumber	 variation	 in	 the	β-defensin	 cluster	 and	deletions	 in	 the	 late	 cornified	
envelope genes point toward a role for the epidermis23,37,38. Various environmental 
factors	can	trigger	psoriasis,	including	infections,	medication	and	trauma	to	the	skin	
(Koebner phenomenon)40.	A	schematic	overview	of	the	evolution	of	a	psoriatic	lesion	
is depicted in Figure 123,41.	An	initial	trigger	induces	activation	of	myeloid	dendritic	cells	
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through	the	production	of	cytokines	(tumor	necrosis	factor	α	(TNF-α),	interferon-α,	
interleukin	 (IL)-1β,	 and	 IL-6)	 by	 innate	 immune	 cells.	When	 activated,	 the	myeloid	
dendritic	cells	migrate	into	draining	lymph	nodes.	The	migrated	dendritic	cells	present	
antigens	to	naïve	T	cells	and	release	IL-12	and	IL-23	inducing	differentiation	of	naïve	
T-cells	into	effector	cells	such	as	type	1	helper	T	cells	(Th1)	and	type	17	helper	T	cells	
(Th17). T cells subsequently secrete mediators (IL-17A, IL-17F, IL-22) leading to the 
activation	and	proliferation	of	keratinocytes.	Activated	keratinocytes	in	turn	produce	
proinflammatory	 cytokines,	 chemokines	 and	 antimicrobial	 peptides,	 creating	 a	
feedback	 loop.	 The	 hyperproliferation	 of	 the	 keratinocytes	 induces	 the	 clinical	
features	 of	 scaling	 and	 induration,	 while	 the	 chemokines	 and	 cytokines	 lead	 to	
inflammation	of	the	skin23.
Figure 1. Pathogenesis of psoriasis (a)*, clinical picture of psoriasis vulgaris with sharply 
dermarcated erythematosquamous plaque on the right lower leg (b) and corresponding 
hematoxylin-eosin stained histology (c).
*adapted	from:	Nestle	FO23
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2.5 Treatment
Psoriasis is a skin disease that is not curable at present. However, there are a number 
of	treatment	options	available	to	reduce	or	clear	the	symptoms.	 In	mild	disease	the	
most commonly applied therapy is topical treatment. The mainstay of topical therapy 
are	 topical	 corticosteroids40,42,43. These are either used as monotherapy or in 
combination	with	other	topical	therapies	including	vitamin	D3	analogues,	calcineurin	
inhibitors, dithranol or coal tar40.	 Topical	 corticosteroids	 exhibit	 anti-inflammatory,	
	vasoconstrictive	and	antimitotic	effects43.	Vitamin	D3	analogues	 inhibit	keratinocyte	
proliferation	and	promote	normal	keratinocyte	differentiation40,42. Calcineurin inhibitors 
reduce	 calcium-dependent	 signal	 transduction	 in	 T	 cells	 and	 decrease	 synthesis	 of	
cytokines	and	inflammation43.	Coal	tar	and	dithranol	both	have	antiproliferative	and	
immunomodulatory	effects44. 
When	topical	therapy	is	not	sufficiently	effective,	phototherapy	can	be	added	to	the	
treatment regimen. Various ultraviolet (UV) B and UVA wavelengths are used for the 
treatment of psoriasis; phototherapy with broadband UVB (280-320 nm), narrowband 
UVB (emission peak at 311 nm) and UVA (320-400 nm). Photochemotherapy (PUVA) 
is	the	combined	use	of	photosensitizing	psoralens	and	UVA	radiation.	Psoralens	are	
either applied systemically (oral PUVA) or locally (topical bath and cream PUVA)45,46. 
Phototherapy results in UV-induced immunosuppression, which may play a major 
role	 in	 the	antipsoriatic	effect45,47.	The	carcinogenic	effect	of	oral	PUVA	therapy	to	
induce squamous cell carcinoma (SCC) and to a lesser extend basal cell carcinoma 
(BCC)	is	well	established.	Furthermore,	oral	PUVA	may	induce	melanoma	after	long	
term	treatment.	In	contrast	to	oral	PUVA,	the	potential	carcinogenic	effect	of	topical	
PUVA and UVB phototherapy is controversial48-52. 
In more severe psoriasis systemic treatment is frequently required. The systemic 
treatments	most	commonly	used	for	psoriasis	are	methotrexate,	ciclosporin,	acitretin	and	
fumarates. Methotrexate inhibits the enzyme dihydrofolate reductase and diminishes 
nucleic	acid	synthesis	resulting	in	antiproliferative	and	immunomodulatory	effects40,42,45. 
Ciclosporin	decreases	the	number	of	T	cells	in	the	skin	leading	to	diminished	production	of	
cytokines40,53.	Acitretin	is	a	synthetic	retinoid	closely	related	to	vitamin	A.	Retinoids	have	
antiproliferative	and	immunomodulatory	properties,	though	the	exact	mechanism	of	
action	is	not	clearly	understood40,45.	Fumarates	inhibit	maturation	of	dendritic	cells	and	
induce	apoptosis,	particularly	 in	activated	T	cells42,45. Biologicals are the latest available 
medicinal	drugs	to	treat	moderate	to	severe	psoriasis.	This	class	of	pharmaceuticals	are	
large molecules produced by living organisms54,55.	Biologicals	interfere	in	the	pathogenetic	
cascade	of	psoriasis	by	blocking	the	effects	of	cytokines	TNF-α,	IL-17A	or	IL-12	and	IL-2323,40. 
The biological treatments currently available in the Netherlands are etanercept, 
infliximab,	adalimumab,	ustekinumab	and	secukinumab42,56.
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3. Nonmelanoma skin cancer 
3.1 Epidemiology
Skin	 cancer	 is	 the	most	 common	 type	of	 cancer	 in	 the	Caucasian	population.	 Skin	
malignancies can be divided in two major groups that encompasses melanoma and 
NMSC,	which	represent	about	10%	and	90%	of	skin	cancer,	respectively57,58. Incidence 
of skin cancer increases rapidly. In NMSC alone, there is a rise of 3% to 8% each year 
worldwide59-62.	The	term	nonmelanoma	skin	cancer	is	predominantly	used	to	define	
BCC and SCC59.	Actinic	keratosis	 (AK)	and	Morbus	Bowen	are	premalignant	 lesions	
which are able to progress into invasive SCC58.	In	2002	it	is	described	that	the	lifetime	
risk to develop BCC is around 30% and to develop SCC around 9%60. The major risk 
factor	for	development	of	BCC	and	SCC	is	exposure	to	ultraviolet	radiation,	though	
the	 relation	 between	 sun	 exposure	 and	 BCC	 is	 controversial59.	 Cumulative	 sun	
exposure	has	a	strong	association	with	SCC,	whereas	 in	BCC	intermittent	sun	exposure	 
and exposure during childhood might be more important59. There is an increased risk 
for NMSC in fair skinned, blue-eyed individuals and in those with clinical signs of 
actinic	damage	(e.g.	solar	lentigines,	actinic	keratosis)59. The use of immunosuppression, 
exposure	to	carcinogens	(e.g.	psoralens,	arsenic,	ionizing	radiation),	the	presence	of	
chronic	 ulcers	 or	 burn	 scars,	 infection	 with	 human	 pappillomavirus	 or	 genetic	
syndromes (e.g. albinism) increase the risk for developing SCC60. In a minority of 
cases, SCC might be life threatening and accounts for 25% to 35% of skin cancer 
related mortality. On the contrary, BCC rarely causes mortality (<0,1%) because BCC 
has	 a	 very	 low	 potential	 to	 metastasize.	 However,	 there	 might	 be	 considerable	
functional	and	cosmetical	morbidity	due	to	localized	tissue	invasion59,61,62.
3.2 Clinical features
Basal	 cell	 carcinoma	 consist	 of	 several	 histopathological	 subtypes	 (superficial,	 nodular,	
micronodular,	infiltrating)	with	each	subtype	having	distinct	clinical	features	(Figure	2)63. 
A	combination	of	multiple	 subtypes	 in	one	 tumor	 is	 frequently	 seen63. Nodular BCC is 
the most common subtype of all BCCs. These lesions consist of papules or nodules with 
a	pearly	shine	and	small	arborizing	telangiectasias.	Sometimes	lesions	ulcerate.	Nodular	
and micronodular BCCs are predominately located on the head, especially the cheeks, 
nasolabial	 folds,	 forehead	 and	 eyelids.	 Superficial	 BCC	 is	 the	 second	 most	 common	 
subtype. A lesion typically appears as a well circumscribed, scaly, pink-to-red macula, 
patch,	thin	papule,	or	thin	plaque.	It	may	demonstrate	a	thin	rolled	border	consisting	of	
small	 papules.	 Superficial	 BCCs	 favor	 the	 trunk	 and	 extremities.	 Infiltrative	BCC	 is	 less	
commonly	encountered,	accounting	for	5%	to	10%	of	all	BCCs.	Lesions	present	as	pink- 
to-ivory-white,	shiny,	smooth,	scar-like,	indurated	plaques	or	depressions	with	ill-defined	
borders.	 Infiltrative	BCC	is	usually	more	aggressive	than	nodular	and	superficial	BCC	as	 
it	progresses	more	rapidly	with	the	potential	for	extensive	local	destruction63. 
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SCC and its precursor lesions AK and Morbus Bowen usually develop on sunexposed 
skin, predominantly in the head and neck area and extensor surfaces of the hands 
and	forearms.	Well	differentiated	SCC	classically	presents	as	thick,	scaly	papules	and	
plaques,	 whereas	 poorly	 differentiated	 SCC	 is	 often	 soft,	 non-scaly,	 ulcerated	 or	
hemorrhagic58. AK usually appears as scaly, skin colored, pink or brown papules or 
plaques,	often	with	an	erythematous	base	(Figure	2)58.
The	majority	of	diagnosis	of	skin	lesions	is	made	clinically,	after	visual	inspection	of	
the	skin.	Sometimes	dermoscopy	is	used	to	assist	in	diagnosis.	The	gold	standard	to	
establish the diagnosis of NMSC, including BCC subtype, is performing a biopsy for 
Figure 2.	Clinical	picture	of	nonmelanoma	skin	cancer	and	premalignant	actinic	keratosis	
with corresponding hematoxylin- eosin stained histology.	Superficial	basal	cell	carcinoma	
(a,e), nodular basal cell carcinoma (b,f),	 actinic	 keratosis	 (c,g) and squamous cell 
carcinoma (d,h).
17
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histopathological	evaluation63.	However,	performing	a	biopsy	has	limitations.	Only	a	
part of the lesion is examined, therefore sample error may occur and more aggressive 
BCC subtypes might be missed64-66. The BCC subtype is one of the main determinants 
for choice of treatment. For this reason, sample error may result in under treatment 
(e.g. a non-surgical treatment is selected which is only appropriate for non-aggressive 
BCC subtypes).
3.3 Histopathology
Basal	 cell	 carcinoma	 can	 be	 classified	 into	 two	 main	 categories;	 non-aggressive	
growth	subtypes	(superficial,	nodular)	and	aggressive	growth	subtypes	(micronodular,	
infiltrative)63,67,68. Aggressive subtypes have a higher recurrence rate and tend to 
cause	 extensive	 local	 destruction.	 Combinations	 of	 subtypes	 in	 one	 lesion	 can	 be	
found in about 40% of all primary BCCs, referred to as a mixed type BCC. BCC is 
characterized	 histologically	 by	 aggregations	 of	 basaloid	 keratinocytes	 with	 sometimes	
peripheral	palisading	of	nuclei.	Usually	the	basaloid	aggregations	are	surrounded	by	
stromal	tissue	(Figure	2).	Frequently,	there	 is	a	microscopically	visible	cleft	present	
between the tumor islands and peritumoral stroma. Nodular BCC is typically 
represented	by	large	nests	of	basaloid	cells	in	the	papillary	or	reticular	dermis	with	
peripheral	palissading	and	peritumoral	clefts.	Cystic	spaces	may	develop	within	larger	
tumor islands secondary to necrosis. Micronodular BCC shows round or oval tumor 
nests similar to nodular BCC. However, tumor nests are smaller, more widely 
dispersed,	 extending	 deeper	 into	 the	 dermis.	 Basaloid	 cells	 in	 superficial	 BCC	
proliferate mainly parallel to the epidermal surface and in the papillary dermis. There 
may	 be	 peritumoral	 clefts	 or	 peripheral	 palisading.	 Infiltrative	 BCC	 demonstrates	
tumor	cells	forming	nodules	with	irregular	contours	in	addition	to	strands	and	cords.	
Heavy	 stromal	 fibrosis	with	 dense	 collagen	 bundles	may	 be	 present,	 growing	 in	 a	
poorly	 circumscribed	 fashion,	and	may	 show	 invasion	of	 the	 subcutis.	Peritumoral	
clefting	is	uncommon	and	there	is	no	peripheral	palisading63. 
AK	is	characterized	histologically	by	keratinocyte	dyplasia	with	aggregates	of	atypical,	
pleomorphic	 keratinocytes	 with	 nuclear	 atypia,	 dyskeratosis	 and	 loss	 of	 polarity.	
Atypical	 keratinocytes	may	extend	 from	 the	basal	 cell	 layer	up	 to	 the	 level	of	 the	
granular	and	cornified	layers	(Figure	2).	By	definition,	AK	is	confined	to	the	epidermis.	
Furthermore, hyperkeratosis, parakeratosis and solar elastosis in the dermis are 
often	seen69.	SCC	has	similar	features	as	its	precursor	AK.	SCC	can	be	distinguished	
from AK due to the presence of tumor cells passing through the basement membrane 
into the dermis. Furthermore, nests of atypical tumor cells are formed in the dermis. 
Usually	there	is	full	thickness	epidermal	atypia	and	a	dermal	inflammatory	infiltrate	
(Figure 2)69.
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3.4 Treatment 
Surgical	excision	or	radiation	therapy	is	the	preferred	treatment	for	SCC	and	high	risk	
BCC.	Fluorouracil	 crème	can	be	applied	 to	 treat	 low	risk	 superficial	BCC.	 In	 recent	
years,	novel	treatment	options	for	low	risk	superficial	BCCs	have	become	available,	
including imiquimod crème and photodynamic therapy67,70. In case of a small, low risk 
BCC	 liquid	 nitrogen	 cryotherapie	 or	 curettage	 with	 electrodessication	 might	 be	
applied. The most commonly applied treatment for AK is liquid nitrogen cryotherapy. 
Fluorouracil	 crème,	 imiquimod	 crème	 and	 photodynamic	 therapy	 are	 particularly	
suited	 to	 treat	 multipele	 or	 more	 extensive	 AK.	 Other	 therapies	 for	 AK	 include	
ingenolmebutaat or diclofenac 3% gel71,72. 
4. Reflectance confocal microscopy
4.1 History 
The confocal microscope was invented by Marvin Minsky in 195773,74.	At	that	time,	the
microscope was only suited for imaging of ex vivo tissue	samples.	Then,	the	device	
was	adapted	by	inserting	a	spinning	disk	of	pinholes	and	a	white	light	source.	These	
changes made it possible to image human skin in vivo75. Further improvement was 
achieved	through	the	application	of	laser	light	and	a	spinning	polygon	mirror76. This 
latter	technique	with	the	spinning	polygon	mirror	was	subsequently	commercialized	
by Lucid Inc. (Rochester, New York, USA) in 1997. Their devices, the VivaScope 1500 
and	 3000,	 are	 currently	 the	 most	 frequently	 used	 RCM	 devices	 in	 the	 field	 of	
dermatology (Figure 3).
4.2 Principles of RCM
A	 reflectance	 confocal	 microscope	 uses	 a	 point	 source	 of	 light,	 derived	 from	 a	
near-infrared	830	nm	laser,	to	illuminate	a	horizontal	plane	within	the	skin.	Skin	tissue	
components	 reflect	 the	 laser	 light.	 Subsequently,	 a	detector	 collects	 the	 reflected	
laser light through a small aperture (pinhole) and out of focus light will be blocked 
from	detection.	The	point	source	of	the	light,	the	illuminated	spot	in	the	tissue,	and	
the	pinhole	aperture	are	situated	in	optically	conjugate	focal	planes,	hence	the	name	
confocal	(Figure	4).	The	measured	lateral	resolution	of	RCM	is	0.5-1	μm	and	the	axial	
resolution	is	less	than	5	μm.	This	technique	produces	images	of	the	skin	parallel	to	the	
skin surface (en face) and	can	examine	the	skin	up	to	a	depth	of	250	μm.	Therefore,	in	
normal	skin,	RCM	can	visualize	the	epidermis,	papillary	dermis	and	superficial	part	of	
the	reticular	dermis.	Each	skin	layer	has	distinct	RCM	features	(Figure	5).	Contrast	in	
the	images	is	provided	by	difference	in	the	refractive	index	between	cells,	subcellular	
structures	and	 the	surrounding	tissue.	The	contrast	 is	mainly	provided	by	melanin	
and	keratin	and	to	a	lesser	extent	white	blood	cells,	chromatin,	collagen	and	elastin	
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(Figure 5). The applied laser power is around 5 to 10 mW and therefore does not have 
any	adverse	effects	on	the	skin76-80. 
4.3 Clinical application
In	order	to	obtain	 images	of	a	clinical	 lesion,	first	a	metal	ring	with	a	polymer	window	 
is	attached	to	the	skin.	This	ring	is	magnetically	connected	to	the	objective	lens	housing.	 
To	reduce	the	amount	of	backscattering	of	 light	and	to	optimized	image	quality	a	drop	 
of water or oil is applied between the window and the skin. Furthermore, ultrasound gel 
is	 used	 between	 the	 window	 and	 the	 objective	 lens	 housing.	 The	 standard	 acquired	 
RCM	image	depicts	an	area	of	500x500	µm	of	the	skin	(confocal	 image).	The	objective	 
lens	 can	move	 in	 the	 horizontal	 plane	 to	 create	 a	mosaïc	 of	 images	 (VivaBlock).	 Also	 
the	objective	lens	can	move	vertically	to	capture	images	in	depth	(VivaStack).	In	addition,	
videos at 15-25 frames per second can be captured to document dynamic features. 
Figure 3. Vivascoop 1500 device (a).	A	metal	ring	with	adhesive	window	is	attached	to	
the	skin	after	application	of	a	drop	of	water	or	oil	to	the	skin	(b,c). Next, ultrasound 
gel	 is	 placed	 on	 the	 window	 and	 then	 the	 objective	 lens	 housing	 is	 magnetically	
attached	 to	 the	metal	 ring	 (c,d).	Optionally,	 the	Vivacam	can	be	used	 to	acquire	a	
clinical	image	of	the	skin	prior	to	reflectance	confocal	microscopy	(RCM)	imaging	for	
correlation	to	the	obtained	RCM	images	(e).
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5. Relevance of RCM in clinical dermatology 
Melanin	and	melanocytes	are	key	histopathological	features	of	melanocytic	lesions.	
These	 compounds	 and	 cells	 have	 a	 high	 refractivity	 and	 therefore	 provide	 strong	
contrast in RCM images78,81.	For	this	reason,	when	RCM	was	introduced	in	the	field	of	
dermatology	most	 research	 focussed	on	melanocytic	 skin	 lesions3. At the start of this 
thesis, there was increasing evidence for the applicability of RCM to improve diagnosis 
of	melanocytic	skin	 lesions3-8.	 In	other	fields	of	dermatology,	 including	 inflammatory	
skin	 lesions	 and	 NMSC,	 few	 research	 was	 performed.	 This	 research	 constituted	
predominantly of low-quality studies comprising case reports, case series or retro -
spective	studies	with	a	low	number	of	lesions2,9-20.
Figure 4.	Schematic	illustration	of	a	reflectance	confocal	microscope.
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Figure 5. Conventional	transverse	histological	tissue	section	of	normal	skin	with	lines	
indicating	 the	 level	 at	which	 the	 reflective	 confocal	microscopy	 (RCM)	 images	 are	
obtained (a,c).	 Illustration	 depicting	 the	 refractivity	 of	 cellular	 and	 subcellular	
structures of the skin in decreasing brightness (b).	RCM	images	of	normal	skin,	starting	
with the stratum corneum (SC) and subsequently in depth the stratum granulosum 
(SG),	stratum	spinosum	(SS),	dermal	epidermal	junction	(DEJ)	and	dermis	(D).	SC	appears	 
as gray, no nuclei or cellular outlines are observed. SG and SS can be recognized by 
the appearance of dark round nuclei with surrounding bright cytoplasm in a regular 
honeycomb	pattern.	At	the	DEJ	the	dermal	papillae	are	visible	as	dark	rings.	The	dermis	
appears	as	dark	gray	with	reflective	reticular	fibers	(c).
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In	 dermatology	 the	majority	 of	 diagnosis	 is	made	 clinically,	 after	 visual	 inspection	 
of	 the	 skin.	 When	 clinical	 diagnosis	 of	 a	 skin	 lesion	 is	 difficult,	 histopathological	
examination	of	a	biopsy	 is	 the	gold	standard	 for	 further	 investigation82. The possibility 
of	a	noninvasive	biopsy,	obtained	by	noninvasive	 skin	 imaging,	would	have	multiple	
advantages. First, an unlimited number of lesions can be examined and the exact 
same	lesion	can	be	followed	over	time.	Furthermore,	a	whole	lesion	can	be	investigated,	
which might reduce the risk of sample error and decrease delay in diagnosis and 
appropriate	 treatment.	 For	 these	 reasons,	 skin	 imaging	 may	 potentially	 increase	
efficiency	 and	 efficacy	 of	 dermatological	 care.	 Increasing	 efficiency	 and	 efficacy	 is	
particularly	 important	 in	 the	 field	 of	 skin	 cancer,	 due	 to	 the	 high	 and	 rising	
incidence60,61. 
The	possibility	 of	 noninvasive	diagnosis	might	 also	be	beneficial	 for	 inflammatory	 skin	
diseases, another frequently encountered problem in dermatology40. To improve 
patient	care	for	patients	with	inflammatory	skin	diseases	it	 is	 important	to	acquire	
more knowledge about the pathofysiological mechanisms, including changes at the 
cellular level. These studies might result in development of novel targeted therapies. 
In	addition,	dynamic	processes	in	the	skin	are	difficult	to	study	using	static	histological	
images obtained by an invasive biopsy. Noninvasive skin imaging would give the 
opportunity	to	study	dynamic	histopathological	changes	over	time83. Furthermore, 
it would enable monitoring of microscopic response to treatment noninvasively84,85.
6. Aims and outline of this thesis
In literature, there is increasing evidence for the applicability of RCM to improve 
diagnosis	of	melanocytic	skin	lesions.	Compared	to	melanocytic	skin	lesions,	there	is	
less known about the value of RCM in two other major problems in dermatology; 
NMSC	and	inflammatory	skin	diseases.	
The	overall	objective	of	this	thesis	is	to	explore	the	use	of	RCM	in	the	field	of	clinical	
dermatology.	The	thesis	focuses	on	2	primary	aims:
1.	 To	investigate	the	application	of	RCM	in	inflammatory	skin	disease	(Chapter 2). 
2.	 To	investigate	the	application	of	RCM	in	NMSC	(Chapter 3). 
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Since the department of Dermatology of the Radboudumc Nijmegen, the Netherlands 
has	an	extensive	past	performance	 in	psoriasis	 research,	we	 initially	 focus	on	 this	
disorder	 as	 an	 example	 of	 an	 inflammatory	 skin	 disease.	 In	 the	 second	 part,	 we	
expand our knowledge towards NMSC. In Chapter 2.1 it will be studied whether RCM 
is able to visualize established histological features of psoriasis. Chapter 2.2 addresses 
the	question	whether	RCM	allows	noninvasive	monitoring	of	microscopic	therapeutic	
response	 in	psoriatic	patients	 treated	with	UVB	phototherapy.	 To	 improve	patient	
care	 for	patients	with	 inflammatory	skin	diseases	 it	 is	a	key	 issue	 to	acquire	more	
knowledge	 about	 the	 dynamic	 pathofysiological	 mechanisms,	 which	 is	 difficult	 to	
obtain	 using	 static	 histological	 images	 acquired	 through	 a	 biopsy.	 Therefore	 in	
Chapter 2.3 it	will	be	 investigated	whether	RCM	can	assess	dynamic	 inflammatory	
processes in the skin in vivo using an established model. In Chapter 2.4 the use of 
RCM to study in vivo	 the	 dynamics	 of	 neutrophil	 accumulations	 in	 psoriasis	
(microabscesses of Kogoj and Munro), which are pathognomonic for this disease, will 
be	explored.	Psoriatic	 lesions	are	heterogeneous,	both	clinically	and	histologically.	
Therefore in Chapter 2.5	RCM	will	be	investigated	as	a	tool	to	gain	more	knowledge	
about	the	distribution	of	histological	 features	of	psoriasis	 in	active,	expanding	and	
chronic non-expanding lesions. 
NMSC,	and	in	particular	BCC,	is	the	most	common	cancer	in	the	Caucasian	population.	
Treatment	 of	 BCC	 is	 in	 part	 based	 on	 expected	 biological	 behavior,	 correlating	 to	
histological subtypes of BCC. Since non-surgical treatments are increasingly applied, 
which	 are	 only	 suited	 for	 superficial	 BCC,	 establishment	 of	 the	 BCC	 subtype	 is	
becoming even more important. In Chapter 3.1 the accuracy of a punch biopsy to 
determine BCC subtypes will be assessed, which is the gold standard for establishing 
the BCC subtype. Former studies showed that RCM is able to diagnose BCC. However, 
no	studies	are	performed	so	far	which	evaluate	the	ability	of	RCM	to	distinguish	BCC	
subtypes12-14,19,20,86. For these reasons, in Chapter 3.2 it will be explored whether RCM 
can assess BCC subtypes noninvasively. In Chapter 3.3 the	clinical	application	of	RCM	
in	taking	a	guided	biopsy	in	a	clinically	indistinct	lesion	will	be	demonstrated.	
The	 results	 presented	 in	 this	 thesis	 regarding	 the	 application	 of	 RCM	 in	 clinical	
dermatology are summarized and discussed in Chapter 4.
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CHAPTER 2
Abstract
Background: In vivo	 reflectance	 confocal	 microscopy	 (RCM)	 is	 a	 novel,	 exciting	
imaging	technique.	It	provides	images	of	cell-and	tissue	structures	and	dynamics	in	
situ,	 in	 real	 time,	without	 the	need	 for	ex vivo	 tissue	 samples.	 RCM	visualizes	 the	
superficial	part	of	human	skin	up	to	a	depth	of	250	µm.	In	psoriasis,	an	erythemato-
squamous skin disease, we evaluated well known histological features of stable 
psoriasis vulgaris (PP) with RCM. RCM images were correlated to morphological 
and	cell	biological	findings	in	routine	hematoxylin-eosin	(HE)	and	immunohistochemical	
stained	histology	with	CD3	and	antifilaggrin	antibodies.
Methods:	Lesional	and	nonlesional	skin	of	eight	patients	with	PP	were	evaluated	with	
RCM,	after	which	4-mm	punch	biopsies	were	taken	and	cut	vertically	 in	two	equal	
parts.	One	part	was	processed	in	the	conventional	vertical	way,	the	other	horizontally	
(en face)	 for	 optimal	 correlation	 to	 RCM	 images.	We	 evaluated	 and	 quantificated	 
nine	 histopathological	 features	 of	 psoriasis:	 parakeratosis,	 epidermal	 and	 dermal	
inflammatory	 infiltrate,	 diminished	 or	 absent	 stratum	 granulosum,	 epidermal	
thickening, thinning of the suprapapillary epidermal plate, increased height of the 
papillary dermis, increase in number of dermal papillae and increase in number and 
volume of papillary capillaries.
Results:	Quantification	and	evaluation	of	cell	biological	and	histological	features	of	 
PP	with	RCM	correlated	highly	to	evaluation	in	HE,	CD3	and	filaggrin-stained	histology.
Conclusions:	RCM	is	a	novel	technique	which	can	be	used	for	real	time,	cytometric	
evaluation	and	quantification	of	PP	features.	RCM	might	be	suited	equally	for	cytometric	
evaluation	of	other	superficial	tissues.
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Introduction
In vivo	 reflectance	 confocal	microscopy	 (RCM)	 is	 a	novel,	 cytometric	 technique	 to	
obtain	 cell-specific	 information	 of	 tissue	 and	 single	 cells.	 In	 contrast	 to	 standard	
microscopy	 and	 flow	 cytometry	 for	 which	 biopsy	 specimens	 are	 needed,	 RCM	 is	
noninvasive.	RCM	uses	a	near	infrared	830-nm	laser	beam,	to	visualize	tissue	up	to	a	
depth	of	250	µm.	RCM	images	tissue	en face,	in	situ,	at	real	time	and	therefore	can	
record	 dynamics	 like	 capillary	 blood	 flow.	 Contrast	 is	 provided	 by	 difference	 in	
refractive	 index	between	cellular,	 intercellular,	and	subcellular	 structures.	To	date,	
applications	of	RCM	include	the	study	of	morphological	microstructure	of	normal	and	
diseased	tissue	e.g.	melanoma	and	nonmelanoma	skin	cancer1-10. It is also used for 
in vivo and ex vivo	 evaluation	of	 nondermatological	 diseases	 such	 as	 neoplasia	 of	
mucosal	 tissues	 from	 mouth	 and	 cervix,	 mammary	 glands	 and	 neural	 tissue11-14. 
Besides	diagnostic	purposes,	RCM	can	be	used	for	follow	up	or	evaluation	of	changes	
in	 cellular	 features	 over	 time.	 In	 psoriasis,	 only	 sparse	 research	 using	 RCM	 is	
performed. In 1999 Gonzalez et al. showed that well known histological features of 
psoriasis	could	be	identified	using	RCM.	Further	correlation	to	routine	histology	was	
performed by Ardigo et al. in 200915,16. 
	 Psoriasis	 is	 an	 inflammatory	 skin	 disease	 with	 a	 prevalence	 of	 about	 2%	
worldwide. As the disease is generally chronic and persistent in nature, the prevalence 
of	psoriasis	increases	with	age.	There	are	several	clinical	variations.	Plaque	psoriasis	
(PP), the most common variant, is characterized by erythematosquamous lesions. 
Usually they are coin or palm sized and located on extensor surfaces of elbow and 
knee,	but	every	 skin	 location	can	be	affected17.	 PP	has	a	distinguished	histological	
representation.	It	comprises	parakeratosis	(nuclei	retainment	of	corneocytes),	absent	
or diminished granular layer, acanthosis (epidermal thickening), thinning of the 
suprapapillary plate (epidermal thickness between top of stratum corneum and top 
of	dermal	papillae)	and	elongation	of	the	dermal	papillae.	Trafficking	of	inflammatory	
cells through epidermis (micropustules of Kogoj) or in corneocytes (microabscesses 
of	Munro)	can	sometimes	be	seen,	which	is	highly	specific	for	psoriasis.	Inflammatory	
infiltrate,	and	tortuous,	dilated	capillaries	can	be	seen	in	the	reticular	and	papillary	
epidermis18 (Figure 1). 
	 The	presentation	of	the	skin	lesion	is	usually	characteristic,	so	diagnosis	is	mainly	
made	clinically.	Sometimes	PP	is	mistaken	for	other	erythematosquamous	diseases,	
e.g.	eczema	and	pityriasis	rubra	pilaris,	resulting	in	a	delayed	appropriate	treatment.	
A	 skin	 biopsy	 with	 histologic	 examination	 to	 confirm	 the	 diagnosis	 is	 frequently	
omitted,	though	it	remains	the	‘‘gold	standard’’.	For	the	follow	up	of	therapies	on	a	
cell	biological	level,	biopsy	is	always	necessary.	However,	a	biopsy	has	its	limitations.	
In	a	larger	lesion	there	is	the	risk	of	sample	error,	when	tissues	compose	of	different	
subtypes and only one type is biopsied. No follow up of the exact same lesion is 
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possible	over	time	and	the	inherent	post-inflammatory	artifact	distorts	the	follow	up.	
Using	RCM,	a	whole	lesion	can	be	imaged	for	an	unlimited	number	of	times.	Cellular	
changes	can	be	followed	over	time,	with	no	artificial	post-inflammatory	effect.	
	 In	 the	 present	 study	 we	 assess	 and	 quantify	 the	 well	 known	 histopathologic	
features	of	psoriasis	using	RCM-imaging	and	perform	correlation	 to	 the	morphological	 
cell	 biological	 findings	 evaluated	 in	 routine	 hematoxylin-eosin	 (HE)	 staining	 and	
	immunohistochemical	(IHC)	staining	with	CD3	and	filaggrin.
Materials and Methods 
Patients
Eight	patients	diagnosed	with	stable	PP	were	included.	They	were	recruited	from	the	
Department of Dermatology, Radboud University Nijmegen Medical Centre, Nijmegen, 
The	Netherlands.	The	local	medical	ethics	committee	approved	this	study.	All	patients	
gave	written	 informed	 consent	 before	 inclusion.	 Age	 ranged	 from	 23	 to	 74	 years	
(mean	±	SD	age	was	52.8	±	17.6),	all	male.	Duration	of	psoriasis	varied	between	5	months	
and	 15	years	 (mean	±	SD	duration	was	 10.9	±	4.8).	Exclusion	criteria	 included	 light	
treatment	(UVA,	UVB,	PUVA)	four	weeks	prior	to	the	study.	Also	patients	were	not	
Figure 1. Psoriatic	and	normal	skin.	Overview	of	transverse	histology	section	of	psoriatic	
skin,	the	insert	represents	normal	skin	at	the	same	magnification.	Contrasting	to	normal	
skin,	parakeratosis,	thinning	of	the	suprapapillary	height,	acanthosis,	reduction	of	the	
stratum	granulosum	and	inflammatory	cells	in	the	dermis	are	distinct.	Lines	represent	
the	level	of	the	different	epidermal	layers.	A:	Stratum	corneum,	B:	Stratum	granulosum,	
C:	Stratum	spinosum,	D:	Dermo-epidermal	junction,	E: Dermis.
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allowed	to	use	immunosuppressive	medication	or	drugs	leading	to	exacerbation	of	
psoriasis	 (e.g.,	 lithium,	beta-adrenergic	blocking	agents,	 antimalarials)	 at	 least	one	
month	(systemical)	or	one	week	(topical)	before	evaluation.
Study protocol
Seven days before the study all lesions were desquamated using daily 10% salicyl 
petrolatum,	to	limit	light	scatter	and	optimize	penetration	depth.	In	each	patient,	one	
lesional and one distant nonlesional skin site (>8 cm from lesional skin) were 
examined.	 Routine	 evaluation	 included	 a	 relevant	 dermatological	 history,	 physical	
examination,	and	dermascopic	photography.	Lesions	were	located	on	the	lower	back,	
outer	forearm,	 leg	or	outer	thigh.	Confocal	 imaging,	biopsy	and	routine	HE	histological	
evaluation	were	performed	consecutively.	The	clinical	and	confocal	evaluation	was	
performed	by	one	nonindependent	observer,	as	was	the	histological	evaluation	and	
the	 agreement	 between	 RCM	and	 histopathologic	 findings.	 The	 observer	was	 not	
blinded	to	the	RCM	images	or	dermascopic	findings.	Based	on	the	histopathological	
criteria	 for	psoriasis,	we	evaluated	HE	stained	tissue	samples	and	RCM	 images	 for	
nine	features:	parakeratosis,	diminished	or	absent	stratum	granulosum,	acanthosis,	
thinning of the suprapapillary epidermal plate (SP), increase in height of papillary 
dermis,	epidermal	and	dermal	inflammatory	infiltrate,	papillomatosis	and	dilated	and	
increased number of papillary capillaries18. Hyperkeratosis was established, but could 
not	be	considered	as	a	valid	parameter	because	of	the	use	of	keratolytic	ointment.	
IHC	 staining	with	 filaggrin	 and	 CD3	 on	en face	 as	well	 as	 transverse	 sections	was	
performed	 to	 quantify	 the	 amount	 of	 (matrix)	 of	 keratohyaline	 granulae	 in	 the	
stratum	granulosum	and	T-cells	respectively	as	described	previously19.
Dermascopic study
Lesional skin was evaluated and documented by epiluminescence microscopy using a 
dermascope	(Delta	20;	Heine	Ltd,	Herrsching,	Germany)	in	combination	with	a	digital	
camera for dermascopic photographs (Nikon D 200). The VivaCam Macro Camera is 
an external macro camera (VivaCam; Lucid Inc, Rochester, New York) adapted to the 
confocal microscope, which produces pictures comparable with the dermascope. 
Evaluation	of	the	number	of	red-white	dots	seen	with	dermascopy	and	correlation	to	
the number of dermal papillae (DP) at RCM and en face	HE	stained	histology	sections	
was	 carried	 out	 using	 NIH	 ImageJ	 software20. On the dermascopic picture a 
representative	area	with	clearly	visible	red-white	dots	was	outlined	and	the	amount	
of dots counted.
RCM imaging
Confocal imaging was performed with a commercially available VivaScope 1500 System 
(Lucid Inc, Rochester, NY). This confocal microscope comprised a diode Class 3B laser 
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with	an	operating	maximum	power	of	22	mW	at	tissue	level.	The	auto	image	control	
function	was	used,	so	applied	laser	power	was	automatically	adjusted	using	VivaScan	
7.0	Software,	for	optimal	brightness	of	the	acquired	images.	The	system	included	a	
30x	0.9	NA	water-immersion	objective	 lens.	Real	time	RCM	operates	by	detecting	
back	scattered	photons	from	the	 illuminated	 living	tissue.	The	contrast	 in	confocal	
images	 is	 provided	 by	 refractive	 index	 differences	 between	 cellular	 structures,	
subcellular	structures	and	their	surroundings.	Melanin	and	keratin	are	highly	refractile	
and	to	a	lesser	extent	white	blood	cells,	chromatin,	collagen,	and	elastin	in	the	dermis.	
RCM	 provides	 a	 resolution	 comparable	 to	 conventional	 light	 microscopy.	 The	
measured	lateral	resolution	has	been	shown	to	be	0.5–1	μm	and	the	measured	axial	
resolution	less	than	5	μm21.	Further	descriptions	of	the	system	have	been	published	
previously22,23.	The	system	was	attached	to	the	skin	 through	placement	of	an	adhesive	 
ring	which	contained	a	plastic	disposable	window.	The	ring	was	magnetically	attached	
to the lens housing to stabilize the site of imaging. We used oil or water as an 
immersion medium between the skin and the ring and ultrasound gel between the 
ring	and	objective	 lens.	 Images	were	obtained	using	VivaScan	7.0	Software,	which	
included	various	options:
Captured confocal images are two-dimensional images with an effective 
field of view of 500 µm x 500 µm
1.	 VivaBlock	 confocal	 images	 are	 a	 sequence	 of	 images	 captured	 and	 stitched	
together	in	software	to	create	a	mosaic,	with	a	field	of	view	of	4–8	mm.	In	each	
psoriatic	lesion	VivaBlocks	of	6	mm	×	6	mm	were	performed	at	the	level	of	the	
stratum corneum (SC), stratum granulosum (SG), stratum spinosum (SS), and der-
mo-epidermal	junction	(DEJ).
2. VivaStack confocal images are a sequence of images captured in depth, with 
steps	of	1–10	μm.	VivaStacks	were	performed	in	each	VivaBlock	at	five	areas:	in	
the	center,	 in	the	right	and	left	upper	quadrant	and	in	the	right	and	left	lower	
quadrant.	Imaging	started	at	the	beginning	of	the	SC	to	a	depth	of	200	μm,	with	
steps	of	5	μm.
3.	 Confocal	 Movies	 are	 videos	 captured	 in	 time	 to	 document	 dynamic	 events.	
Movies	 were	 performed	 at	 the	 level	 of	 the	 DEJ	 to	 visualize	 blood	 flow	 and	
leukocyte	 trafficking	 in	 the	 dermal	 papillae	 at	 5	 locations.	 Lesional	 skin	 was	
imaged	first,	then	the	whole	procedure	was	carried	out	in	nonlesional	skin	of	the	
same	patient15.
Biopsy procedure and HE staining
After	RCM	imaging,	4-mm	punch	biopsies	were	obtained	from	imaged	lesional	and	
nonlesional	skin	under	local	anesthesia	with	1%	xylocain/adrenalin.	After	the	excised	
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tissue	was	 fixed	 in	 formalin	 10%	 the	 biopsy	was	 sectioned	 vertically	 in	 two	 equal	
parts.	One	part	was	step	sectioned	in	5	μm	skin	samples	 in	the	traditional	vertical	
way, the other en face	 for	 optimal	 correlation	 to	 the	 RCM	 images.	 After	 routine	
processing, the slides were HE stained for assessment of histopathological features.
Immunohistochemistry
The immunohistochemical staining procedure was performed using an IgG labeled 
polymer horseradish peroxidase technique (En Vision), as described previously24. Par-
affin-embedded	 sections	 were	 stained	 with	 the	 monoclonal	 antibodies	 anti-CD3	
(1:100)	(clone	F7.2.38,	Abcam,	Cambridge,	UK)	and	anti-filaggrin	(1:10000)	(Biomedical	
Technologies, Stoughton, MA).
Parakeratosis and agranulosis
The surface percentage of total horizontal involvement of parakeratosis compared to 
orthokeratosis	was	estimated	in	transverse	HE	histology	and	VivaBlocks	at	the	level	
of	the	SC,	and	categorized	in	seven	groups:	0,	10,	30,	50,	70,	90	and	100%.	The	amount	
of	SG	was	evaluated	according	this	algorithm	after	immunohistochemical	staining	of	
transverse	 histology	 sections	 with	 filaggrin.	 Brightness	 of	 SG	 was	 evaluated	 by	
outlining the area of SG in a confocal image and measuring brightness using ImageJ 
1.37. Cell size of the SG was evaluated by the average of 10 cells in the plain just 
beneath	the	SC	cell	layer,	using	VivaScan	7.0	Software.
Height epidermal layers
Evaluation	of	thickness	of	epidermal	layers	was	assessed	at	transverse	HE	histology	≥	
5	representative	locations,	and	their	values	averaged,	in	RCM	by	counting	the	amount	
of	steps	of	5	µm	in	VivaStacks	covered	by	the	layer:
1.	 Stratum	corneum:	first	 visible	 cells	 of	 the	 SC	 to	 the	first	 cells	 of	 the	 SG	or	 SS	
(agranulosis). 
2.	 Suprapapillary	 epidermal	 plate:	 first	 cells	 of	 the	 SC	 to	 the	 z-plane	 with	 first	
distinct	dermal	papillae.	
3.	 Total	epidermal	height:	first	visible	cells	of	the	SC	till	the	level	of	the	dermis.
Papillomatosis
The	number	of	dermal	papillae	was	assessed	counting	the	number	of	papillae	in	a	6	
mm x 6 mm VivaBlock and en face	HE	stained	tissue	coupe	at	the	level	of	the	DEJ.	
Areas	with	dermal	papillae	were	selected,	excluding	areas	depicting	other	epidermal	
layers	or	artifacts.	Dermal	papillae	were	outlined,	25	per	location,	using	an	external	
draw	 board	 to	 assess	 shape	 parameters:	 total	 area,	 perimeter,	 Feret’s	 diameter	
(maximum caliper diameter), Min Feret (minimum caliper diameter), mean gray 
value, modal gray value and circularity. Dermal papillae of a lesion were categorized 
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as edged or nonedged, depending on the dark papillae being surrounded by a bright 
rim	of	basal	cells	or	not,	respectively21.
Inflammatory cells
IHC	 staining	 with	 CD3	 antibody	 was	 performed	 on	 transverse	 tissue	 sections	 of	
involved and uninvolved skin and on en face	 HE	 tissue	 sections	 after	 they	 were	
discolored	of	HE.	At	RCM	inflammatory	cells	were	identified	by	a	round	to	oval	shape,	
high	 refractivity	and	small	 size25.	 The	amount	of	 inflammatory	cells	with	RCM	was	
counted at the depth on transverse histology at which most CD3+ cells were seen. 
RCM	images	depicting	500	x	500	µm2 at the corresponding level in two stacks were 
evaluated	in	each	patient	and	numbers	averaged.	ImageJ20 was used to evaluate the 
number	of	CD3+	cells/mm2 in histology.
Capillaries
The	number	of	capillaries	in	the	dermal	papillae	was	evaluated	in	five	movies	and	en 
face HE histology at the level of the DEJ25.	Capillaries	were	identified	by	open	spaces	
with	no	HE-staining,	sometimes	filled	with	red	blood	cells.	
Statistics 
Pearson’s	 correlation	 coefficient	 (r)	 and	 Spearman’s	 rho	 correlation	 coefficient	 (s) 
were	used	for	correlation	of	parameters	evaluated	with	RCM	and	histology.	Paired	
sampled t-test (t)	 was	 applied	 for	 evaluation	 of	 features	 as	 a	 distinguishing	 RCM	
parameter	in	psoriatic	compared	to	uninvolved	skin.	All	data	analyses	were	performed	
using SPSS version 16.0 (SPSS Inc, Chicago IL). 
*Correlation	is	significant	at	the	0.05	level	(2-tailed).
**Correlation	is	significant	at	the	0.01	level	(2-tailed).
Results 
Parakeratosis,	epidermal	inflammatory	cells,	acanthosis,	papillomatosis	and	number	
and	 volume	 of	 papillary	 capillaries	 could	 be	 evaluated	 and	 quantified	 with	 RCM.	
Overall	RCM	showed	a	high	correlation	to	HE	histology.	Data	are	summarized	in	Table	1.	
Evaluation	of	presence	or	absence	of	SG	was	difficult.	Total	epidermal	height,	height	
of	papillary	dermis	and	presence	of	dermal	inflammatory	cells	could	not	be	evaluated	
with	RCM	in	psoriatic	skin,	due	to	acanthosis	and	the	limited	penetration	depth	of	the	
laser	beam.	The	maximum	penetration	depth	with	sufficient	resolution	to	distinguish	
cell	type	was	in	psoriatic	skin	deeper	(mean	±	SD	180.9	μm	±	119.6)	compared	with	
uninvolved	 skin	 (mean	 ±	 SD	 119.6	 μm	 ±	 16.8).	 Not	 all	 psoriatic	 lesions	 showed	 all	
known histopathologic features. Uninvolved skin showed no pathological features.
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Dermascopic findings
In	all	psoriatic	lesions	pink-red	dots	in	an	evenly	dispersed	pattern	were	observed	at	
dermascopy,	with	 a	 high	 correlation	 to	 the	 number	 of	DP	 in	en face HE histology 
sections	 (r = 0.80*) and RCM images (r = 0.88**).	About	eight	times	more	DP	were	
identified	with	RCM	(mean	DP/mm2 ± SD 293.8 ± 132.9) compared with dermatoscopy 
(mean ± SD 36.7 ± 14.5).
Epidermal height
In	psoriatic	lesions	height	of	SC	and	SP	correlated	highly	as	evaluated	by	RCM	and	HE	
with r = 0.89** and r = 0.80*	respectively.	A	trend	of	concordant	values	was	seen	in	
evaluation	of	height	of	SC,	SP	and	total	epidermis	of	uninvolved	skin.
Parakeratosis
Parakeratosis	 in	 psoriatic	 skin	 showed	 distinct	 RCM	 features:	 a	 highly	 refractile	
nucleus surrounded by dark cytoplasm, in which no individual cellular outlines could 
be	distinguished	 (Figure	2).	 Some	psoriatic	 lesions	displayed	besides	parakeratosis	
areas	 with	 orthokeratotic	 cells,	 which	 were	 imaged	 at	 RCM	 markedly	 differently	
compared	to	orthokeratosis	 in	uninvolved	skin:	darker,	with	a	more	homogeneous	
aspect	and	less	visible	cellular	outlines.	Uninvolved	skin	showed	a	highly	refractile	SC	
with	a	blended	aspect.	Correlation	of	evaluation	of	parakeratosis	in	RCM	and	HE	was	
high	 in	psoriatic	skin	 (Spearman’s	rho	0.93**). In uninvolved skin there was a 100% 
concordance with all cases displaying a horizontal surface percentage of 100% 
orthokeratosis in both RCM as HE.
Stratum granulosum
In	psoriatic	and	uninvolved	 skin	all	 cells	 located	directly	beneath	 the	SC	appeared	
relatively	bright	compared	with	surrounding	and	overlying	SC,	which	in	psoriatic	skin	
was	notably	darker	 than	 in	uninvolved	skin	 (Figure	2).	There	was	no	correlation	of	
presence	or	absence	of	SG	in	RCM	images	to	amount	of	filaggrin	surface	percentage	
at	IHC	and	quantification	could	not	be	performed.	PP	horizontal	surface	percentage	
of	 positive	 filaggrin-stained	 cells	 compared	 with	 the	 total	 horizontal	 epidermal	
surface ranged from 0 to 90% (mean ± SD 48.8% ± 32.3). Uninvolved skin showed 
100%	concordance;	all	patients	showed	a	continuous	SG	with	a	surface	percentage	of	
100%.	 One	 psoriatic	 lesion	 showed	 a	 two	 to	 three	 times	 increased	 height	 of	 SG,	
imaged	with	 RCM	 as	 a	 strikingly	 bright	 grainy	 cytoplasm	 at	 a	 relatively	 low	 laser	
power (0.6 mW), clearly demarcated from the surrounding dark orthokeratosis and 
about	15	μm	thick.	In	psoriatic	skin	SG	appeared	to	have	a	“flattened”	honeycombed	
pattern	and	smaller	cell	size	(mean	23	μm).	In	uninvolved	skin	SG	was	1	to	2	cell	layers	
thick,	characterized	in	RCM	by	a	relatively	large	cell	size	(mean	30	μm)	and	a	round	to	
oval	 “blown	 up”	 cell	 shape	 in	 a	 honeycombed	 pattern.	 Surface	 percentage	 of	 SG	
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showed	no	correlation	to	refractivity.	Laser	power	showed	a	medium-high	correlation	
to	refractivity	of	SG	in	uninvolved	skin	(r = 0.75*).
Inflammatory cells
Inflammatory	cells	were	located	surrounding	the	dermal	papillae,	in	highest	amounts	
at	the	tips	of	the	dermal	papillae	in	psoriatic	skin	(Figure	3).	The	number	of	suspected	
Figure 2. SG	 in	psoriatic	and	uninvolved	 skin.	A,E,I:	 Transverse	HE	histology.	B,F,J:	
Corresponding RCM image at the level of the SC-SG. C,G,K:	Corresponding	en face HE 
histology at the level of the SC-SG. D,H,L:	Transverse	IHC	filaggrin	stained	histology,	
depicting	SG	cells	 (brown).	A–D:	Psoriatic	skin	with	parakeratosis	 (green	asterisks),	
characterized in RCM by white nuclei in a dark surrounding at a laser power of 2.6 
mW. In HE histology retainment of purple nuclei in the corneocytes is visible. SC is 
directly followed in z-axis by SS cells (white arrows) with bright cytoplasm and oval 
shape	in	RCM.	Filaggin	staining	is	negative.	E–H:	Uninvolved	skin	of	the	same	patient	
as	A–D	with	a	continuous	1	to	2	cell	layer	thick	SG	(black	arrows)	characterized	with	
RCM	by	a	relatively	large	size,	“blown”	up	shape,	white	nucleoli	dots,	honeycombed	
pattern,	surrounded	by	highly	refractile	orthokeratosis	(red	asterisks)	at	a	laser	power	
of 0.6 mW. Smaller sized SS cells are seen (white arrows). Filaggrin staining is 
continuous.	I–L:	Psoriatic	skin	with	increased	amount	of	SG	characterized	with	RCM	
by islands of SG cells with strikingly bright cytoplasm surrounding a dark nucleus 
(black	arrows).	There	is	a	“flattened”	pattern	surrounded	by	dark	orthokeratosis	(red	
asterisks) at the same laser power as in B. In HE histology no dark nuclei are visible in 
the	 corneocytes.	 Filaggrin	 staining	 is	 continuous	 and	 thickened	 (HE,	 hematoxylin-	
eosin;	IHC,	immunohistochemical;	RCM,	reflectance	confocal	microscopy;	SC,	stratum	
corneum; SG, stratum granulosum; SS, stratum spinosum).
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inflammatory	 cells	 in	 a	RCM	confocal	 image	 correlated	medium	 to	 the	 amount	of	
CD3+ T-cells in transverse histology (r = 0.59**) and to en face histology (r = 0.55*). The 
number of CD3+ cells evaluated en face	sections	correlated	highly	to	evaluation	 in	
transverse	sections	(r = 0.77**).	In	one	patient	there	where	highly	refractile,	elongated	
cells visible at the level of the SC, clustered together in large numbers (Figure 4). HE 
histology revealed a Munro microabscess, a clustering of leucocytes pathognomonic 
for	psoriasis.	A	negative	CD3	staining	confirmed	these	findings.
Dermal papillae
In	psoriatic	skin	all	DP	showed	nonedged	papillae,	which	contrast	to	edged	DP	by	not	
being surrounded by a rim of bright basal cells21. In uninvolved skin 75% showed 
nonedged papillae. The number of DP evaluated with RCM correlated highly to the 
amount of DP in en face	HE	sections	in	psoriatic	skin	(r = 0. 89**) and uninvolved skin 
(r	=	−0.96*).	Near	three	times	more	DP	were	identified	with	RCM	compared	with	HE.	
In three en face	 HE	 histology	 sections	 the	 number	 of	 DP	 could	 not	 be	 correctly	
evaluated	 due	 to	 a	 flat	DEJ.	 There	was	 a	 trend	 of	 higher	 surface	 area,	 perimeter,	
Feret’s diameter and Feret Min in PP compared to uninvolved skin (Table 2). Circularity 
was	higher	in	psoriatic	skin	(mean	±	SD	0.79	±	0.02)	than	uninvolved	skin	(mean	±	SD	
0.75 ± 0.03) with paired sampled t-test t = 3.7**. Mean and mode gray value were 
lower in psoriasis with paired sampled t-test (t	=	−2.9*) and (t	=	−3.1**)	respectively.
Capillary blood flow
DP	showed	an	trend	of	increased	number	of	papillary	capillaries	in	psoriatic	skin	with	
more	prominent	blood	flow	compared	with	uninvolved	skin	when	evaluated	by	RCM	
and	HE.	RCM	evaluation	yielded	a	significantly	higher	number	of	capillaries	in	psoriasis	
compared with uninvolved skin with paired t-test t = 4.9**.
Figure 3. Inflammatory	cells	at	the	dermo-epidermal	junction.	Consecutively:	reflectance	
confocal	microscopy	 image	of	500	μm	×	500	μm;	corresponding	en face hematoxylin- 
eosin	 staining	and	 immunohistochemical	 staining	with	CD3	of	psoriatic	 skin	of	 the	
same	patient,	showing	numerous	highly	refractile	round	to	oval	 inflammatory	cells	
located inter and intra papillary (arrows).
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Figure 4. Munro	microabscess	in	psoriatic	skin.	A:	Transverse	HE	histology	showing	
acanthosis	with	dermal	inflammatory	infiltrate,	parakeratosis	(asterisks)	and	presence	
of	multiple	leucocytes	(arrows)	at	the	level	of	the	SC.	B,C:	Corresponding	en face HE 
histology	of	the	same	lesion	at	the	level	of	the	SC,	in	B	with	a	higher	magnification.	
Multiple	small	 leucocytes	are	seen	surrounded	by	parakeratosis.	D:	Corresponding	
RCM	image	at	the	level	of	the	SC	with	multiple	highly	refractile	elongated	leucocytes	
clustered	together,	surrounded	by	dark	SC.	(HE,	hematoxylin-eosin;	RCM,	reflectance	
confocal microscopy; SC, stratum corneum).
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Discussion
In this study the morphological and cell biological features of PP and uninvolved skin 
were	evaluated	and	quantified	using	RCM.	Correlation	to	HE	stained	transverse	and	
en face	tissue	sections	was	assessed,	as	well	as	to	IHC	staining	with	filaggrin	and	CD3	
antibody.	Overall,	RCM	showed	a	high	correlation	to	HE	histology.	In	this	study	RCM	
evaluation	was	performed	by	nonblinded,	nonindependent	observers	 for	HE	histology,	
which could bias the results.
	 Our	results	confirm	the	earlier	results	of	Gonzalez	and	Ardigo	et	al.15,16. Gonzalez 
concluded	in	a	descriptive	study	that	histological	hallmarks	of	psoriasis	skin	could	be	
visualized	with	RCM.	Ardigo	et	al.	established	a	good	correlation	to	histopathological	
features	in	routine	HE	staining,	which	was	performed	in	a	semiquantitative	way.	Yet,	
to	use	RCM	as	a	tool	for	follow	up	of	histological	features	over	time,	to	yield	more	
specific	and	reproducible	evaluations	and	for	comparison	of	lesions	intra	and	inter-
individually,	 more	 precise	 quantification	 of	 features	 is	 necessary.	 Therefore,	 we	
developed	an	 algorithm	 for	 further	quantification	of	 the	well	 known	histopathological	
features of psoriasis with RCM and set a standard of measurements compared to 
uninvolved	 skin.	We	 evaluated	tissue	 sections	 besides	 the	 routine	 transverse	way	
also en face,	for	better	correlation	to	the	en face RCM images. This gives opportunity 
to evaluate possible new RCM features of psoriasis, e.g. size and circularity of dermal 
papillae.	 All	 studies	 performed	 so	 far	 evaluated	 RCM	 features	 descriptively.	 We	
performed	IHC	staining	with	CD3	and	filaggrin	to	further	establish	the	nature	of	the	
Table 2. Shape	descriptors	of	dermal	papillae	in	psoriatic	and	uninvolved	skin.	
Psoriasis Uninvolved
Mean SD Mean SD T-test P-value
Area (µm2) 4186.5 1496.9 3095.8 2082.6 1.3 0.23
Mean gray value 41.7 8.2 50.5 13.2  -2.9* 0.02
Mode gray value 34.7 5.9 40.9 9.5 -3.2 * 0.02
Perimeter (µm2) 247.2 48.7 211.0 70.9 1.3 0.25
Feret (µm2) 80.5 15.7 70.4 24.7 1.1 0.33
MinFeret (µm2) 63.9 12.8 51.3 15.3 2.0 0.91
Circularity 0.79 0.02 0.75 0.03 3.7** <0.01
Circularity,	mean	and	mode	gray	value	of	dermal	papillae	are	statistically	significant	RCM	parameters	
in	psoriatic	and	uninvolved	skin.	(*P < 0.01, **P < 0.001).
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parameters and imaged a Munro microabsces with RCM, which to our best knowledge, 
is not performed before.
 Diminished or absent SG is a well known histological feature of PP. We performed 
IHC	with	filaggrin,	to	identify	SG	in	histology	and	for	optimal	quantitative	correlation	
to	the	amount	of	SG	evaluated	with	RCM.	Correlation	was	high	in	uninvolved	skin	but	
poor	in	psoriatic	skin.	This	was	due	to	difficulty	in	recognizing	SG	cells,	despite	their	
distinguished	 description	 in	 literature	 as	 relatively	 large	 size	 compared	 to	 the	
underlying SS, large dark nucleus and bright grainy cytoplasm. Applying these criteria, 
did	 not	 result	 in	 a	 correct	 evaluation	 in	 psoriatic	 skin.	 RCM	 evaluation	 yielded	
presence of SG while absent in HE histology and vice versa. SG appeared similarly 
when	SG	was	normal,	diminished	or	absent,	so	no	differentiation	between	the	amount	
of	SG	was	possible	 in	psoriatic	skin.	There	was	no	correlation	to	the	amount	of	SG	
surface percentage with brightness of the SG cell layer. Only in one case of increased 
amount of SG these criteria were markedly present with a strikingly bright grainy 
cytoplasm	 compared	 to	 the	 surroundings.	 However,	 this	 patient	 was	 presumably	
misdiagnosed	and	was	not	affected	by	PP.	In	uninvolved	skin	SG	cells	did	show	the	
characteristic	criteria.	Therefore	we	conclude	that	distinguishing	cells	as	SG	is	well	
performed	in	uninvolved	skin,	but	poor	in	psoriatic	skin.
	 Because	 laser	 power	was	 automatically	 applied,	 and	 therefore	 different	 in	 all	
lesions, this could be a disturbing factor when using brightness of cells as a RCM 
feature. The exact same cells imaged at a higher laser power appeared brighter; and 
brighter	 cells	 are	designating	easier	 as	 SG	 cells.	 In	uninvolved	 skin	 increased	 laser	
power resulted in increased brightness of the SG, though SG amount remained the 
same (r = 0.75*). Besides applied laser power, brightness was also based on the 
amount	of	SG.	When	SG	amount	increased,	there	was	a	trend	of	lower	automatically	
applied	laser	power,	while	brightness	of	RCM	images	was	similar.	So	both	automatically	
applied laser power and amount of SG contribute to brightness of the SG in an RCM 
image. Other factors could contribute to brightness, e.g. thickness of overlying SC, 
previous	 topical	 treatment,	 desquamation,	 height	 and	 surface	 percentage	 of	 SG,	
constitution	 of	 extracellular	 fluid	 or	 intracellular	 fluid	 and	 pathology	 of	 the	 skin.	
Higher surface percentage of SG correlated to a larger average cell size. Therefore cell 
size	directly	beneath	the	SC	could	be	of	help	for	correct	evaluation	of	SG	presence.	
Brightness	of	SC	might	be	a	new	psoriasis	RCM	feature:	plaques	showed	dark	homo-	
geneously SC in contrast to bright SC with a blended aspect in distant uninvolved skin.
	 Numbers	 of	 capillaries	 evaluated	 in	 both	 psoriatic	 and	 uninvolved	 skin	 were	
significantly	higher	with	RCM	compared	to	histology.	This	might	be	due	to	capillaries	
being	hard	 to	 identify	on	en face	 sections.	Performing	 IHC	 for	 the	endothelial	 cell	
lining of the capillaries might solve this problem.
	 Twenty-five	 percent	 of	 the	 patients	 showed	 edged	DP	 in	 uninvolved	 skin	 and	
nonedged DP in psoriasis. Loss of brightness of the basal cells might be due to 
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epidermal	hyperproliferation	and	upward	spread	of	melanocytes;	melanin	 in	basal	
cells	 is	divided	over	more	cells,	 resulting	 in	 less	melanin	 in	 the	basal	 layer.	Loss	of	
edged papillae can be regarded as a RCM feature for psoriasis. In light skin type, for 
example most redheaded people, nonedged DP are physiological, so loss of melanin 
in pathologic skin might not be noted26. Mean and modal gray value of DP were higher 
in	uninvolved	skin.	This	might	be	caused	by	the	presence	of	basal	cells	with	a	relatively	
high	amount	of	reflective	melanin	in	edged	papillae	or	higher	applied	laser	power.
	 Although	in	general,	correlation	of	SC	and	SP	height	evaluated	by	RCM	and	HE	
histology	was	high,	 lower	correlation	seen	in	one	patient	might	be	caused	by	local	
variation	in	SC	and	SP	height.	Maximum	penetration	depth	of	the	laser	beam	at	RCM	
imaging was on average a factor 1.5 deeper in PP compared to uninvolved skin, 
probably	due	 to	 the	acanthosis	 in	PP	and	 the	more	distinguished	RCM	features	of	
epidermal	cells	compared	with	the	dermis,	so	at	a	lower	resolution	epidermal	cells	
can	be	distinguished	more	easily.
 In conclusion RCM is a tool to evaluate histological features on a cell biological 
level	and	can	assess	well	known	histological	hallmarks	of	PP	with	a	high	correlation	to	
histology.	New	features	were	identified	and	a	pathognomonic	Munro	microabscess	
could	be	visualized.	Biopsies,	a	major	burden	for	patients,	may	be	avoided	using	RCM	
as	well	as	inherent	biopsy	artifacts.	Imaging	can	be	performed	for	a	unlimited	number	
of	times	and	to	an	unlimited	number	of	locations.	This	gives	way	to	a	wide	range	of	
opportunities:	 to	 document	 the	 natural	 course	 of	 lesions	 or	 to	 evaluate	 therapy.	
Besides	psoriasis,	RCM	could	be	applied	for	other	tissues	in vivo but also ex vivo e.g. 
other	 epidermal	 diseases	 or	 evaluation	 of	 oral	 or	 cervical	 mucosa.	 However,	 its	
limitations	due	to	limited	penetration	depth	have	to	be	taken	into	account.
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CHAPTER 2
Abstract
Background: In vivo	 reflectance	confocal	microscopy	(RCM)	is	a	novel,	noninvasive	
imaging	technique	which	enables	imaging	of	skin	at	a	cellular	resolution	comparable	
to	conventional	microscopy.
Objectives: We performed a pilot study to evaluate RCM as a noninvasive tool for 
monitoring ultraviolet (UV) B phototherapy in psoriasis.
Methods:	In	six	patients	with	psoriasis,	lesional	and	nonlesional	skin	was	selected	for	
RCM imaging using a standardized protocol. Well-known histological features of 
psoriasis	 were	 visualized:	 parakeratosis,	 acanthosis,	 agranulosis,	 papillomatosis,	
presence	of	epidermal	inflammatory	cells,	increased	number	of	papillary	capillaries	
and	 increased	 capillary	 blood	 flow.	 RCM	 imaging	 was	 performed	 before	 the	 first	
irradiation	with	UVB	phototherapy,	after	nine	irradiations,	at	clearance	and	12	weeks	
after	clearance.	 In	 four	patients,	4-mm	punch	biopsies	were	obtained	and	stained	
with	haematoxylin-eosin.	Additionally,	immunohistochemical	staining	was	performed	
with	monoclonal	antibodies	specific	for	CD31,	CD3,	filaggrin,	K16,	Ki67	and	CD1a	for	
correlation	to	RCM	images.
Results:	There	was	a	high	correlation	between	clinical,	RCM	and	histological	features.	
Normalization	 of	 RCM	 and	 histological	 features	 corresponded	 highly	 to	 clinical	
improvement of psoriasis.
Conclusions:	This	study	is	the	first	to	establish	the	use	of	RCM	as	an	effective	tool	for	
noninvasive	monitoring	of	UVB	phototherapy	in	patients	with	psoriasis.	Potentially,	
RCM	could	be	used	in	many	other	skin	diseases	for	monitoring	therapeutic	response	
on	a	cellular	level	in	a	clinical	or	research	setting.
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Introduction
Psoriasis	is	a	chronic	inflammatory	skin	disease	with	a	prevalence	of	about	2%	worldwide.	
Psoriasis is clinically characterized by sharply demarcated erythematosquamous 
papules or plaques, mainly located on elbows, knees, umbilicus and lumbar areas1,2. 
On	microscopic	examination	psoriasis	has	a	distinctive	histological	representation3. 
However,	 diagnosis	 is	 mainly	 made	 clinically	 as	 clinical	 presentation	 is	 usually	 
highly	 characteristic.	 Therefore	 a	 skin	 biopsy	 to	 confirm	 diagnosis	 is	 frequently	
omitted.
	 Established	treatment	options	for	psoriasis	include	topical	application	of	cortico-
steroids and vitamin D
3 analogues, psoralen plus ultraviolet (UV) phototherapy 
(PUVA),	UVB	phototherapy	and	systemic	therapy.	Choice	of	treatment	is	affected	by	
body	surface	area,	severity	of	lesions,	efficacy	and	side-effects	of	therapeutic	options,	
comorbidities	and	convenience	for	the	patient1,4-6.	Until	now,	studies	evaluating	the	
histological	effects	of	treatments	required	a	biopsy.	Currently,	studies	are	performed	 
to	 test	 safety	 and	 efficacy	 of	 new	 treatment	 options	 for	 psoriasis,	 e.g.	 innovative	
biologic	 therapies.	 For	monitoring	 the	histological	 effects	 of	 these	new	 treatment	
options	a	biopsy	is	inevitable.	However,	performing	a	biopsy	has	several	disadvantages.	
It	is	not	possible	to	evaluate	exactly	the	same	lesion	over	time,	the	inherent	postin-
flammatory	response	potentially	disturbs	follow-up	and	the	number	of	biopsies	that	
can	be	performed	is	limited.	In	addition,	a	biopsy	represents	only	a	small	sample	of	
the	lesion,	which	potentially	results	in	sample	error,	and	it	is	an	invasive	procedure	
for	the	patient	with	potential	scarring.
 In vivo	reflectance	confocal	microscopy	(RCM),	a	novel	imaging	technique,	could	
be	 used	 to	 overcome	 the	 limitations	 associated	 with	 biopsies.	 RCM	 evaluates	
histological features of the skin in vivo,	noninvasively,	with	a	resolution	comparable	
to	conventional	light	microscopy.	It	obtains	en face images of the epidermal strata up 
to	a	depth	of	200	μm,	the	level	of	the	reticular	dermis7,8. RCM features of psoriasis 
were	first	described	by	Gonzalez	et al.	 in	 1999,	and	 later	studies	confirmed	a	high	
correlation	to	well-known	histopathological	features9-11. Typical histological and RCM 
features	 of	 psoriasis	 include:	 the	 presence	 of	 parakeratosis,	 acanthosis,	 increased	
number	 of	 papillary	 capillaries,	 increased	 capillary	 blood	 flow,	 papillomatosis	 and	
presence	of	epidermal	inflammatory	infiltrate,	including	Munro	microabscesses3.
	 Narrowband	UVB	phototherapy	(NBUVB,	311–313	nm)	is	an	established	treatment	
option	for	psoriasis5,12-18.	Therapeutic	efficacy	depends	on	both	dose	and	frequency	of	
the	 treatment	 regimen.	 Further,	 radiation	 spectrum	 is	 an	 important	 parameter.	
NBUVB phototherapy has proven to be superior to broadband UVB in reversing 
psoriasis	at	low	doses	given	three	times	weekly17.	NBUVB	is	similar	in	efficacy	to	PUVA,	
clearing	up	to	80%	of	patients	using	a	three	times	weekly	regimen19.	Mode	of	action	
is	 based	 on	 targeting	 both	 epidermal	 keratinocytes	 and	 lymphocytes,	 resulting	 in	
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immune	suppression,	alteration	of	cytokine	expression	and	cell	cycle	arrest,	which	
may	all	contribute	to	the	suppression	of	disease	activity	in	psoriatic	lesions19,20.
	 Studies	evaluating	RCM	as	a	noninvasive	tool	to	monitor	therapy	are	scarce	and,	
to	the	best	of	our	knowledge,	to	date,	none	have	been	performed	in	inflammatory	
skin	 diseases.	 However,	 studies	 evaluating	 therapeutic	 response	 in	 nonmelanoma	
skin cancer show promising results21-25. Therefore, in this study we evaluated the use 
of	RCM	as	a	noninvasive	tool	for	monitoring	therapeutic	response	of	UVB	phototherapy	 
in	patients	with	psoriasis.
Materials and Methods 
Patients
We	included	six	patients	with	psoriasis	(three	men	and	three	women)	treated	with	
UVB phototherapy at the Department of Dermatology, Radboud University Nijmegen 
Medical Centre, Nijmegen, the Netherlands. This study was approved by the local 
medical	 ethics	 committee	 and	 was	 conducted	 according	 to	 the	 principles	 of	 the	
Declaration	of	Helsinki.	All	patients	gave	written	informed	consent	before	inclusion.	
The	age	of	the	patients	varied	from	34	to	58	years	(mean	age	±	SD,	44·3	±	8·5	years).	
Lesions were located on the upper leg, lower leg, upper arm, lower arm and lower 
back.	 Exclusion	 criteria	 were	 the	 use	 of	 immunosuppressive	 medication,	 cortico-
steroids	or	drugs	potentially	leading	to	exacerbation	of	psoriasis	(e.g.	lithium,	beta-	
adrenergic blocking agents) at least 1 month (systemic) or 1 week (topical) before 
inclusion.	Patients	were	not	allowed	to	use	any	other	psoriatic	treatment	during	the	
study besides nonmedicated topical dressings.
Study protocol
In	each	patient,	one	lesional,	and	additionally	in	four	patients,	one	nonlesional	skin	
site (> 8 cm from lesional skin) were selected for RCM imaging. Transparent body 
charts	were	used	to	outline	the	skin	areas	at	baseline	to	permit	colocalization	during	
follow-up	 examination4,24.	 Five	 days	 before	 RCM	 evaluation	 all	 lesions	 were	
desquamated using daily 10% salicyl-petrolatum, an established procedure in UVB 
phototherapy	to	optimize	treatment	efficacy.	Additionally,	it	limits	light	scatter	and	
optimizes	penetration	depth	for	RCM	evaluation.	RCM	imaging	was	performed	before	
the	 first	 irradiation	 with	 UVB	 phototherapy	 (baseline),	 after	 nine	 irradiations,	 at	
clearance	and	12	weeks	after	clearance.	In	case	clearance	was	not	reached,	a	follow-up	
visit	was	scheduled	after	the	last	irradiation.
Ultraviolet B phototherapy
For	irradiation,	a	Waldmann	UV	70001	light	cabin	(Waldmann	Medizinische	Technik,	
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Villingen-Schwenningen, Germany) with Philips TL-01 lamps (Philips, Eindhoven, the 
Netherlands) (311 nm) was used. Minimal erythema dose (MED) was determined on 
the	 lower	back	 following	standard	procedures	 1	day	before	starting	phototherapy.	
For	patients	with	Fitzpatrick	skin	phototype	I,	II	and	III	the	administered	doses	were	
0·20,	0·40,	0·60,	0·80,	1·00	and	1·20	J	cm−2.	Patients	with	skin	phototype	IV	received	
doses	of	0·50,	0·70,	0·90,	1·10,	1·30	and	1·50	J	cm−2. The MED was recorded as the 
lowest	 dose	 to	 produce	 perceptible	 erythema.	 Patients	were	 treated	 three	 times	
weekly.	Increments	given	at	each	visit	were	based	on	40%	of	the	previous	irradiation	
dose	 and	 the	 grade	 of	 erythema	 response	 48h	 after	 the	 last	 treatment.	 Protocol	
adjustments were needed due to erythema. Other reasons included holiday and 
minor	medical	discomfort	 (e.g.	 a	 cold)	 resulting	 in	more	 than	3	days	without	UVB	
irradiation.
Dermatoscopic study
Before RCM imaging, clinical and dermatoscopic pictures were taken using a digital 
camera (Nikon D 200; Nikon, Tokyo, Japan) and the VivaCam Macro Camera (VivaCam; 
Lucid Inc., Rochester, NY, U.S.A.). The VivaCam Macro Camera is an external macro 
camera adapted to the confocal microscope, which produces pictures comparable to 
a dermatoscope.
Reflectance confocal microscopy imaging
Confocal imaging was performed with a commercially available VivaScope 1500 
System (Lucid Inc.). This confocal microscope comprised a near-infrared 830 nm, 
low-power laser beam. RCM obtains horizontal (en face) images of the skin, in contrast 
to	 the	 vertical	 sections	 at	 histological	 evaluation.	 Images	 were	 obtained	 using	
VivaScan	7.0	Software	(Lucid	Inc.,	Rochester,	NY,	USA).	More	detailed	description	of	
the system has been published previously7,8,26.
 RCM imaging was performed according to a standardized protocol. A horizontal 
mapping	 (4	×	4	mm)	was	made	at	 the	 level	of	 the	 stratum	corneum	 (SC),	 stratum	
granulosum	(SG),	stratum	spinosum	(SS)	and	at	the	dermal–epidermal	junction	(DEJ).	
A	vertical	mapping	was	performed	by	capturing	a	series	of	images	in	depth	(0·5	×	0·5	
mm)	with	 steps	 of	 5	 μm.	 The	mapping	 started	 at	 the	 top	 of	 the	 SC	 until	 the	 DEJ	
(psoriatic	skin)	or	dermis	(nonlesional	skin).	Movies	were	made	at	the	level	of	the	DEJ	
at	five	locations	to	visualize	capillary	blood	flow	in	the	dermal	papillae	(DP)	and	to	
evaluate	the	number	of	dermal	capillaries	per	optical	section	(0·5	×	0·5	mm).	After	
imaging of lesional skin the whole procedure was carried out in nonlesional skin. 
Based	on	previous	studies	we	evaluated	the	following	RCM	parameters	for	psoriasis:	
parakeratosis,	 diminished	 or	 absent	 SG,	 acanthosis,	 epidermal	 inflammatory	 cells,	
papillomatosis,	number	of	papillary	capillaries	and	amount	of	capillary	blood	flow	in	
the DP. The clinical and histological observer was not blinded to the RCM images.
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Biopsies: haematoxylin-eosin staining and immunohistochemistry
After	RCM	imaging	4-mm	punch	biopsies	were	taken	from	imaged	lesional	skin	in	four	
patients	and	of	nonlesional	skin	in	two	patients.	Local	anaesthesia	was	used	with	1%	
xylocaine/adrenaline.	 The	 biopsies	 were	 fixed	 in	 formalin	 10%	 and	 embedded	 in	
paraffin.	Sections	(5	μm)	were	stained	with	haematoxylin-eosin	(HE)	for	assessment	
of	histopathological	features.	Additionally,	immunohistochemical	(IHC)	staining	was	
performed	with	monoclonal	antibodies	specific	for	CD31	(1	:	500)	(clone	JC70A;	Dako,	
Glostrup,	Denmark),	CD3	(1	:	100	and	1	:	500)	(clone	F7.2.38;	Abcam,	Cambridge,	U.K.),	
filaggrin	(1	:	500	000)	(Biomedical	Technologies,	Stoughton,	MA,	U.S.A.),	K16	(1	:	500)	
(clone	LL025;	Novocastra	Laboratories,	Newcastle,	U.K.),	Ki67	(1	:	100)	(clone	MIB-1;	
Dako)	and	CD1a	 (1	 :	500)	 (clone	010;	Dako)	 together	with	a	haematoxylin	counter-
staining.	 Preparation	was	 performed	 according	 to	 standard	 histological	 protocols.	
Sections	were	photographed	at	 a	magnification	of	 10×	or	 20×	using	 a	microscope	
(Axioskop2 MOT; Zeiss, Oberkochen, Germany), digital camera (Axiocam MRc5; Zeiss) 
and	AxioVision	software	(Zeiss).
Results
The	number	of	UVB	irradiations	per	patient	ranged	from	22	to	33	(mean	±	SD	number	
of	treatments,	26·3	±	4·4).	Four	patients	achieved	total	clearance	of	psoriasis.	In	two	
patients	irradiations	were	stopped	before	clearance	of	the	lesion	was	achieved	due	
to general improvement of psoriasis. Dermatoscopic and RCM images of psoriasis at 
baseline,	after	nine	irradiations	with	UVB	phototherapy,	at	clearance	and	12	weeks	
after	clearance	are	summarized	in	Figure	1.	Figure	2	represents	the	corresponding	HE	
and	 IHC	 staining	with	monoclonal	 antibodies	 specific	 for	CD31,	 CD3,	filaggrin,	 K16,	
Ki67 and CD1a.
 Histological features of psoriasis could be easily visualized with RCM. Improvement 
of RCM and (immuno) histological features corresponded highly to clinical improvement 
of	psoriasis.	Twelve	weeks	after	clearance	all	clinical,	RCM	and	(immuno)	histological	
features were comparable to those of nonlesional skin. In nonresponders to UVB 
phototherapy, clinical and corresponding (immuno) histological features of psoriasis 
persisted.
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Reflectance confocal microscopy evaluation of psoriasis before initiation 
of treatment (baseline)
Red dots at dermatoscopy
Numerous round to oval red dots were seen at dermatoscopy, corresponding to 
abundant	papillary	capillaries	at	the	DEJ	with	high	capillary	blood	flow.	In	two	patients,	 
the red dots had a markedly larger diameter compared with those in the other 
patients	 (average	 diameter	 172	 and	 77	 μm)	 corresponding	 to	 large,	 clustering,	
tortuous	capillaries	of	about	200	μm	in	diameter	(Figure	1	and	3).
Parakeratosis and agranulosis
Parakeratosis, visualized as retainment of bright nuclei in dark corneocytes, and a 
smaller amount of orthokeratosis was seen in all lesions. Orthokeratosis was depicted 
as	homogeneously	dark	anuclear	cells	with	indistinct	cellular	boundaries,	in	contrast	
to	the	high	refractivity	of	the	corneocytes	in	nonlesional	skin.	SG	was	absent.
Munro microabscess and inflammatory cells
In	 two	 patients,	 highly	 refractive,	 large,	 oval	 and	 elongated	 polymorphonuclear	
granulocytes	focally	clustered	together	at	the	transition	of	SC	to	SS,	representing	Munro	
microabscesses.	 In	 four	 patients,	 round	 to	 oval	 and	 spindle-shaped	 inflammatory	
cells were visualized at the SS and DEJ.
Cellular atypia at the stratum spinosum
There was mild cellular and nuclear atypia of the SS with heterogeneity in cell size and 
shape,	resulting	in	an	atypical	honeycomb	pattern.	The	diameter	of	the	keratinocytes	
was	similar	in	all	epidermal	layers,	corresponding	to	dyskeratinization.
Papillomatosis and increased blood flow
Papillomatosis was established in all lesions. DP were homogeneously distributed, 
about	54	DP	per	optical	section.	Half	of	the	patients	displayed	nonedged	DP	(dark	DP	
not	surrounded	by	a	demarcating	bright	rim	of	basal	cells)	and	half	displayed	confluent	
DP (DP surrounded by a bright rim of basal cells in which individual cellular outlines and 
nuclei	could	not	be	identified).	Blood	vessels	in	the	DP	were	readily	visualized	due	to	the	
presence	 of	 dynamic	 blood	 flow,	 identified	 by	 the	 quick	 movement	 of	 numerous	
prominent	highly	refractive,	round	to	oval	inflammatory	cells	and	medium	refractive	
red blood cells in a dark capillary lumen. Blood vessels displayed both a canalicular and 
round appearance corresponding to a parallel or perpendicular (en face)	orientation	to	
the skin surface.
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Reflectance confocal microscopy evaluation of psoriasis after nine 
irradiations of ultraviolet B
The	 psoriatic	 skin	 improved	 clinically	 as	well	 as	 (immuno)	 histologically.	 Clinically,	 
the redness of the lesions diminished. At a histological level the number and redness 
of the dots observed at dermatoscopy decreased, corresponding to a markedly 
decreased	capillary	blood	flow	in	the	DP.	Parakeratosis,	the	amount	of	capillary	blood	
flow	 and	 the	 number	 of	 inflammatory	 cells	 inside	 the	DP	 diminished.	 The	 cellular	
atypia	of	 the	SS	 improved.	Round	to	oval	 inflammatory	cells	at	 the	 level	of	 the	SS	
were	visualized	in	one	patient.
Reflectance confocal microscopy evaluation of psoriasis at  
clinical clearance
Dermatoscopic	evaluation	showed	a	normal	or	pigmented	pattern.	The	majority	of	RCM	
and histological features were comparable to those in nonlesional skin, displaying 
orthokeratosis,	a	 regular	honeycomb	pattern	at	 the	SG	and	SS	and	a	 low	capillary	
blood	 flow	 inside	 the	 DP.	 SG	 was	 visualized	 by	 large	 polygonal	 cells	 with	 a	 dark	
nucleus, surrounded by a broad ring of bright grainy cytoplasm. However, acanthosis 
persisted	and	the	DP	dominantly	displayed	a	continuous	aspect.
Reflectance confocal microscopy evaluation of psoriasis 12 weeks  
after clearance
RCM, dermatoscopic and histological features further improved compared with 
clearance and corresponded completely to uninvolved skin. The SS displayed a regular 
honeycomb	 pattern	 with	 a	 cell	 diameter	 that	 diminished	 as	 deeper	 layers	 of	 the	
epidermis	 were	 visualized,	 representing	 normal	 keratinization.	 All	 lesions	 showed	
edged	DP.	The	number	of	DP	with	blood	flow	decreased	from	84%	at	baseline	to	40%.	
The size and diameter of blood vessels was markedly decreased compared with 
baseline.	 Capillary	 blood	 flow	 was	minimal	 or	 absent.	 Further,	 orientation	 of	 the	
blood vessels was transverse, opposed to the mainly en face	orientation	at	baseline.	
The	 suprapapillary	 height	 decreased	 from	 58	 μm	 at	 baseline	 to	 24	 μm,	 which	 is	
comparable to nonlesional skin.
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Figure 1. Dermatoscopic	and	reflectance	confocal	microscopy	images	of	psoriasis	lesional	
skin.	The	columns	(left	to	right)	represent,	respectively,	psoriasis	lesional	skin	at	baseline,	
after	nine	 irradiations	with	ultraviolet	B	phototherapy,	at	clearance	and	12	weeks	after	
clearance. (a–d) Dermatoscopic images with abundant red dots (a, b) and normal-appearing 
skin	with	mild	to	moderate	hyperpigmentation	(c,	d).	(e–h) Parakeratosis (red asterisk) and 
orthokeratosis (green asterisk) at the level of the stratum corneum. (i–l) Agranulosis (i, j) 
and presence of stratum granulosum (k, l). (m–p) Stratum spinosum displaying mild (o) and 
moderate	(m,	n)	cellular	atypia	and	a	normal	honeycombed	pattern	(p).	(q–t) Nonedged 
(q,	r)	and	edged	dermal	papillae	(s,	t)	at	the	dermoepidermal	junction.
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Figure 2. Haematoxylin-eosin (HE) and immunohistochemical staining of psoriasis 
lesional	skin.	The	columns	represent	histology	sections	of	psoriasis	 lesional	skin	at	
baseline (a1–g1),	 after	 nine	 irradiations	with	UVB	phototherapy	 (a2–g2), clearance 
(a3–g3)	and	12	weeks	after	clearance	(a4–g4).	Original	magnification:	10×	(f)	and	20×	
(a–e, g). (a1–a4) HE staining. There was a decrease of acanthosis and papillomatosis 
from	 baseline	 to	 clearance	 and	 further	 improvement	 12	 weeks	 after	 clearance.	
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Stratum corneum displayed parakeratosis at baseline, compact orthokeratosis at 
clearance	and	a	normal,	loose	basket-weave	arrangement	12	weeks	after	clearance.	
(b1–b4)	Keratin	16	staining.	K16	was	present	intracellularly	in	all	suprabasal	epidermal	
layers	at	baseline,	diminished	after	nine	irradiations	and	was	not	present	at	clearance,	
coinciding	 with	 improvement	 of	 stratum	 spinosum	 architecture	 at	 reflectance	
confocal microscopy (RCM) imaging. (c1–c4) Ki67 staining. The horizontal surface 
percentage	 covered	 by	 Ki67,	 a	 hyperproliferation	marker,	 diminished	 from	 nearly	
100%	at	baseline	to	about	50%	at	clearance,	and	10%	at	 12	weeks	after	clearance,	
pointing	towards	normalization	of	keratinization	comparable	with	nonlesional	skin.	
(d1–d4) and (e1–e4)	CD3	and	CD1a	staining.	CD3-positive	T	cells	and	CD1a-positive	
dendritic	cells	were	present	at	baseline,	mainly	located	at	the	level	of	the	tips	of	the	
dermal	papillae,	and	diminished	in	number	after	nine	irradiations.	CD3-positive	T	cells	
were	absent	in	the	epidermis	at	clearance	and	12	weeks	after	clearance,	corresponding	 
to	RCM	findings.	The	number	of	CD1a-positive	dendritic	cells	diminished	at	clearance	
and	 was	 comparable	 to	 nonlesional	 skin	 12	 weeks	 after	 clearance.	 Dendritic	 cells	
could not be visualized with RCM. (f1–f4)	CD31	 staining.	At	baseline,	CD31-positive	
endothelial cells of the papillary capillaries were prominent in number and size and 
had an en face	orientation.	After	nine	irradiations	they	diminished	in	number	and	size	
corresponding	to	capillary	RCM	findings.	At	clearance	and	12	weeks	after	clearance	
CD31-positive	endothelium	cells	were	mainly	located	in	the	reticular	dermis	and	the	
capillary	orientation	changed	from	en face to transverse. (g1–g4) Filaggrin staining. 
At	baseline	and	after	nine	irradiations	stratum	granulosum	is	absent.	At	clearance	and	
12	weeks	after	clearance	stratum	granulosum	forms	a	continuous	layer	covering	the	
whole epidermal surface.
Figure 3. 	 Large	globuli	at	dermatoscopy	and	reflectance	confocal	microscopy	imaging	
in	psoriasis	lesional	skin.	In	two	patients,	large	round	to	oval	red	dots	at	dermatoscopy	
were visualized at baseline (a), corresponding to a clustering of tortuous capillaries in a 
parallel	orientation	 to	 the	skin	surface	 (en face) at the level of the dermoepidermal 
junction	(white	arrows),	forming	large	globuli	inside	the	dermal	papillae	(b).
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Discussion 
In	the	present	study	we	evaluated	RCM	as	a	noninvasive	tool	to	monitor	therapeutic	
response	of	UVB	phototherapy	 in	patients	with	psoriasis.	 Staining	with	HE,	 and	 IHC	
staining	with	monoclonal	antibodies	specific	for	CD31,	CD3,	filaggrin,	K16,	Ki67	and	CD1a	
was	performed	 for	 correlation	 to	RCM	 images.	 Features	of	psoriasis	 could	be	easily	
visualized	with	RCM.	We	found	a	high	correlation	between	clinical,	RCM	and	histological	
features.	 Normalization	 of	 RCM	 and	 (immuno)	 histological	 features	 corresponded	
highly	to	clinical	 improvement	of	psoriasis.	Our	results	confirm	earlier	 results	of,	 for	
example, Ulrich et al. and Ahlgrimm-Siess et al., which showed that RCM allows 
noninvasive monitoring of treatment response in vivo21,24. However, to the best of our 
knowledge,	this	study	is	the	first	to	establish	the	use	of	RCM	as	an	effective	tool	for	
noninvasive	monitoring	of	inflammatory	skin	disease	and	UVB	phototherapy.
	 Previous	studies	have	shown	that	dendritic	cells,	either	activated	melanocytes	or	
Langerhans cells, can be visualized with RCM27-29.	IHC	analysis	of	psoriatic	skin	showed	
the	 presence	 of	 CD1a-positive	 dendritic	 cells	 at	 all	 time	 points.	 However,	 these	
dendritic	cells	were	not	visualized	during	RCM	evaluation.	Therefore,	we	hypothesize	
that	 the	 dendritic	 cells	 in	 our	 study	may	 be	 non	 activated	 resident	macrophages.	
Possibly,	only	on	activation	may	this	type	of	dendrite	be	visualized	with	RCM.
 No clinical features of psoriasis were present at clearance. However, RCM and 
(immuno)	 histological	 evaluation	 showed	 persistence	 of	 psoriatic	 features.	 Just	 12	
weeks	 after	 clearance,	 RCM	 and	 IHC	 features	 were	 completely	 comparable	 to	
nonlesional skin. For example, at clearance, SC displayed orthokeratosis with an 
abnormal	compact	aspect,	while	12	weeks	after	clearance	SC	showed	a	normal	loose	
basket-weave appearance. Thus, RCM was able to detect subclinical features of 
psoriasis. Non responders to UVB phototherapy displayed large clustered tortuous 
capillaries	at	baseline	in	contrast	to	solitary	and	smaller	capillaries	in	patients	who	
responded well to UVB phototherapy. Therefore, presence of large globuli might be 
related to nonresponsiveness to UVB phototherapy.
	 Until	 now,	 studies	 which	 evaluated	 the	 histological	 effects	 of	 treatments	 for	
psoriasis and other skin diseases required a biopsy. However, RCM may make these 
biopsies redundant, which has numerous advantages. RCM enables imaging of the 
exact same skin site, the number of ‘virtual’ biopsies is unlimited and a larger area of 
tissue	can	be	visualized.	Due	to	the	 in vivo imaging, dynamic events such as blood 
flow	can	be	documented	and	a	histological	report	is	directly	available	with	no	delay	
due	to	fixation,	paraffin	embedding	or	staining	of	histological	sections.	Additionally,	
RCM	 is	 noninvasive,	 resulting	 in	 less	 discomfort	 for	 the	 patients	with	 no	 scarring.	
Future research might focus on technical improvement of the RCM device, especially 
putting	effort	into	optimizing	the	horizontal	resolution	and	penetration	depth.	This	
could	lead	to	new	opportunities	to	use	RCM	as	a	widespread	diagnostic	tool.
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	 In	summary,	this	study	is	the	first	to	establish	the	use	of	RCM	as	an	effective	tool	
for	noninvasive	monitoring	of	therapeutic	response	to	UVB	phototherapy	in	patients	
with	 psoriasis.	 There	was	 a	 high	 correlation	 between	 RCM,	 clinical	 and	 (immuno)	
histological	features.	Additionally,	subclinical	features	of	psoriasis	could	be	visualized.	
Therefore,	RCM	could	potentially	be	used	in	psoriasis	and	other	 inflammatory	skin	
diseases	 for	 monitoring	 therapeutic	 response	 on	 a	 cellular	 level	 in	 a	 clinical	 or	
research	setting,	without	performing	a	biopsy.
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CHAPTER 2
Abstract
Background:	Application	of	leukotriene	B4	(LTB4)	is	an	established	in vivo model that 
locally	 induces	skin	 inflammation.	Currently	 in	this	model,	a	biopsy	is	 inevitable.	 In 
vivo	reflectance	confocal	microscopy	(RCM),	a	noninvasive	imaging	technique,	could	
overcome	this	limitation.	To	find	out	to	what	extent	RCM	may	be	an	in vivo	investigative	
and	diagnostic	tool	in	neutrophilic	conditions,	we	studied	the	dynamics	of	polymor-
phonuclear	neutrophil	 (PMN)	migration	 from	dermis	 to	stratum	corneum	using	an	
established LTB4 model.
Methods: Leukotriene B4 was topically applied on the skin of the lower back of seven 
volunteers.	The	skin	sites	were	evaluated	by	RCM	for	three	consecutive	days	with	a	
24h	time	interval.	For	histological	correlation,	3-mm	punch	biopsies	were	obtained.	
The	 tissue	 sections	 were	 hematoxylin-eosin	 and	 immunohistochemical	 stained.	
Minimal and average epidermal thickness was measured.
Results:	RCM	imaging	showed	highly	reflective	 ill-defined	particles	with	a	granular	
content	 throughout	 the	 epidermis	 24h	 after	 application	 of	 LTB4.	 Over	 time,	 the	
appearance of these cells changed throughout the epidermis. Epidermal thickness 
increased	over	time,	and	the	measurements	based	on	the	RCM	images	corresponded	
very well with the histological images.
Conclusions:	 RCM	 was	 able	 to	 visualize	 PMN	 migration,	 accumulation,	 and	
degeneration	over	time	in	the	used	LTB4	model.	The	noninvasive	character	and	the	
possibility	to	obtain	multiple	in vivo	images	from	the	same	location	over	time	make	
that	RCM	 in	combination	with	 this	model	a	useful	 tool	 to	study	 the	dynamics	and	
function	of	PMN	in	inflammatory	processes	in	the	skin.
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Introduction
Experiments	 on	 inflammatory	 skin	 lesions	 provide	 us	 with	 static	 and	 complex	
information	of	 the	 disease	 and	 inflammatory	 processes.	 These	 in vivo models are 
rarely	 used	 due	 to	 their	 invasive	 character,	 induction	 of	 inflammation,	 and	 the	
complexity	 to	 interpret	 the	 data.	 Information	 distracted	 from	 static	 data	 is	 not	
suitable to study dynamic in vivo	 processes	 like	 migration,	 accumulation,	 and	
degeneration	of	polymorphonuclear	neutrophils	(PMN).	Further	in	diseased	skin,	it	is	
hard	to	obtain	a	biopsy	at	the	most	appropriate	time,	a	biopsy	can	be	obtained	too	
early	or	too	late.	In	vitro	studies	can	be	investigated	continuously	and	provide	a	quite	
dynamic picture, but lack the complex in vivo environment.
	 Topical	 application	 of	 human	 leukotriene	 B4	 (LTB4)	 is	 an	 established	 in vivo 
model	that	locally	induces	skin	inflammation.	Leukotrienes	are	intracellular	signaling	
molecules	 that	 are	overproduced	during	an	allergic	 and	 inflammatory	 response	 in	
several	 tissues,	 including	 the	 skin1,2. These leukotrienes are primary made by 
inflammatory	cells	like	neutrophils,	basophils,	eosinophils,	monocytes,	macrophages,	
and mast cells2,3. Leukotrienes, are metabolites of arachidonic acid derived from the 
5-lipoxygenase pathway1,3,4.	LTB4	has	been	shown	to	have	potent	chemo-attractant	
activity	for	PMN,	resulting	in	PMN	infiltration	into	the	skin	within	24h	after	topical	
application,	which	subsequently,	is	followed	by	a	mononuclear	infiltrate	in	the	dermis	
between 48 and 72h1-3,5-7.	Topical	application	of	LTB4	causes	a	dose	dependent	acute	
response	and	attracts	 a	homogenous	population	of	 inflammatory	 cells.	 Therefore,	
this	model	could	be	used	for	studying	the	specific	role	of	PMN	in	inflammatory	skin	
diseases like psoriasis8,9. Currently, in this model, a biopsy is inevitable. Performing a 
biopsy has several disadvantages; it is invasive, which in most cases will result in scar 
formation,	and	which	makes	it	impossible	to	evaluate	exactly	the	same	location	over	
time.	Moreover,	biopsies	will	induce	an	inflammatory	response,	which	may	interfere	
with	the	study	observations.	In	the	LTB4	model,	several	biopsies	of	healthy	volunteers	
are	needed	to	study	the	inflammatory	processes	over	time.	Noninvasive	reflectance	
confocal	microscopy	(RCM)	could	be	used	to	overcome	these	limitations	associated	
with biopsies.
 Noninvasive RCM is an in vivo imaging technique, which is able to obtain 
information	on	tissue	and	cell	morphology.	Imaging	the	skin	is	possible	up	to	a	depth	
of	250	µm	and	the	resolution	of	this	technique	is	comparable	to	conventional	light	
microscopy10. Several studies have shown that RCM can be used to diagnose 
inflammatory	skin	diseases11-16.	Also,	it	is	a	useful	device	in	studying	efficacy	and	side	
effects	 of	 inflammatory	 skin	 disease	 therapies	 like	 UVB	 phototherapy	 and	 topical	
application	of	corticosteroids	and	vitamin	D3 analogs
17,18.
	 To	date,	mainly	“lymphocyte-rich”	inflammatory	skin	lesions	have	been	studied	
by	RCM.	It	is	known	that	inflammatory	cells	have	a	relative	high	refractive	index	and	
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appear	as	small	homogenous	bright	particles	in	RCM	images19. In a case report of a 
patient	with	folliculitis,	Gonzalez	et	al.	described	bright	appearing	inflammatory	cells	
in the corneal layer and around hair follicles, corresponding to neutrophils on 
conventional	 histopathology20. These images were obtained with an older RCM 
system	and	 are	 therefore	hard	 to	 compare	with	 newer	 images	 that	 have	 a	 better	
resolution.	With	the	newer	RCM	system,	only	one	study	reported	the	appearance	of	
neutrophils within the epidermis. They appear as a shiny granular sludge or 
polylobulated	ill-defined	particles	with	a	bright,	highly	reflective	granular	content15. 
These	cells	were	morphologically	clearly	different	from	lymphocytes.
 Polymorphonuclear leukocytes, including neutrophils, have a crucial role in a 
number of skin diseases including the frequent occurring epidermal dermatoses 
psoriasis,	seborrheic	dermatitis,	and	a	number	of	less	frequent	skin	conditions,	which	
often	 provide	 a	 diagnostic	 challenge21.	 In	 psoriatic	 lesions,	 it	 is	 known	 that	 the	
accumulation	of	PMN	is	a	dynamic	cyclic	pattern22. Wolberink et al. described that 
RCM	 can	 visualize	 this	 dynamics	 and	 time-phasing	 of	 PMN	 migration	 in vivo in 
psoriatic	lesions23. Although visualized, the exact mechanism for PMN diapedesis and 
migration	in vivo	are	not	yet	fully	understood.	The	findings	reported	by	Wolberink	et	
al. are based on data obtained in a complex diseased environment, which make it 
hard	 to	unravel	 the	mechanism	and	dynamics	of	one	specific	cell	 type	 like	PMN23. 
Therefore,	to	find	out	to	what	extent	RCM	may	provide	an	in vivo	investigative	and	
diagnostic	tool	in	neutrophilic	conditions,	we	studied	the	dynamics	of	PMN	migration	
from	dermis	to	stratum	corneum	using	the	well-established	LTB4	model.	In	particular,	
we	will	address	the	following	questions:	(i)	 Is	RCM	able	to	visualize	PMN	migration	
from dermis to stratum corneum in this model. (ii) Does RCM enable to visualize 
PMN	accumulation	and	degeneration	 in	 the	stratum	corneum.	 (iii)	 Is	 it	possible	 to	
differentiate	between	PMN	and	mononuclear	cells	with	RCM.	Studying	the	dynamics	 
of	 PMN	 migration,	 accumulation,	 and	 degeneration	 in	 this	 PMN-specific	 skin	
inflammation	 model	 can	 improve	 our	 understanding	 on	 the	 pathogenesis	 of	
neutrophilic	conditions	and	therefore	might	contribute	to	the	development	of	new	or	
personalized treatments.
Materials and methods
Healthy volunteers
This	study	was	conducted	according	to	the	principles	of	the	Declaration	of	Helsinki	
and	was	approved	by	the	local	medical	ethics	committee.	Seven	healthy	adults,	one	
male,	and	six	female,	with	a	mean	age	of	23	(range	20–28)	were	included	in	this	study	
after	giving	written	informed	consent.	Volunteers	with	a	history	of	skin	disease,	an	
activated	immune	system,	or	immunocompromised	volunteers	were	excluded	from	
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participation.	Measurements	were	 performed	 at	 the	 department	 of	Dermatology,	
Radboud University Medical Center, Nijmegen, The Netherlands.
LTB4 model
In	all	volunteers,	10	µl	ethanol-LTB4	solution	containing	100	ng	LTB4	was	applied	in	an	
8 mm cylinder at three sites on the lower back skin. The ethanol was evaporated with 
a	stream	of	nitrogen,	resulting	in	only	LTB4	on	the	skin.	Afterward,	the	test	sides	were	
covered with patch test chambers for 8h to prevent the LTB4 for being displaced.
RCM imaging
RCM imaging was performed with the commercially available VivaScope 1500 system 
(Lucid Inc., Rochester, NY, USA). This system produces en face images of the skin and 
is able to examine the skin at a depth of 250 µm. Images were obtained and analyzed 
using	 Vivascan	 7.0	 software	 (Lucid	 Inc.,	 Rochester,	 NY,	 USA).	 A	 more	 detailed	
description	 of	 the	 system	 has	 been	 published	 previously10,24,25. RCM imaging was 
performed	before	LTB4	application,	after	24,	48,	and	72h.	These	time	intervals	were	
based on a literature search9,26,27. The RCM images were obtained according to a 
standardized protocol. A horizontal map of 4 x 4 mm (Vivablock) was made at the 
level of the stratum corneum, stratum granulosum, stratum spinosum, dermal-epi-
dermal	junction,	and	papillary	dermis.	Vertical	mapping	(Vivastack)	was	performed	
by	capturing	a	series	of	images	of	0.5	x	0.5	mm	in	depth	with	steps	of	4.5	μm.	The	
mapping	started	at	the	top	of	the	stratum	corneum	until	the	papillary	dermis.	Moving	
features were captured by making movies.
Histology and immunohistochemistry
For	histological	correlation	with	the	RCM	images,	in	five	volunteers,	24,	48,	and	72h	
after	LTB4	application	3-mm	punch	biopsies	were	taken	under	local	anesthesia	with	
1%	Xylocain/	Adrenalin.	Camp	et	al.	showed	that	application	of	pure	ethanol	without	
LTB4 did not lead to histological changes8. For this reason, a biopsy of healthy skin 
was	obtained	as	 internal	control.	The	biopsies	were	embedded	in	paraffin	after	4h	
fixation	in	formaldehyde.	Paraffin	sections	(6	µm)	were	processed	side-by-side	and	
dewaxed	with	histosafe	(Adamas,	Rhenen,	The	Netherlands)	followed	by	rehydration	
in	decreasing	concentrations	of	alcohol	(100–50%)	and	demineralized	water.	These	
sections	were	 hematoxylin-eosin	 (HE)	 stained	 for	 assessment	 of	 histopathological	
features. Furthermore, immunohistochemical (IHC) staining was performed with 
monoclonal	antihuman	primary	antibodies	 specific	 for	CD3	 (dilution	 1	 :	 500,	 clone	
F7.2.38;	Abcam,	Cambridge,	UK)	and	elastase	(dilution	1	:	50,000,	clone	NP57;	Dako)	
together with a hematoxylin counterstaining. It was shown by de Jong et al. that B 
lymphocytes	did	not	invade	the	dermis	and	epidermis	after	topical	LTB4	application9. 
Therefore only CD3 and elastase staining was performed to stain T lymphocytes and 
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PMN,	 respectively.	 The	 sections	 for	 IHC	 staining	were	 pretreated	with	 peroxidase	
block	 (Dako).	For	 the	CD3	 immunostaining,	 the	sections	were	antigen	retrieved	by	
boiling	the	sections	in	EDTA	(pH	8.0,	0.5%	Tween)	for	10	min.	Antigen	retrieval	was	
not	needed	to	perform	the	elastase	staining.	All	sections	were	air	dried	and	immersed	
in	phosphate	buffered	saline	(PBS).	This	initial	step	was	followed	by	incubation	for	15	
min with 1% bovine serum albumin (Organon Technika, Boxtel, the Netherlands) in 
PBS.	Next,	overnight	incubation	with	the	primary	antibody	was	performed.	This	step	
was	followed	by	incubation	with	HRP	antimouse	Envision	(Dako)	for	30	min.	To	detect	
CD3	or	elastase,	the	sections	were	washed	in	PBS	and	the	HRP	was	visualized	using	
3,3”	 diaminobenzidine.	 Sections	 were	 counter-stained	 with	 Mayer’s	 hematoxylin	
(Sigma,	St	Louis,	MO,	USA)	and	were	after	dehydration	mounted	in	Permount	(BDH	
Chemical,	Poole,	UK).	Finally,	the	sections	were	photographed	at	a	magnification	of	
100x and 200x using a microscope (Axioskop2 MOT; Zeiss, Jena, Germany), digital 
camera	(Axiocam	MRc5;	Zeiss),	and	AxioVision	software	(Zeiss).
Analyses
All	RCM	 images	were	evaluated	 for	 the	presence	of	highly	 reflective	 inflammatory	
cells.	The	location	and	the	appearance	of	these	cells	were	described.	For	each	time	
point, mean values ± SD for average thickness of the stratum spinosum were 
calculated	based	on	the	histological	images	(epidermal	surface/length).	The	minimal	
epidermal thickness was determined for the RCM as well as the histological images. 
For the RCM images, two Vivastacks were evaluated. The stratum spinosum thickness 
was	 determined	 by	 counting	 the	 steps	 (4.5	 μm)	 in	 depth,	 starting	 at	 the	 stratum	
granulosum	till	the	first	dermal	papillae	appeared.	The	minimal	epidermal	thickness	
present	in	the	histological	sections	was	determined	by	the	average	of	the	five	thinnest	
points of the epidermis. RCM and histological minimal epidermal thickness values 
were	 compared	 and	 tested	 for	 statistical	 differences	 by	 an	 independent	 t-test	
analysis. Throughout the analysis, p values	<0.05	were	considered	significant.
Results
PMN appearance through the stratum spinosum
Twenty	four	hours	after	topical	application	of	LTB4,	 in	six	of	 the	seven	volunteers,	
highly	reflective	ill-defined	particles	with	a	granular	content	in	the	stratum	granulosum	
and spinosum were observed by RCM (Figure 1). The clinical, histological, and RCM 
data	 of	 one	 volunteer	 showed	 the	 absence	 of	 an	 inflammatory	 response.	 For	 the	
volunteers	that	showed	a	response,	the	highly	reflective	cells	in	the	stratum	spinosum	
corresponded	to	the	elastase	positive	cells	observed	in	the	elastase	stained	sections	
and	therefore	were	considered	to	be	PMN.	CD3	positive	cells	were	not	present	at	this	
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time	point	(Figure	2).	With	RCM,	the	PMN	appeared	differently	from	bottom	to	top	of	
the	epidermis,	representing	the	changes	of	these	cells	during	migration.	At	the	deep	
stratum	spinosum,	closely	to	the	dermal-epidermal	junction,	these	cells	appeared	as	
solitary	 small	 round	 to	 oval	 bright	 particles.	 Moving	 more	 upward,	 these	 cells	
transformed	 into	 larger	 ill-defined	 granulated	 highly	 reflective	 cells.	 The	 massive	
infiltrate	of	highly	reflective	PMN	cells	disturbs	the	regular	honeycomb	pattern,	which	
is normally seen by RCM at the level of the stratum spinosum (Figure 1). PMN 
visualization	in	the	dermis	was	not	possible	due	to	limited	resolution	in	depth.	The	
resolution	was	limited	by	the	highly	reflective	PMN	cells	in	the	upper	epidermal	layers	
and the development of mild acanthosis (Figure 3).
Accumulation and degeneration of PMN over time
The	accumulations	of	highly	reflective	PMN	were	seen	at	the	upper	stratum	spinosum	
and	the	stratum	corneum.	The	formation	of	these	accumulations	started	24h	after	
LTB4	application.	At	this	time	point	large,	highly	reflective	individual	cells	and	some	
clusters	 of	 cells	 appeared.	 Interestingly,	 high	 in	 the	 stratum	 spinosum,	 these	 cells	
seem to vibrate to some extent. This is demonstrated in the video, which is available 
at	 http://onlinelibrary.wiley.com/doi/10.1111/srt.12181/suppinfo.	 Forty	 eight	 hours	
after	topical	application	of	LTB4,	the	appearance	of	these	cells	became	less	reflective	
and more homogenous with vague cellular contours. One day later, some rests of the 
previously	 highly	 reflective	 cells	 were	 present.	 These	 RCM	 features	 indicated	
degeneration	 of	 the	 PMN	 accumulations,	 which	 was	 confirmed	 by	 the	 CD3	 and	
elastase	IHC	staining.	CD3	positive	cells	were	only	visible	in	the	dermis	at	48-72h	after	
application	of	LTB4.	These	cells	were	not	detectable	with	RCM	due	to	the	location	in	
the dermis and the thickening of the epidermis (Figure 2 and Figure 3).
Stratum spinosum thickness
Based	on	the	histological	sections,	topical	application	of	LTB4	resulted	in	an	increase	
in	the	mean	stratum	spinosum	thickness	over	time	(Figure	3a).	Twenty	four	and	48h	
after	 LTB4	 application,	 the	 maximum	 stratum	 spinosum	 depth	 could	 not	 be	
determined	with	RCM	due	to	the	highly	reflective	clusters	of	cells	located	high	in	the	
stratum	spinosum.	These	cells	reflect	a	large	amount	of	the	laser	light	and	therefore	
prevent	further	penetration	of	the	light	into	the	dermis.	Therefore,	the	mean	stratum	
spinosum thickness could not be determined by RCM. However, it was possible to 
determine	the	minimum	stratum	spinosum	depth,	defined	as	the	depth	at	which	the	
first	dermal	papillae	were	visible.	In	the	studied	skin	inflammation	model,	this	minimal	
epidermal	 thickness	 increased	 over	 time	 and	 measurements	 based	 on	 the	 RCM	
images corresponded very well with measurements performed on the histological 
images.	No	significant	difference	was	found	between	the	two	methods	(Figure	3b).
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Figure 1.	Application	of	leukotriene	B4	(LTB4)	causes	influx	of	highly	reflective	cells	in	
the	 epidermis.	 Reflectance	 confocal	 microscopy	 Vivastack	 images	 of	 normal	 skin	
before	 LTB4	 application	 (a–d)	 and	 24h	 after	 LTB4	 application	 (e–h). The stratum 
granulosum (a) and stratum spinosum (b),	showing	a	regular	honeycomb	pattern.	(c) 
Dermal-epidermal	junction	at	which	the	dermal	papillae	are	visible.	(d) Upper dermal 
layer. (e)	At	 the	 stratum	granulosum,	 large	highly	 reflective	 ill-defined	cells	with	a	
granular content are present. (f) In the stratum spinosum, large and small highly 
reflective	 cells	 are	 visualized.	 (g)	 At	 the	 dermal-epidermal	 junction,	 mainly	 small	
highly	reflective	cells	are	present.	(h)	Highly	reflective	cells	could	not	be	identified	in	
the	dermis	due	to	the	limited	light	penetration	caused	by	the	highly	reflective	cells	in	
the upper epidermal layers.
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Figure 2.	 Accumulation	 of	 polymorphonuclear	 neutrophils	 (PMN)	 24,	 48,	 and	 72h	
after	leukotriene	B4	(LTB4)	application.	(a–d)	Reflectance	confocal	microscopy	(RCM)	
images	 at	 the	 level	 of	 the	 stratum	 spinosum.	 Large,	 highly	 reflective	 cells	 were	
observed	 24h	 after	 LTB4	 application	 (b). Within the next 24h, the appearance of 
these	cells	became	less	reflective	and	more	homogenous	with	vague	cellular	contours	
(c).	At	72h,	some	rests	of	the	previously	highly	reflective	cells	were	present	(d). (e–h) 
Corresponding	elastase	stained	tissue	sections.	Elastase	positive	cells	infiltrated	the	
dermis	and	epidermis	24h	after	LTB4	application.	These	PMN	accumulated	high	in	the	
epidermis corresponding to the RCM images. At 48h, PMN cells started to degenerate 
and	72h	after	LTB4	application	hardly	any	elastase	positive	cell	was	present.	(i–l) CD3 
stained	tissue	sections.	The	first	24h	after	LTB4	application,	no	CD3	positive	T	cells	
were present (i–j).	 At	 48h,	 CD3	 positive	 cells	 infiltrate	 the	 dermis	 (k). A few 
CD3-positive	cells	were	present	in	the	dermal	layer	(l) 24h later.
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Discussion
In this study, the ability and value of noninvasive in vivo RCM imaging as tool for 
studying	dynamic	inflammatory	processes	in	the	skin	was	evaluated	by	using	the	LTB4	
skin	 inflammation	model.	The	changes	 in	 the	skin	were	 followed	with	RCM	during	 
the	 first	 72h	 after	 topical	 application	 of	 LTB4.	 RCM	 images	 were	 correlated	 with	
conventional	histopathology.
	 Conventional	histopathological	HE	stained	sections	displayed	that	topical	application	
of	LTB4	resulted	in	PMN	infiltration	in	the	epidermis	between	8	and	48h.	Our	findings	
are in line with results reported by others5,8,9,26,27. RCM was able to visualize the highly 
Figure 3. Epidermal thickness measurements. (a) Mean epidermal thickness measurement 
based	on	the	histological	sections	of	five	volunteers.	(b) Comparison measurements 
of the minimal epidermal thickness measured on histological pictures (black bars) and 
reflectance	confocal	microscopy	Vivastacks	(white	bars).	(c)	Representative	pictures	
of	hematoxylin-eosin	stained	skin	tissues	before,	24,	48,	and	72h	after	leukotriene	B4	
application.
77
APPLICATION OF RCM IN INFLAMMATORY SKIN DISEASE
2
reflective	PMN	over	this	time	interval.	PMN	migration	and	cellular	appearance	was	
imaged	from	the	dermal-epidermal	junction	up	to	the	stratum	corneum.	High	in	the	
stratum	spinosum,	PMN	appearance	seen	with	RCM	fitted	well	to	the	description	of	
neutrophils by Debarbieux et al.15.	 Over	 time,	 the	 dynamic	 process	 of	 PMN	
accumulation	 and	 degeneration	 at	 the	 level	 of	 the	 stratum	 corneum	 was	 clearly	
visible with RCM. The observed morphological changes correspond to the cell 
biological	knowledge	of	PMN	migration,	accumulation,	and	degeneration,	which	 is	
also	described	in	psoriatic	lesions18,22. Individual cells and clusters of PMN appeared 
as	highly	reflective	cells,	whereas	degenerated	cell	fragments	appeared	as	dense	low	
reflective	 structures	 in	 which	 no	 cellular	 contours	 could	 be	 identified,	 likely	 to	
correspond	to	the	pyknosis	and	karyorrhexis	stages	of	apoptotic	cells22.
	 Epidermal	thickness	as	a	result	of	LTB4	application	is	a	known	phenomenon26,27. 
However,	 to	 the	 best	 of	 our	 knowledge,	 we	 are	 the	 first	 who	 demonstrated	 the	
accurate	 correlation	 between	 stratum	 spinosum	 thickness	 measurements	 on	
histological	sections	and	RCM	images.	The	results	of	this	study	confirm	that	RCM	can	
be	 used	 to	 noninvasively	 evaluate	 dynamic	 inflammatory	 processes	 and	 cell	
morphology in the epidermis.
 Debarbieux et al. stated that with RCM, neutrophils appear morphologically 
clearly	different	from	lymphocytes15.	However,	it	was	not	investigated	whether	it	is	
possible	to	differentiate	between	these	two	cell	types	within	one	lesion.	We	tried	to	
study	this	in	the	LTB4	model	in	which	the	PMN	infiltrate	is	followed	by	a	mononuclear	
cell	infiltrate	in	the	dermis	48-72h	after	application.	Unfortunately,	the	thickening	of	
the	 epidermis,	 as	 a	 result	 of	 LTB4	 application,	 in	 combination	 with	 relative	 high	
reflectivity	 of	 inflammatory	 cells	 in	 the	epidermis	 limits	 light	 penetration	 into	 the	
dermis.	Therefore,	it	was	not	possible	to	distinguish	between	PMN	and	mononuclear	
cells in this model using RCM imaging. However, we would like to stress that the use 
of	RCM	in	combination	with	the	LTB4	model	 is	an	excellent	method	to	study	PMN	
dynamics and morphology in vivo.
	 The	vibration	of	the	PMN	highly	in	the	epidermis	is	a	remarkable	new	feature,	
which	 seem	 to	be	 very	 specific	 for	 PMN.	Probably,	 this	 vibration	on	 the	 real-time	
images	is	caused	by	the	complexity	of	these	polynucleated	cells.	The	light	reflected	
by	these	complex	and	large	cells	will	be	more	scattered	compared	to	cells	with	a	small	
round nucleus. Further, it might be possible that these cells really vibrate to some 
extent,	as	they	are	trafficking	toward	the	stratum	corneum.	However,	the	velocity	of	
the	trafficking	of	these	cells	is	not	yet	investigated.
	 In	 summary,	 RCM	 seems	 to	 be	 a	 promising	 technique	 in	 investigating	 and	
diagnosing	neutrophilic	skin	conditions,	which	often	provide	a	diagnostic	challenge.	
In	 these	cases,	obtaining	a	good	and	efficient	diagnosis	will	 result	 in	direct	proper	
treatment and might even prevent treatment failure. The noninvasive character, the 
specific	PMN	infiltrate,	and	the	possibility	to	obtain	multiple	in vivo images from the 
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same	location	over	time	make	that	RCM	in	combination	with	the	LTB4	model	a	useful	
tool	 to	study	 the	dynamics	and	 function	of	PMN	 in	 inflammatory	processes	 in	 the	
skin.	 Studying	 PMN	 migration,	 accumulation,	 and	 degeneration	 in	 this	 skin	
inflammation	 model	 can	 improve	 our	 understanding	 on	 the	 pathogenesis	 of	
neutrophilic	conditions	and	might	contribute	to	the	development	of	new	therapies.
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CHAPTER 2
Abstract
Reflectance	 confocal	 microscopy	 (RCM)	 is	 an	 imaging	 tool,	 which	 visualizes	 the	
epidermal skin layers in vivo	with	a	cellular	resolution.	Neutrophil	accumulation	is	a	
characteristic	feature	in	psoriasis	and	is	thought	to	play	a	role	in	the	pathophysiology	
of	psoriasis.	Until	now,	imaging	of	neutrophil	accumulation	in vivo is not performed. 
We	 evaluated	 the	 dynamics	 of	 neutrophil	 migration	 in	 active	 psoriatic	 lesions	 by	
non-invasive	RCM	imaging.	Additionally,	we	evaluated	the	time	phasing	and	duration	
of	 neutrophil	 trafficking.	We	performed	RCM	 imaging	 prior	 to	 the	 start	 of	 topical	
treatment	and	for	seven	consecutive	days	with	a	24h	time	interval	at	the	Radboud	
University	Medical	 Center,	 Nijmegen,	 the	 Netherlands.	 Twelve	 psoriatic	 lesions	 in	
three	patients	with	a	severe	exacerbation	of	psoriasis	were	included.	The	four	most	
active	lesions	were	selected	in	each	patient	based	on	the	highest	degree	of	redness,	
induration	and	expansion	in	the	previous	2	weeks.	In	all	 lesions,	a	cyclic	pattern	of	
neutrophil	migration	was	observed,	consisting	of	squirting	papillae,	transepidermal	
migration,	 accumulation	 in	 the	 stratum	 spinosum,	 accumulation	 in	 the	 stratum	
corneum	 and	 degeneration	 of	 the	 abscesses.	 The	 time	 interval	 of	 a	 neutrophil	
trafficking	cycle	was	5–7	days	and	showed	a	synchronic	time	phasing.	This	study	is	the	
first	 to	establish	 the	dynamics	and	time	phasing	of	neutrophil	migration	 in vivo in 
psoriatic	lesions.	Previously	reported	theories	were	confirmed	by	these	novel	in vivo 
data.	RCM	might	distinguish	between	active	or	chronic	psoriatic	areas,	which	might	
contribute to new insights into the pathogenesis of psoriasis.
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Introduction
The	 highly	 characteristic	 morphology	 of	 the	 accumulation	 of	 polymorphonuclear	
neutrophils (PMN) is pathognomonic for psoriasis1.	 This	 accumulation	 of	 neutrophils	
occurs	in	four	consecutive	phases.	First,	the	PMN	migrate	out	of	the	capillaries	inside	
the	dermal	papillae	into	the	overlying	thinned	suprapapillary	plate	(‘squirting	of	the	
papillae’)2,3.	 Subsequently,	 the	 PMN	 traffic	 upwards	 through	 the	 stratum	 spinosum.	
Then,	PMN	accumulate	in	the	upper	part	of	the	Malpighian	layer.	The	keratinocytes	
that	surround	the	PMN	accumulation	degenerate	and	form	a	cavity.	The	accumulation	
of	neutrophils	within	 a	 spongiotic	pustule	 is	 called	 ‘spongiform	pustule	of	 Kogoj’1. 
In	the	last	phase,	neutrophils	migrate	upwards	in	the	direction	of	the	stratum	corneum	 
and form microabscesses of Munro. These microabscesses are located almost exclusively 
within an area of parakeratosis and are typically located above dermal papillae2,4.
	 Although	the	accumulation	of	neutrophils	 is	a	hallmark	of	psoriasis,	 spongiform	
pustules of Kogoj and microabscesses of Munro are reported in only 10% and 41% of 
psoriatic	lesions,	respectively2-4.	The	presence	during	a	limited	time	interval	is	consistent	
with	 a	 cyclic	 pattern3.	 Intermittent	 squirting	 of	 dermal	 papillae	 and	 the	 alternating	
pattern	of	orthokeratosis	and	parakeratosis	are	additional	histological	clues	pointing	
towards	a	cyclic	and	variable	activity	in	a	psoriatic	lesion2,3. The histological heterogeneity 
of	 psoriasis	 is	 consistent	with	 the	 clinical	 variable	 pattern	of	 psoriasis,	 consisting	of	
remissions	and	exacerbations3,5. Van de Kerkhof et al. related the presence of PMN to 
enlarging and very early lesions of psoriasis1,2,6.	Griffin	et	al.	reported	that	the	presence	
of	neutrophils	was	associated	with	acute	areas	within	a	psoriatic	lesion	and	that	the	
absence of PMN was related to more chronic areas7.	Therefore,	active	or	chronic	lesions	
might	be	based	on	a	different	pathophysiological	mechanism.
 Currently, psoriasis is predominantly considered to be a disorder of innate 
immunity.	The	recruitment	and	activation	of	preferentially	T	helper	1	cells	by	natural	
killer	T	cells,	dendritic	cells	and	keratinocytes	play	a	key	role	in	the	pathogenesis	of	
psoriasis8,9.	Further,	growth-related	oncogene	α	and	interleukin-8	are	major	chemo-
attractants	that	contribute	to	neutrophil	diapedesis	and	migration10,11.	Production	of	
interleukin-8	 by	 keratinocytes	 is	 enhanced	by	 interleukin-17,	which	 is	 produced	 in	
large amounts by PMN. Interleukin-17 has a major role in the pathogenesis of psoriasis, 
because	drugs	targeting	this	cytokine	are	highly	effective12,13. Therefore, neutrophils 
are also thought to be important. Drugs causing a dose-dependent decrease in 
neutrophil	counts	are	highly	effective	in	the	treatment	for	psoriasis5,6,14,15.	Additionally,	
established treatments for psoriasis (e.g. ultraviolet B phototherapy, methotrexate 
and	topical	corticosteroids)	have	a	high	variability	in	mode	of	action,	but	all	 inhibit	
PMN	migration6. Although neutrophils are thought to play an important role in the 
pathogenesis	of	psoriasis,	signals	for	neutrophil	diapedesis	and	migration	in vivo are 
not yet fully understood.
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	 Previously,	 the	 dynamics	 of	 PMN	migration	was	 studied	 by	 the	 application	of	
leukotriene	 B4	 (LTB4).	 LTB4	 is	 a	 highly	 specific	 leucocyte	 chemoattractant	 that	 is	
naturally	present	in	lesional	psoriatic	skin.	Epicutaneous	application	of	LTB4	induces	
artificial	 intra-epidermal	 PMN	accumulation	with	well-established	time	 and	 phase	
intervals4,16-21.	However,	 to	 the	best	of	our	 knowledge,	no	 real-time	 in vivo studies 
have	been	performed	so	far	that	evaluate	the	dynamics	of	leucocyte	accumulation	in	
psoriasis	 or	 any	 inflammatory	 skin	 disease.	 The	 random	 pattern	 of	 neutrophil	
migration	in	psoriasis	is	another	major	difficulty	in	studying	the	dynamics	of	neutrophil	
trafficking.	 In vivo	 imaging	 of	 active	 lesions	 and	 imaging-guided	 biopsies	 could	
improve	the	understanding	of	the	cyclic	pattern	of	neutrophil	migration.
	 Reflectance	confocal	microscopy	(RCM)	is	a	novel,	non-invasive	imaging	technique.	 
It	can	 image	the	superficial	 layers	of	 the	skin	with	a	 resolution	that	 is	comparable	 
to	 conventional	 light	microscopy22,23. Currently, this technique is mainly used to study 
melanocytic	cells	and	lesions,	but	also	to	evaluate	skin	barrier	function22,24-26. Further, 
well-established	 histological	 features	 of	 psoriasis	 and	 other	 inflammatory	 skin	 lesions	 
can	be	visualized	with	 this	 technique,	 including	characteristic	PMN	accumulations.	 
It has been shown that these RCM images correlated highly with histology27-31.
	 The	previously	reported	theories	about	the	phases	of	neutrophil	trafficking	and	
the	fact	that	RCM	might	distinguish	between	active	or	chronic	psoriatic	areas	might	
contribute to new insights into the pathogenesis of psoriasis. Therefore, the aim of 
this	study	was	to	evaluate	the	dynamics	and	the	time	interval	of	neutrophil	migration	
by	RCM,	focussing	on	the	previously	described	phases	of	neutrophil	extravasation,	
epidermal	migration,	accumulation	in	the	stratum	spinosum	(micropustules	of	Kogoj)	
and	accumulation	in	the	stratum	corneum	(microabscesses	of	Munro).
Materials and methods
Patients
We	performed	a	pilot	 study	 in	 12	psoriatic	 lesions	of	 three	patients	with	a	 severe	
exacerbation	of	psoriasis,	because	neutrophil	migration	is	more	prominent	in	patients	
with	unstable	psoriasis.	In	each	patient,	the	four	most	active	lesions	were	selected	
based	on	the	most	prominent	redness,	 induration	and	expansion	in	the	previous	2	
weeks.	The	patients	were	recruited	from	the	Department	of	Dermatology,	Radboud	
University Medical Center, Nijmegen, the Netherlands. This study was approved by 
the	local	medical	ethics	committee	and	was	conducted	according	to	the	principles	of	
the	 Declaration	 of	 Helsinki.	 The	 patients	 gave	 written	 informed	 consent	 prior	 to	
inclusion.	The	lesions	displayed	characteristic	erythematosquamous	plaques	covering	
the	trunk,	arms,	legs,	intertriginous	areas,	face	and	scalp.	In	two	patients,	the	lesions	
were	located	on	the	dorsal	side	of	the	forearm,	and	in	one	patient	on	the	extensor	
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surface	of	the	upper	leg.	One	of	the	patients	was	treated	with	dithranol,	topical	cor-
ticosteroids	 and	methotrexate	 22.5	mg	 a	 day.	 The	 other	 patients	 received	 topical	
treatment	with	dithranol	for	4	days	followed	by	tacrolimus,	corticosteroids	and	coal	
tar 10%. The lesions selected for RCM imaging were not treated during the study.
Study protocol
Transparent body charts were used to outline the lesions at baseline to allow 
colocalization	 during	 follow-up.	 RCM	 imaging	 was	 performed	 before	 the	 start	 of	
topical	treatment	(baseline)	and	for	seven	consecutive	days,	with	a	24h	time	interval.	
Before	 RCM	 imaging,	 a	 hyperkeratotic	 scale	was	 carefully	 removed	with	 a	 pair	 of	
tweezers	to	limit	light	scatter	and	optimize	penetration	depth.	An	area	of	15	cm	x	15	
cm	surrounding	the	lesions	was	outlined	and	patients	were	not	allowed	to	the	use	
any	psoriatic	treatment	on	this	area	during	the	study,	besides	non-medicated	topical	
dressings.
RCM imaging
Confocal imaging was performed with a commercially available VivaScope 1500 
System (Lucid Inc, Rochester, NY, USA). This confocal microscope comprises a 
near-infrared 830-nm low-power laser beam. RCM obtains horizontal (en face) images 
of	 the	 skin,	 in	 contrast	 to	 the	 vertical	histological	 sections.	 Images	were	obtained	
using	 VivaScan	 7.0	 Software	 (Lucid	 Inc,	 Rochester,	 NY,	 USA).	 A	 more	 detailed	
description	of	the	system	has	been	published	previously23,27,29,31-33. RCM imaging was 
performed according to a standardized protocol. Horizontal mapping (4 mm x 4 mm) 
was performed at the level of the stratum corneum, stratum granulosum, stratum 
spinosum	and	at	the	dermal-epidermal	junction	(DEJ).	Vertical	mapping	was	obtained	
by capturing a series of images in depth (0.5 mm x 0.5 mm), with steps of 5 µm. The 
mapping	started	at	the	top	of	the	stratum	corneum	until	the	DEJ.	Additional	images	
were	made	when	neutrophil	trafficking	or	accumulation	was	observed.	Movies	were	
made	 at	 the	 level	 of	 the	DEJ	 to	 capture	 capillary	 blood	flow	and	 the	 presence	or	
extravasation	of	neutrophils.
Biopsies: HE staining and immunohistochemistry
After	RCM	imaging,	in	four	lesions	4-mm	punch	biopsies	were	taken	at	day	seven	for	
correlation	 to	 the	 RCM	 images.	 Local	 anaesthesia	 was	 used	 with	 1%	 xylocain/
adrenalin.	The	biopsies	were	fixed	in	formalin	10%	and	embedded	in	paraffin.	Sections	
(5	µm)	were	haematoxylin–eosin	(HE)	stained	for	the	assessment	of	histopathological	
features.	 Additionally,	 immunohistochemical	 staining	was	 performed	with	monoclonal	
antibodies	specific	for	CD3	(1:100	and	1:500)	(clone	F7.2.38,	Abcam,	Cambridge,	UK)	
and	elastase	(1:10	000	and	1:50	000)	(clone	NP57,	Dako,	Denmark).	All	sections	were	
pretreated with peroxidase block (Dako, Copenhagen, Denmark). For the CD3 
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immunostaining,	the	sections	were	antigen-retrieved	by	boiling	the	sections	in	EDTA	
(pH	 8.0,	 0.5%	 Tween)	 for	 10	 min.	 All	 sections	 were	 air-dried	 and	 immersed	 in	
phosphate-	buffered	saline	(PBS).	For	both	stainings,	this	initial	step	was	followed	by	
incubation	for	15	min	with	1%	bovine	serum	albumin	(Organon	Technika,	Boxtel,	the	
Netherlands)	 in	 PBS.	 Next,	 overnight	 incubation	 with	 the	 primary	 antibody	 was	
performed.	 This	 step	 was	 followed	 by	 incubation	 with	 HRP	 anti-mouse	 Envision	
(DAKO, Copenhagen, Denmark) for 30 min. CD3 or elastase were visualized using 3,3- 
diaminobenzidine	 (DAB).	The	 sections	were	counterstained	with	Mayer’s	haematoxylin	
(Sigma, St Louis, USA) and mounted in Permount (BDH chemical, Poole, England). 
For	better	correlation	with	the	en face RCM images, the biopsies were re-embedded 
in	 an	 orientation	 parallel	 to	 the	 skin	 surface	 (en face),	 sectioned	 (5	 µm)	 and	 HE	
stained.	The	sections	were	photographed	at	a	magnification	of	10x,	20x	or	40x	using	
a microscope (Axioskop2 MOT; Zeiss, Oberkochen, Germany), digital camera (Axiocam 
MRc5;	Zeiss)	and	AxioVision	software	(Zeiss).
Results
In	all	lesions,	a	cyclic	pattern	of	neutrophil	migration	was	observed,	consisting	of	four	
consecutive	 phases.	 An	 overview	 of	 the	 RCM	 images	 of	 the	 neutrophil-trafficking	
cycle	and	the	corresponding	HE	stained	tissue	sections	is	shown	in	Figure	1	and	Figure	2.	
The	time	interval	of	one	neutrophil-trafficking	cycle	was	5–7	days.	Within	one	lesion,	
a high variability was seen in the number and size of the areas where neutrophil 
trafficking	occurred.	Further,	the	neutrophil	cycle	showed	a	synchronic	time	phasing	
throughout the lesion. During follow-up, lesions either re-entered a neutrophil- 
trafficking	cycle	or	showed	normalization	of	the	psoriatic	histological	features.	
Neutrophil extravasation and trafficking 
Prior	to	the	start	of	the	neutrophil-trafficking	cycle,	an	increased	capillary	blood	flow	
was seen inside the predominantly en face orientated capillaries at the DEJ. A large 
number	of	red	blood	cells	and	inflammatory	cells	were	observed	inside	the	capillary	
lumen by the quick movement of bright round cells. Neutrophil rolling and adhesion 
to the capillary endothelium was seen as a bright rim of dense, round to oval 
neutrophils adhering to the capillary wall (Figure 1, Figure 2 and Video S1, which is 
available	at	http://onlinelibrary.wiley.com/doi/10.1111/exd.12345/suppinfo).	Then,	the	
PMN extravasated out of the capillaries into the overlying stratum spinosum. Notably, 
the	PMN	extravasated	at	the	same	time	in	a	phasewise	manner,	representing	squirting	
papillae. Subsequently, the PMN migrated through the stratum spinosum towards 
the	stratum	corneum.	The	trafficking	was	located	just	above	the	tips	of	the	dermal	
papillae,	which	formed	a	column-like	appearance	of	upwards	migrating	PMN	(Figure	1).
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Accumulation of neutrophils in the upper epidermal layers
About	24h	after	extravasation,	PMN	accumulated	at	the	level	of	the	upper	stratum	
spinosum and stratum corneum, and here, they formed micropustules of Kogoj and 
microabscesses	of	Munro,	respectively.	The	micropustules	of	Kogoj	were	seen	as	an	
aggregation	of	bright	cells	surrounded	by	a	dark	acellular	area.	Based	on	histology,	
these cells corresponded to the presence of PMN. The surrounding stratum spinosum 
showed	a	flattened	honeycomb	pattern.	The	Munro	microabscesses	had	a	distinct	
morphology	 of	 large,	 polyform,	 very	 bright	 cells	 aggregating	 at	 the	 level	 of	 the	
stratum corneum. Based on histology, these cells represented PMN. In all lesions, 
parakeratosis was observed adjacent to the Munro microabscesses, which was shown 
as retainment of bright nuclei in dark corneocytes.
Figure 1.	Reflectance	confocal	microscopic	images	of	a	psoriatic	lesion	with	neutrophil	
extravasation,	migration	and	accumulatin.	(a) Vivablock of 1 mm x 1 mm at the level of 
the	tips	of	the	dermal	papillae.	Accumulations	of	polymorphonuclear	neutrophils	(PMN)	
are	 observed	 just	 above	 the	 tips	 of	 the	 dermal	 papillae	 (white	 asterisk).	 The	 PMN	
migrate towards the stratum corneum and aggregate (red asterisk). (b) Stack showing a 
squirting	papilla.	Leucocyte	rolling	and	adhesion	to	the	capillary	endothelium	occurs	at	
the	 level	 of	 the	 dermal-epidermal	 junction	 (b1). PMN cluster, extravasate (b2) and 
migrate	out	of	the	tips	of	the	dermal	papillae	into	the	overlying	stratum	spinosum	(b3). 
Finally, they travel towards the stratum corneum and form a micro- abscess of Munro 
(b4). (c)	At	the	level	of	the	dermal-epidermal	 junction,	there	is	 leucocyte	rolling	and	
adhesion	to	the	capillary	endothelium	in	areas	with	high	capillary	blood	flow.
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Degeneration of abscesses
The	abscesses	started	to	degenerate	about	24h	after	their	formation.	An	overview	of	
the	RCM	images	showing	abscess	degeneration	is	given	 in	Figure	3.	First,	the	PMN	
became	 less	 bright	 and	 had	 an	 increasingly	 vague	 cellular	 contour,	 resulting	 in	 a	
homogeneous grey area. About 24h later, a dark area was seen with only a few 
scattered	bright	round	PMN,	representing	further	degeneration	of	the	abscess.
Figure 2. Transverse and corresponding en face	histology	of	neutrophil	accumulations	
in	a	psoriatic	lesion.	(a)	Tissue	sections	stained	with	haematoxylin-eosin	(HE)	(a1), CD3 
(a2) and elastase (a3).	The	histology	displays	characteristic	psoriatic	features	including	
parakeratosis	 and	 acanthosis.	 Accumulation	 of	 polymorphonuclear	 neutrophils	 (PMN)	 
in the stratum corneum (arrow b1) and upper stratum spinosum (arrow b2) is seen. 
These	accumulations	predominantly	consist	of	elastase	positive	cells	(a3) and almost 
no	CD3	positive	cells	(a2). (b) En face	HE	stained	tissue	slides	corresponding	to	the	
levels indicated in a1. The PMN migrate upwards and accumulate at the stratum 
corneum. Further, adjacent parakeratosis is seen (asterisk, b1). Then, they migrated 
through the stratum spinosum (arrow), cluster together and form a large abscess 
(b5,	with	a	higher	magnification	in	b2).	At	the	tips	of	the	dermal	papillae,	the	PMN	
extravasate	out	of	the	capillaries	into	the	overlying	stratum	spinosum,	representing	
squirting	 papillae	 (b3). There is leucocyte adhesion to the capillary endothelium 
(arrow	b4)	at	the	level	of	the	dermal-epidermal	junction.	Many	red	blood	cells	can	be	
seen	in	the	capillary	lumen,	with	high	capillary	blood	flow	during	RCM	imaging	(b4).
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Neutrophil morphology
Interestingly,	the	morphology	of	the	PMN	changed	during	the	several	phases	of	the	
neutrophil-trafficking	 cycle.	When	 the	 PMN	were	 located	 inside	 the	 capillaries	 or	
extravasated	 into	the	overlying	stratum	spinosum,	they	were	highly	refractive	and	
had	a	round	to	oval	shape.	While	trafficking	though	the	stratum	spinosum,	the	PMN	
showed a less round and more polyform appearance. When the PMN accumulated 
and formed microabscesses of Munro, they had a prominent appearance of very 
bright, large cells with a polygonal shape.
Figure 3.	Reflectance	confocal	microscopic	(RCM)	images	of	a	Munro	microabscess	and	
micropustules	of	Kogoj	at	baseline	and	after	24,	48	and	72h.	(a) RCM image at the level 
of	the	upper	stratum	spinosum.	There	are	multiple	accumulations	of	highly	reflective	
polymorphonuclear neutrophils (PMN) surrounded by a dark area (white arrows). These 
accumulations	 are	 located	 above	 the	 tips	 of	 the	 dermal	 papillae	 forming	 circular	
patterns	with	a	size	comparable	to	the	underlying	papillae.	The	red	asterisk	represents	
an	area	of	stratum	spinosum	surrounding	the	neutrophil	accumulations.	(b) At the level 
of the stratum corneum, the PMN aggregate (white asterisk) and form abscesses (red 
asterisk). Stratum spinosum cells degenerate and individual cellular boundaries cannot 
be	 identified.	 (c)	 After	 24h,	 the	 PMN	 cluster	 into	 one	 large	 abscess	 forming	 a	
microabscess of Munro. The PMN are very bright, large and display a polymorph 
appearance. (d)	After	48h,	the	refractivity	of	the	PMN	diminishes	and	the	 individual	
cellular outlines cannot be observed. This results in a more homogeneous appearance, 
representing	mild	degeneration	of	the	Munro	abscess.	(e)	After	72h,	only	sparse	PMN	
are	seen	(arrows),	representing	prominent	degeneration	of	the	Munro	abscess.
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Biopsies: HE staining and immunohistochemistry
The	HE	stained	tissue	sections	of	all	lesions	displayed	characteristic	psoriatic	features	
including	parakeratosis,	acanthosis	and	accumulation	of	PMN	(Figure	2).	The	accumulations	
of	neutrophils	consisted	of	elastase	positive	cells	and	no	CD3	positive	cells.	The	psoriatic	
features in the HE stained en face	tissue	sections	corresponded	highly	to	the	features	
found in the RCM images.
Discussion
In	the	present	study,	we	confirm	for	the	first	time	the	previously	described	theory	of	
the	dynamics	of	neutrophil	migration	in	psoriatic	lesions	with	in vivo data, using RCM. 
Further,	we	add	novel	data	about	the	description	of	the	duration	and	time	phasing	of	
neutrophil	 trafficking.	 In	 all	 lesions,	 a	 cyclic	 pattern	 of	 neutrophil	 migration	 was	
observed.	 This	 consisted	 of	 rhythmic	 neutrophil	 extravasation	 out	 of	 the	 dermal	
papilla,	 epidermal	 migration	 towards	 the	 stratum	 corneum,	 accumulation	 in	 the	
stratum	spinosum,	accumulation	in	the	stratum	corneum	and	phases	of	microabscesses	
degeneration.	In	the	studied	lesions,	the	time	interval	of	a	neutrophil-trafficking	cycle	
was	5–7	days.	Though,	there	could	be	a	slightly	different	interindividual	variability	in	
a	larger	study	population.	
	 Pinkus	et	al.	hypothesized	that	cycling	squirting	of	dermal	papillae	and	leucocyte	
migration	and	accumulation	can	be	found	in	psoriatic	lesions3. They described that 
these	events	are	limited	in	time	and	repeat	themselves	periodically.	However,	these	
ideas	were	only	based	on	non-dynamic	data.	Our	data	confirm	these	hypotheses	by	
in vivo	data.	Further,	 it	 is	described	that	 the	squirting	papillae	reaction	may	result	
from	focal	and	pulsed	expression	of	the	chemokines	growth-related	oncogene-α	and	
interleukin-811. However, it was also suggested that complement factor C5a is more 
closely	 related	 to	 neutrophil	 chemotactic	 activity	 than	 interleukin-8.	 Interleukin-8	
appears	to	be	a	proinflammatory	cytokine	involved	in	the	induction	of	more	baseline	
inflammatory	changes34.
	 Different	pathophysiological	mechanisms	in	acute	and	chronic	lesions	have	been	
described	 by	 Terui	 et	 al.	 They	 report	 that	 psoriatic	 lesions	 are	 not	 uniform	 but	
heterogeneous, both clinically and histologically. They propose that in chronic lesions, 
a	 T-cell-mediated	 inflammation-sustaining	 loop	 maintains	 background	 ‘chronic’	
inflammatory	changes.	In	this	loop,	lymphokines	produced	by	activated	T	cells	induce	
proliferation	 of	 the	 epidermis.	 These	 stimulated	 keratinocytes	 release	 several	
cytokines,	which	 in	 turn	enhance	 the	activation	of	T	 cells,	 forming	a	vicious	cycle.	 
In	 contrast,	 in	acute	 lesions,	 island-like	 ‘acute’	 inflammatory	changes	are	 induced.	
These	 are	 scattered	 over	 the	 chronic	 psoriatic	 plaques	 by	 a	 neutrophil-associated	
	inflammation-boosting	 loop.	 In	 this	 loop,	 accumulated	 neutrophils	 influence	 the	
93
APPLICATION OF RCM IN INFLAMMATORY SKIN DISEASE
2
growth	and	differentiation	of	keratinocytes	but	also	activate	T	cells.	These	T	cells	in	
turn	 influence	the	transepidermal	neutrophil	 trafficking	through	the	effect	of	their	
lymphokines	 on	 the	 keratinocyte	 production	 of	 proinflammatory	 mediators35. 
However, no in vivo research has been performed so far that evaluates this hypothesis, 
and	 the	 significance	 of	 PMN	accumulations	 in	 the	 epidermis	 still	 remains	 unclear.	
RCM	could	be	a	useful	tool	to	investigate	these	ideas.
	 In	dynamic	diseases	like	psoriasis,	conventional	histology	does	not	always	display	
characteristic	histological	features.	A	biopsy	might	be	obtained	too	early	or	too	late	
in the disease process and therefore is not always conclusive28. Furthermore, the 
diagnosis is mainly made clinically and a biopsy is not necessary to render the 
diagnoses.	However,	studying	dynamic	processes	like	neutrophil	accumulation	could	
improve our understanding on the pathogenesis of psoriasis. This might contribute to 
the development of new or personalized treatments. RCM will be very suitable for 
the	evaluation	of	dynamic	processes	and	new	treatments	due	to	 the	possibility	 to	
obtain	multiple	in vivo	images	from	the	same	location	non-invasively	and	over	time36. 
A	combination	of	RCM	with	novel	computational	methods	will	further	improve	the	
standardization	and	reliability	of	this	technique37.
	 In	summary,	this	study	is	the	first	to	establish	the	dynamics	and	time	phasing	of	
neutrophil	migration	in vivo	in	patients	with	psoriasis.	Therefore,	RCM	could	be	used	
to	 study	 cyclic	 neutrophil	 exocytosis	 in	 psoriasis	 and	 in	 other	 inflammatory	 skin	
disorders	non-invasively.	In	future,	RCM	might	distinguish	between	active	or	chronic	
psoriatic	 lesions,	 which	 may	 contribute	 to	 new	 insights	 into	 the	 pathogenesis	 of	
psoriasis.
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Introduction
Distinguishing	 between	 stable	 and	 unstable	 plaque	 psoriasis	 is	 of	 importance	 to	
obtain	information	on	the	course	of	psoriasis	and	to	choose	therapeutic	strategies.	
Currently,	 patient	 reports,	 clinical	 assessment,	 and	histopathology	provide	 limited	
information.	 We	 examined	 the	 ability	 of	 in vivo	 reflectance	 confocal	 microscopy	
(RCM) to noninvasively examine stable and unstable psoriasis.
Materials and Methods
Twelve	stable	and	14	unstable	psoriatic	plaques	from	13	patients	with	chronic	plaque	
psoriasis from the Radboud University Medical Center (Nijmegen, The Netherlands) 
were	 imaged	 by	 RCM	 (Vivascope	 1500)	 after	 clinical	 assessment	 (SUM	 scores).	
Statistical	analyses	(t-test, Mann Whitney, and Fisher exact tests) were applied to 13 
scored	 RCM	 features	 characteristic	 for	 psoriasis.	 Differences	 between	 center	 and	
margin were examined (Wilcoxon signed rank test), according to the hot and cold 
spot hypothesis1.	 Moreover,	 regression	 analyses	 were	 performed	 to	 define	 a	 hot	
spot.
Results
We	 found	 highly	 significant	 differences	 between	 stable	 and	 unstable	 psoriasis.	
Unstable	 plaques	 showed	a	 greater	 number	of	 inflammatory	 cells	within	 the	 (epi)
dermis, including Munro and Kogoj microabscesses (all P values < 0.01), a larger 
diameter of dermal papillae (DP) (P	=	0.03),	and	a	higher	capillary	flow	(P < 0.01) with 
more tortuous capillaries (P = 0.04) (Table 1 and Figure 1). The subgroup analyses in 
the	unstable	psoriatic	patients,	respectively	acute	exacerbated	patients	(<3	months)	
versus	chronic	progressive	patients,	showed	higher	numbers	of	dermal	inflammatory	
cells (P	 =	 0.02)	 and	 epidermal	 inflammatory	 cells	 (P = 0.01) (including Munro and 
Kogoj abscesses; P < 0.01 and P = 0.05) and edged DP (P = 0.05) in the acute 
exacerbated	patients,	which	can	be	accounted	for	by	the	duration	of	 the	unstable	
phase	in	this	group	compared	with	that	in	the	chronic	progressive	patients	(Table	1	
and Figure 1).
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Figure 1. Psoriasis. A-C,	Dermoscopic	pictures	by	Vivacam:	stable	(A), unstable (B:	chronic 
progressive; C:	 acute	 exacerbated)	 plaque.	 D-F,	 Reflectance	 confocal	 microscopy	
(RCM)	images	at	stratum	spinosum:	2	bright	round	refractive	small	inflammatory	cells	
(D),	 some	 inflammatory	 cells	 (E),	many	 inflammatory	 cells,	 but	 individual	 cells	 are	
discernible and not yet merged together to form an abscess (F). G-I, RCM images at 
dermoepidermal	 junction:	 non-edged	 dermal	 papillae	 (DP)	 with	 some	 round	 high	
refractive	inflammatory	cells	(G),	enlarged	DP	and	increased	number	of	inflammatory	
cells within the DP (H),	enlarged	DP	and	clearly	an	increased	number	of	inflammatory	
cells within the DP (I).
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Table 1.	Reflectance	confocal	microscopy	features	of	stable	and	unstable	psoriasis	
plaques (including chronic progressive and acute exacerbated psoriasis plaques). 
Stable	and	unstable	groups	were	provided	by	6	patients,	each	providing	2	psoriatic	
plaques.	Chronic	progressive	plaques	were	provided	by	3	patients,	each	providing	 
2	 psoriatic	 plaques	 (unstable	 since	 5	 to	 8	months).	 Acute	 exacerbated	 plaques	
were provided	by	3	patients,	each	providing	2	psoriatic	plaques	(unstable	since	1	to	3	
months). The results are displayed as median (range) or n (%).
Reflectance confocal  
microscopy feature
Stable plaques  
(n=12)
Unstable plaques 
(n=12)
P value
Thickness SC (µm) 21 (15-69) 25 (16-69) 0.47
Presence parakeratosis (%) 23 (4-40) 24 (2-42) 0.57
Presence SG Partly present
Absent
12
0 
(100%)
(0%)
10
2 
(83%)
(17%)
0.48
Epidermal  
inflammatory	cells	
(Nr	/cm2) 97 (0-1172) 2152 (425-10985) <0.01
Munro (Nr	/cm2) 2 (0-8) 10 (2-55) <0.01
Kogoj (Nr	/cm2) 0 (0-16) 12 (3-135) <0.01
Height of the SP (µm) 71 (51-156) 77 (59-124) 0.69
Number of DP (Nr	/cm2) 1812 (766-3031) 1996 (1406-2914) 0.29
Diameter DP                               (µm) 67 (59-79) 79 (59-147) 0.03
Edged DP (%) 24 (0-58) 0 (0-91) 0.99
Dermal  
inflammatory	cells
(Nr	/cm2) 660 (0-2925) 4713 (686-9594) <0.01
Capillary	flow Low 
High
8
4 
(67%) 
(33%)
0 
12 
(0%)
(100%)
<0.01
Section	capillaries Less tortuous
Tortuous
5
7
(42%) 
(58%)
0 
12
(0%)
(100%)
0.04
Subgroups  
unstable plaques
Chronic 
progressive  
(n=6)
Acute 
exacerbated 
(n=6)
Epidermal  
inflammatory	cells	
(Nr	/cm2) 1076 (425-4010) 4458 (1336-10985) 0.01
Munro (Nr	/cm2) 6 (2-10) 16 (11-55) <0.01
Kogoj (Nr	/cm2) 9 (3-66) 64 (10-135) 0.05
Edged DP (%) 58 (0-91) 0 (0-13) 0.05
Dermal  
inflammatory	cells
(Nr	/cm2) 1021 (686-5812) 5782 (4146-9594) 0.02
SC, Stratum corneum; SG, stratum granulosum; SP, suprapapillary plate; DP, dermal papillae.
102
CHAPTER 2
Discussion
No	differences	were	seen	between	center	and	margin,	except	there	were	more	edged	
DP at the margin in stable plaques (P = 0.01), which presumably can be accounted for 
by	a	mechanism	actively	keeping	the	 lesion	from	expanding	and	therefore	actively	
showing features of normal skin being edged DP, because edged DP are a feature of 
normal healthy skin2. In contrast, non-edged DP in psoriasis seems to be the result of 
the	inhibitory	effect	of	TNF-alfa	on	melanogenesis3.	Based	on	our	RCM	findings,	we	
can	question	the	margin	zone	model,	which	describes	more	activity	at	 the	margin	
than within the center of a plaque4.	however,	a	pitfall	in	the	present	study	might	be	
that	the	most	active	foci	could	have	been	missed	by	the	clinical	determination	of	the	
imaged	 foci.	 It	 would	 be	 reasonable	 to	 have	 an	 impression	 of	 the	 total	 psoriatic	
plaque	before	imaging	specific	spots.
 Numbers	of	epidermal	inflammatory	cells	were	predictive	for	unstable	plaques	
(P	=	0.02),	which	may	be	considered	to	be	an	RCM-defined	hot	spot.	Even	so,	we	have	
to	take	into	account	that	the	number	of	inflammatory	cells	within	a	psoriatic	plaque	
are	in	a	cyclic	pattern	from	dermis	up	to	epidermis	to	finally	form	microabscesses5. 
Future	 RCM	 technique	 development	 will	 hopefully	 lead	 to	 further	 differentiation	
between	 leukocytes.	 Furthermore,	 it	would	be	 interesting	 to	 follow	up	 (hot	 spots	
within)	psoriatic	plaques	with	RCM	after	initiating	(systemic)	therapy.
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Abstract
Background: Basal cell carcinoma (BCC) is the most frequently occurring cancer in 
humans. Worldwide incidences rise about 10% each year, increasing the burden on 
dermatologists,	general	practitioners	and	pathologists	as	well	as	increasing	costs	for	
the	health	care	system.	Increasingly	non-surgical	treatment	options	are	used	in	the	
treatment	 of	 BCC,	 without	 histological	 confirmation	 of	 BCC	 subtype,	 potentially	
resulting	in	under-treatment.
Objective: We	 evaluated	 the	 diagnostic	 accuracy	 of	 a	 punch	 biopsy	 for	 the	 BCC	
histological subytpe in a primary BCC and the prevalence of biopsy-based under-diag-
nosis	of	aggressive	subtypes.	Accuracy	of	a	punch	biopsy	was	defined	as	concordance	
of the diagnosis of subtype of BCC at punch biopsy and excision.
Methods: A	retrospective	chart-review	was	performed	of	primary	BCC,	which	were	
proven	 by	 punch	 biopsy	 and	 subsequently	 treated	 by	 excision.	 The	 first	 100	
consecutive	 BCCs	 per	 year	 during	 the	 years	 2004–2009	were	 included,	 yielding	 a	
total of 500 evaluated BCCs.
Results: The overall accuracy of punch biopsy for BCC subtype at excision was 69%, in 
single-type BCC 83% (n = 343) and in mixed-type BCC 37% (n = 157). Accuracy varied 
substantially	according	to	BCC	subtype,	being	highest	in	the	superficial	subtype	(84%)	
and	 subsequently	 in	 infiltrative	 (69%),	 nodular	 (63%)	 and	 micronodular	 subtype	
(38%). In 11% of all cases, an unsuspected more aggressive subtype was present.
Conclusion: Punch biopsy has a high accuracy in single-type BCCs and a considerably 
lower accuracy in mixed-type BCCs for establishing BCC subtype compared to 
excision. The presence of an unsuspected aggressive subtype could explain therapy 
failure of non-surgical treatments like imiquimod or photodynamic therapy.
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Introduction
Basal cell carcinoma (BCC) is the most frequently occurring cancer in humans. 
Incidence is rising rapidly, 10% each year worldwide, with about 750 000 new cases 
each year in the US alone. Soon, prevalence will equal that of all other cancers 
together.	The	rising	incidence	and	morbidity	 increase	the	burden	posed	on	patients,	
general	 practitioners,	 dermatologists,	 surgeons	 and	 pathologists.	 Furthermore,	 it	
increases	the	economic	burden	on	the	health	care	system:	in	the	United	States,	skin	
cancer	has	taken	the	fifth	place	with	respect	to	cancer	costs,	after	prostate,	lung	and	
bronchus, colon and rectum and breast cancer1-4. For these reasons it is necessary to 
revisit	 current	 diagnostic	 and	 therapeutic	 strategies	 to	 increase	 efficiency	 and	
efficacy.
	 BCC	is	a	malignant	proliferation	of	basaloid	cells.	Superficial,	nodular,	micronodular	
and	 infiltrative	 BCC	 are	 the	 most	 prevalent	 BCC	 histological	 subtypes5. Current 
management	of	BCC	 is	 largely	based	on	expected	biological	behaviour,	 correlating	
highly	to	the	histological	type	of	BCC.	Other	variables	affecting	the	choice	of	treatment	
include	 tumour	 location,	 size,	primary	or	 recurrent	 lesion,	patient	 compliance	and	
patient	preferences.	About	40%	of	all	BCCs	are	mixed-type	BCCs	 (BCC-MH).	These	
BCCs	consist	of	multiple	BCC	subtypes	 in	one	 tumour,	 in	 contrast	with	 single-type	
BCCs, which display only one subtype6-8. In BCC-MH misdiagnosis of subtype could 
well	occur	due	to	sample	error:	at	punch	biopsy	only	part	of	the	tumour	is	evaluated,	
compared	with	complete	examination	after	excision.
 Previous studies have shown discordance rates ranging between 18% and 49% 
with	respect	to	the	BCC	subtype,	comparing	initial	punch	–	or	shave	biopsy	with	the	
excision specimen6,9-12.	 If	 a	more	aggressive	 subtype	 is	missed	at	 initial	biopsy	 this	
could result in treatment failure, higher recurrence rates, unnecessary high costs and 
avoidable	burden	on	the	capacity	of	the	hospital	organization6. The gold standard to 
determine	 BCC	 subtype	 is	 the	 subtype	 established	 at	 final	 excision13. However, 
subtype at biopsy becomes more important due to the increasing use of non-surgical 
treatments,	e.g.	photodynamic	therapy	(PDT)	or	topical	application	of	Imiquimod,	for	
less aggressive histological subtypes. Non-surgical treatments have no possibility for 
histopathological	confirmation	of	subtype	and	tumour	free	margins	after	treatment14-17.
 To date, only few studies have evaluated the concordance of BCC subtype of 
initial	 punch	 biopsy	 to	 histological	 subtype	 at	 therapeutic	 excision.	 These	 studies	
show	 a	 large	 variation	 in	 biopsy	 method	 and	 type	 of	 excised	 BCCs,	 resulting	 in	
accuracy rates varying between 51% and 81%6,9-12. Reported underdiagnosis of 
aggressive subtypes ranged from 7% to 27%9,10. Izikson et al. reported that 21% of the 
BCCs	may	have	been	undertreated	due	to	application	of	a	treatment	modality	only	
appropriate	for	the	initially	diagnosed	non-aggressive	subtype10.
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	 Because	of	these	large	discrepancies,	we	evaluated	the	diagnostic	accuracy	of	a	
punch biopsy for the BCC histological subtype in a primary BCC. Furthermore, we 
evaluated the prevalence of biopsy-based underdiagnosis in more aggressive BCC 
subtypes.
Materials and methods
Patients
A	 retrospective	 chart-review	 was	 performed	 of	 biopsy-proven	 primary	 BCCs	 that	
were	subsequently	treated	by	excision.	The	first	100	consecutive	BCCs	per	year	during	
the	 years	 2004–2009	 were	 included,	 yielding	 a	 total	 of	 500	 evaluated	 BCCs.	 All	
biopsies comprised standard 3 mm punch biopsies. The Dutch pathologic anatomic 
national	computerized	database	(PALGA)	was	used	to	select	appropriate	charts	from	
the Department of Dermatology of the Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands. The PALGA database retains histopathological reports 
and	histological	diagnosis	of	all	tissues	evaluated	by	pathologists	in	The	Netherlands.	BCCs	
that	met	the	following	criteria	were	included:	(i)	diagnosis	of	a	punch	biopsy-proven	
primary BCC that was subsequently treated by excision (ii) pathology reports included 
histological subtype of both biopsy and excision specimen (iii) excision was performed 
by a dermatologist. The following exclusion criteria were applied (i) no residual BCC 
was present in the excision specimen (ii) previous radiotherapy (iii) BCC with 
incompletely excised margins at excision (iv) previous documented BCC at the same 
location,	which	could	represent	a	recurrent	BCC.
Classification and epidemiologic parameters
The	histological	classification	of	BCCs	was	reported	according	the	Dutch	guideline18. 
Superficial	 BCCs	 were	 identified	 by	 nests	 of	 basaloid	 cells	 residing	 highly	 in	 the	
epidermis,	usually	in	a	multifocal	pattern.	Nodular	BCCs	were	characterized	by	large	
nests with basaloid cells, well-circumscribed from the surroundings. Micronodular 
BCCs	were	identified	by	well-circumscribed,	small	nests	of	basaloid	cells,	with	a	size	
comparable	 to	 the	 bulbus	 of	 a	 hair	 follicle.	 Infiltrative	 BCCs	 constituted	 of	 small	
strands	 of	 basaloid	 cells	 surrounded	 by	 desmoplastic	 cytoplasm	 with	 an	 unclear	
demarcation	 to	 surrounding	 tissue.	 Four	 different	 dermatohistopathologists	 evaluated	 
the	biopsies	 and	excision	 specimens.	 The	dermatohistopathologists	 routinely	 reported	 
all subtypes seen. In case of a BCC-MH the most unfavourable subtype was noted, 
consecutively:	 infiltrative,	micronodular,	nodular	and	superficial	subtype.	Morphea	
subtype	was	categorized	as	 infiltrative	BCC.	The	dermatohistopathologists	evaluated	 
all	 the	 tissue	 slides.	 The	 corresponding	 pathology	 reports	 were	 regarded	 as	
representative.	 Histopathological	 diagnosis	 of	 the	 BCC	 subtype	 at	 excision	 was	
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considered	the	‘diagnostic	gold	standard’.	The	following	parameters	were	evaluated:	
age	 and	 gender	 of	 the	 patient,	 BCC	 location,	 BCC	 size,	 total	 number	 of	 BCCs	 per	
patient,	recurrences	and	dermatohistopathologist	who	evaluated	the	punch	biopsy	
or excision.
Statistical analysis
The	 continuous	 variables	 are	 presented	 as	mean	 and	 standard	 deviation	 and	 the	
categorical	variables	as	number	and	percentage.	Positive	predictive	value	(PPV)	was	
used to measure the accuracy of punch biopsy for BCC subtype at excision. The PPV 
of a type was calculated as the percentage of the cases with that type present at 
punch	biopsy	to	the	total	at	excision	with	that	specific	type.
Results
In	total,	356	patient-charts	(58.8%	male;	mean	±	SD	age	at	analysis	65.6	±	13.0	years,	
Table 1) were evaluated yielding a combined total of 500 BCCs. Prevalence of the BCC 
subtypes	were	consecutively	superficial	BCC	(41.8%),	nodular	BCC	(30.0%),	infiltrative	
BCC (19.6%) and micronodular BCC (8.6)%. Results of the subtypes at punch biopsy 
and excision are summarized in Table 2. 
 The overall accuracy of BCC subtype at punch biopsy for BCC subtype at excision 
was 69%, thus 31% showed discordance in BCC subtype (Table 3). Accuracy varied 
between	the	BCC	subtypes	at	biopsy:	accuracy	was	highest	in	superficial	BCC	(84%)	
and	lower	in	nodular	(63%),	infiltrative	(69%)	and	micronodular	BCC	(38%).	In	contrast	
with	 our	 expectation,	 in	 11%	 of	 all	 BCCs	 a	more	 aggressive	 subtype	was	 found	 at	
excision.
 A mixed-type BCC was found in 18.6% of all BCCs at punch biopsy and in 19.8% of 
all	 BCCs	 at	 excision.	 Prevalence	 of	 the	 BCC	 subtypes	 in	 BCC-MH	was	 sequentially	
nodular	BCC	(36.3%),	infiltrative	BCC	(35.0%),	micronodular	BCC	(16.6%)	and	superficial	
BCC	(12.1)%.	Overall	accuracy	rate	was	significantly	higher	 in	single-type	BCC	(83%,	 
n = 343) compared with BCC-MH (37%, n	=	157).	Particularly,	the	micronodular	subtype	
showed poor accuracy in BCC-MH, with an accuracy of only 27% (Table 3). In 26.8% of 
all evaluated BCCs, both biopsy and excision were evaluated by the same dermato-
histopathologist. Overall accuracy rate was similar (69%) for BCCs rated by the same 
or	by	two	different	dermatohistopathologists.
 Recurrence occurred in four BCCs (0.8%). The average follow-up was 42 months. 
Three	recurrent	BCCs	showed	a	superficial	subtype	at	punch	biopsy,	excision	and	at	
recurrence.	One	case	showed	a	superficial	 subtype	at	primary	punch	biopsy	but	a	
nodular subtype at excision and recurrence. The number of recurrences were too 
small	to	establish	correlations	with	documented	variables.
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Table 1.	Descriptive	statistics	of	the	BCCs	analysed	including	demographics,	BCC	
location,	BCC	size,	total	number	of	BCCs	per	patient	and	recurrence	rate.		
All BCCs  
(n = 500)
Single type 
(n = 343)
Mixed type  
(n = 157)
Demographics
            Male, no. (%)
            Age, Mean (SD), years
294 (58.8)
65.6 (13.0)
196 (57.1)
64.2 (12.4)
98 (62.4)
66.3 (14.2)
BCC location, no. (%)
											Head:	H-zone
											Head:	no	H-zone
           Neck
											Upper	extremities
           Anterior trunk
           Posterior trunk
											Lower	extremities
69 (13.8) 
74 (14.8) 
30 (6.0) 
45 (9.0) 
99 (19.8) 
145 (29.0) 
38 (7.6)
43 (12.5) 
44 (12.8) 
19 (5.5) 
34 (9.9) 
72 (21.0) 
103 (30.0) 
28 (8.2)
26 (16.6) 
30 (19.1) 
11 (7.0)
 11 (7.0) 
27 (17.2) 
42 (26.8) 
10 (6.4)
BCC size, no. (%)
           < 10 mm
           > 10 < 20 mm
           > 20 mm
          Unknown
186 (37.2) 
103 (20.6) 
29 (5.8) 
182 (36.4)
123 (35.9) 
71 (20.7) 
18 (5.2) 
131 (38.2)
63 (40.1) 
32 (20.4) 
11 (7.0) 
51 (32.5)
Total number of BCCs  
per patient, Mean (SD)
4.8 (7.2) 5.2 (7.8) 3.9 (5.7)
Recurrences 4 (0.8) 3 (0.9) 1 (0.6)
The	 columns	 represent	 consecutively	 all	 BCCs	 evaluated	 (column	 1),	 BCCs	 composed	 of	 one	 subtype	
(Single	type,	column	2)	and	BCCs	composed	of	multiple	subtypes	(Mixed	type,	column	3).	BCC	=	basal	cell	
carcinoma.
113
APPLICATION OF RCM IN NONMELANOMA SKIN CANCER
3
Table 2. BCC subtype at biopsy vs. excision. The percentage of corresponding subtype 
at excision in parenthesis.  
BCC subtype at excision
Superficial Nodular Micronodular Infiltrative Total
No. (%) No. (%) No. (%) No. (%)
BCC subtype  
punch biopsy
Superficial BCC 158 (84) 17 (9) 4 (2) 8 (4) 187 (100*)
Nodular BCC 32 (20) 101 (63) 12 (7) 16 (10) 161 (100)
Micronodular BCC 7 (11) 19 (30) 24 (38) 13 (21) 63 (100)
Infiltrative BCC 12 (13) 13 (15) 3 (3) 61 (69) 89 (100)
Total within  
BCC subtype 
Subtype at excision
209 (42) 150 (30) 43 (9) 98 (20) 500 (100*)
BCC	=	basal	cell	carcinoma.	*Numbers	do	not	add	up	to	100	due	to	percentages	round	off.
Table 3.	Positive	predictive	value	(PPV)	of	basal	cell	carcinoma	(BCC)	subtype	at	
punch	biopsy	 for	 subtype	at	 excision.	 In	 the	first	 column	all	 the	evaluated	BCC	 
subtypes	are	listed.	The	columns	represent	consecutively	the	PPV	per	BCC	subtype:	
for all evaluated BCCs (All), BCCs in which the punch biopsy and the excision were 
evaluated by one dermatohistopathologist (1 Pat), BCCs evaluated by two derma-
tohisto	pathologist	 (2	 Pat),	 BCCs	which	 constituted	 of	 one	 subtype	 (Single)	 and	
BCCs	constituting	of	≥2	subtypes	(Mixed).	
BCC Subtype All 1 Pat 2 Pat Single Mixed 
Superficial	BCC 84 88 84 94 -
Nodular BCC 63 65 62 71 41
Micronodular BCC 38 42 36 67 27
Infiltrative	BCC 69 69 68 81 57
All subtypes 69 69 69 83 37
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Discussion
Current management of BCC is largely based on the expected biological behaviour, 
which correlates highly to the histological type of BCC. Excision is an established 
treatment	option	for	BCC	with	a	high	efficacy	and	low	recurrence	rate19,20. However, 
the	 last	 10	years	non-surgical	 treatment	modalities	such	as	PDT	and	application	of	
imiquimod	or	5-fluorouracil	have	been	applied	increasingly.	As	non-surgical	treatment	
is	only	suited	for	less	aggressive	BCC	subtypes,	correct	evaluation	of	BCC	subtype	at	
the	diagnostic	biopsy	becomes	more	 important21.	 In	addition,	 the	 total	number	of	
BCCs	is	rising	rapidly,	which	increases	the	need	to	optimize	management	of	BCC.	For	
these	reasons	the	aim	of	the	present	study	was	to	evaluate	the	diagnostic	accuracy	of	
punch biopsy for BCC subtype at excision. Furthermore, we evaluated the prevalence 
of biopsy based underdiagnosis of aggressive BCC subtypes.
 The overall accuracy of punch biopsy for BCC subtype at excision was 69%, thus 
two	of	three	BCCs	were	correctly	classified.	Other	studies	report	accuracy	rates	of	
51%–82%.	These	large	discrepancies	might	be	explained	by	the	variation	in	the	type	
of BCCs studied (primary or recurrent BCCs), method of presurgical biopsy (punch or 
shave biopsy) and method of excision (Mohs micrographic surgery or excision with a 
standard margin). It is an important factor for the accuracy of punch biopsy whether 
BCCs	consisted	of	one	or	multiple	subtypes:	accuracy	was	high	 in	single	type	BCCs	
(83%) and considerably lower in mixed-type BCCs (37%). In our study, 31% of the BCCs 
were	 incorrectly	 classified,	 whereas	 Russell	 et	 al.	 reported	 a	 discordance	 rate	 of	
19.3%12.	However,	Russell	et	al.	included	only	three	subtypes	(superficial,	nodular	and	
infiltrating)	 and	 excluded	 the	 micronodular	 type,	 which	 in	 our	 study	 showed	 the	
lowest	accuracy	(27%).	The	rate	of	discordance	might	be	influenced	by	other	factors,	
e.g.	size	of	the	punch	biopsy	compared	with	the	size	of	the	total	lesion,	location	of	the	
tumour	 and	 selection	 of	 the	 biopsy	 location.	 Due	 to	 retrospective	 review	 of	 the	
histological reports the histopathologist who rated the excision specimen could 
potentially	be	 influenced	by	 the	 report	of	 the	 initial	 biopsy,	 favouring	 the	original	
subtype.	Furthermore,	there	could	be	selection	bias	because	some	BCCs	were	treated	
by	other	treatment	options	than	excision.
	 According	the	Dutch	guideline,	low	risk	superficial	and	nodular	BCCs	on	the	trunk	
≤10	mm	should	be	excised	with	a	margin	of	3	mm.	High	 risk	BCCs	 (location	at	 the	
H-zone,	infiltrative	or	micronodular	subtype,	recurrences)	or	BCCs	>10	mm	should	be	
excised with a margin of 5 mm18.	Taken	into	account	this	current	guideline,	2%–5.2%	
of all evaluated BCCs should have been excised with a margin of 5 mm instead of 3 
mm, which might result in a higher recurrence rate at follow-up. However, in our 
study the recurrence rate was only 0.8%.
	 Non-surgical	 treatments	 like	 PDT	 and	 imiquimod	 are	 less	 effective	 in	 (micro)
nodular	and	infiltrative	BCC21.	Interestingly,	this	study	showed	that	in	11%	of	all	BCCs	
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an unsuspectedly more aggressive subtype was present at excision. This could explain 
therapy	 failure	 in	 BCCs	 treated	 by	 non-surgical	 treatment	 options.	 Izikson	 et	 al.	
reported	 that	 21%	 of	 BCCs	may	 have	 been	 under-treated	 due	 to	 application	 of	 a	
treatment	modality	which	would	have	been	appropriate	 for	 the	 initially	diagnosed	
non-aggressive subtype10.	 In	our	 study,	6%	of	BCCs	 initially	 regarded	as	 superficial	
and	17%	of	BCCs	initially	regarded	as	nodular	BCC,	had	a	more	aggressive	component	
at excision. These numbers are corresponding to documented numbers of therapy 
failure	of	PDT	in	superficial	BCC	(7.8%)	and	nodular	BCC	(13.5%)20,22.
	 In	current	management	of	BCC,	a	biopsy	is	performed	for	two	reasons:	to	confirm	
diagnosis	of	a	clinical	suspect	 lesion	and	to	establish	BCC	subtype	to	prioritize	the	
treatment	options.	However,	sometimes	treatment	selection	is	not	affected	by	the	
BCC	subtype	due	 to	e.g.	 location	of	 the	BCC,	patient	preferences	or	availability	of	
therapeutic	modalities.	In	this	case	a	biopsy	could	be	omitted.	Furthermore,	it	might	
be	discussed	whether	a	biopsy	 is	always	necessary	to	confirm	clinical	diagnosis,	as	
clinical diagnosis in its own right has a high accuracy of 86%23. Possibly, in high-risk 
patients	(e.g.	history	of	multiple	BCCs,	organ	transplant	recipients	with	prolonged	use	
of	 immunosuppressive	 medication,	 light	 skin	 type,	 multiple	 sunburns	 in	 history,	
previous	radiotherapy)	with	a	BCC	displaying	clinical	distinct	features	(e.g.	teleangiec-
tasias, central erosion, pearly shine or raised peripheral edges) there is a high 
probability	 that	 a	BCC	 is	present	and	 therefore	 the	additional	 value	of	 a	biopsy	 is	
limited.	 In	 these	 cases,	 a	 biopsy	 might	 be	 omitted	 before	 treatment,	 eliminating	
unnecessary	treatment	delay	and	therefore	 increasing	the	efficacy	of	patient	care.	
Interestingly,	our	study	showed	that	the	accuracy	of	a	biopsy	for	BCC-MH	is	only	37%.	
Cohen et al. reported that 96% of BCC-MH referred for Mohs micrographic surgery 
were located on the head and neck area6. Thus, it can be discussed whether a biopsy 
in	the	head-neck	area	is	of	additional	value	to	establish	BCC	subtype.
 In conclusion, punch biopsy has a good accuracy for single type BCCs and a 
considerably lower accuracy for mixed-type BCCs. We would like to stress that one 
should be aware, that the accuracy of the biopsy is low if the biopsy report documents 
a mixed-type BCC. In this case, there is a high probability that an unsuspected more 
aggressive subtype is present.
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CHAPTER 3
Abstract
Background: Reflectance	 confocal	 microscopy	 (RCM)	 is	 a	 non-invasive	 imaging	
technique. Currently, RCM is mainly used for the diagnosis of melanoma and 
non-melanoma	skin	cancer	including	basal	cell	carcinoma	(BCC).	Until	now,	it	has	not	
been	possible	to	distinguish	between	subtypes	of	BCC	using	RCM.
Objective: To establish the RCM features for subtypes of BCC.
Methods: 57 lesions were selected for RCM imaging. Clinical and dermatoscopic 
pictures were taken and a 3 mm biopsy was obtained.
Results: It was demonstrated that tumor nests with peripheral palisading, branch-like 
structures,	fibrotic	septa	and	increase	in	vascular	diameter	were	characteristic	RCM	
features for nodular and micronodular BCC. The size and shape of the tumor nests 
allowed	 further	 distinction	 between	 these	 BCCs.	 Solar	 elastosis	 and	 tumor	 nests	
connected	with	the	basal	cell	layer	characterize	superficial	BCC.
Conclusion: This study presents RCM features for BCC, which might allow in vivo 
diagnosis	 of	 the	 nodular,	micronodular	 and	 superficial	 subtype	 of	 BCC.	 This	 could	
prevent	a	skin	biopsy,	resulting	 in	direct	proper	treatment.	Further,	RCM	allows	to	
evaluate the total lesion, which makes it possible to detect mixed-type BCCs.
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Introduction
Basal cell carcinoma (BCC) is the most common skin cancer1-3. BCC accounts for 
70–75%	of	all	cases	of	non-melanoma	skin	cancer	with	a	varying	incidence	over	the	
world1,3,4. This incidence is rising rapidly with 10% each year worldwide5,6.
 Clinically, BCC is characterized by pink to red-brown patches or papules, central 
erosion	or	ulceration	with	or	without	 the	presence	of	crusts,	a	pearly	 shine	and	a	
raised border with the presence of telangiectasias7. BCC can be divided into 4 main 
subtypes	based	on	the	histopathological	growth	pattern:	nodular	(nBCC),	micronodular	
(mnBCC),	infiltrating	(iBCC)	and	superficial	(sBCC)1,2.
 At the histopathological level, nBCC shows large nests of basaloid cells in either 
the	papillary	or	reticular	dermis.	Tumor	nests	of	mnBCC	have	a	similar	appearance	as	
nBCC, but they are smaller and more widely spread into the dermis. Further, these 
tumor	nests	are	accompanied	by	prominent	stromal	proliferation.	 iBCCs	appear	as	
irregularly sized and shaped nests of tumor cells. The tumoral stroma of these BCCs is 
often	fibrotic	with	plump	proplastic	fibroblasts2,8.	sBCC	is	characterized	by	multifocal	
nests of basaloid tumor cells, and it predominately shows horizontal growth and only 
infiltrates	the	upper	papillary	dermis1,2.
	 Determination	of	the	subtype	of	BCC	is	important	for	the	choice	of	treatment	and	
determination	of	the	surgical	excision	margin.	Worldwide,	surgical	excision	is	the	most	
common	treatment	option	for	BCC.	In	Europe,	the	margin	for	excision	depends	on	the	
subtype of BCC. In the Netherlands, small nBCC and sBCC are removed with a margin of 
3 mm. In contrast, the more aggressive BCC subtypes mnBCC and iBCC are excised with a 
margin	of	5	mm.	In	addition	to	excision,	non-invasive	therapies	like	photodynamic	therapy	
and	topical	application	of	imiquimod	are	available	and	are	increasingly	applied9-11. These 
therapies	may	be	used	 in	 sBCC	or	nBCC,	when	 surgery	 is	 considered	 suboptimal:	 in	
patients	with	multiple	comorbidities,	a	high	risk	of	postsurgical	hypertrophic	scarring	
with	or	without	functional	 impairment,	 large	lesions	in	functional	areas	or	when	the	
cosmetic	 outcome	 is	 of	 major	 concern9,12,13.	 The	 different	 excision	margins	 and	 the	
increasing	use	of	non-invasive	therapies	makes	correct	evaluation	of	the	BCC	subtype	
more	 important.	However,	 clinical	 examination	 is	 limited	 in	 its	 ability	 to	 distinguish	
between histopathological BCC subtypes1. Currently, the gold standard for establishing the 
diagnosis	of	a	BCC	and	the	subtype	is	the	evaluation	of	a	skin	biopsy	by	a	pathologist.
	 Reflectance	confocal	microscopy	 (RCM)	 is	a	non-invasive	 technique	 for	 in vivo 
imaging of the skin that uses a near-infrared laser beam of 830 nm. This technique 
produces horizontal (en face) images of the skin14,15.	The	resolution	of	these	images	is	
comparable	with	 conventional	 histology15. Nowadays, RCM imaging is mainly used for 
the diagnosis of melanoma and non-melanoma skin cancer16-21. Besides, RCM has been 
shown	to	be	a	useful	tool	for	monitoring	and	follow-up	of	therapy	of	inflammatory	
skin disorders and BCC22,23.
122
CHAPTER 3
	 Until	now,	several	RCM	features	of	BCC	have	been	described.	RCM	can	visualize	
islands of monomorphic elongated basaloid cells with nuclei that are orientated 
along the same axis3,14,15,24,25. These	 tumor	 nests	 are	 often	 surrounded	 by	 cleft-like	
dark	 spaces,	 bright	 stromal	 tissue	 and	 the	 presence	 of	 multiple	 inflammatory	
cells14,25,26.	 Further	 in	 the	 stratum	spinosum,	elongated	monomorphic	keratinocyte	
nuclei that are polarized along one axis can be found3,7,27.	 Additionally,	 prominent	
enlarged	capillaries	with	a	horizontal	orientation	can	be	observed	surrounding	the	
tumor nests3,14,15,19,24,27.	Although	these	RCM	features	allow	to	confirm	the	diagnosis	of	
BCC,	it	is	currently	not	feasible	to	differentiate	among	the	various	histopathological	
subtypes of BCC24. Therefore, the aim of this study was to evaluate whether RCM is 
able	to	distinguish	between	subtypes	of	BCC.
Materials and methods
Subjects
In	 34	 patients,	 57	 clinically	 suspicious	 lesions	 for	 BCC	were	 included	 in	 this	 study	
between	December	2011	and	April	2013.	Patients	were	recruited	from	the	Department	of	
Dermatology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 
This	study	was	approved	by	the	local	medical	ethics	committee,	which	was	conducted	
according	to	the	principles	of	the	Declaration	of	Helsinki.	If	required,	patients	gave	
their	written	 informed	 consent	 before	 inclusion.	 The	 lesions	were	 located	 on	 the	
face, neck, scapula, chest, abdomen, back, arms and legs.
Study protocol
Clinical and dermatoscopic pictures of the lesions were taken prior to RCM imaging 
using a digital camera (Nikon D 200, Nikon, Tokyo, Japan) and a Vivacam Macro 
Camera (Vivacam; Lucid Inc., Rochester, N.Y., USA). These photographs were 
evaluated by an experienced dermatologist. RCM imaging was performed according 
a standardized protocol. A horizontal map of 4 x 4 mm (Vivablock) was made at the 
level of the stratum corneum, stratum granulosum, stratum spinosum, dermal- 
epidermal	junction	and	papillary	dermis.	Vertical	mapping	(Vivastack)	was	performed	
by	capturing	a	series	of	images	of	0.5	x	0.5	mm	in	depth	with	steps	of	4.5	μm.	The	
mapping	started	at	the	top	of	the	stratum	corneum	until	the	papillary	dermis.	Movies	
were	made	at	the	level	of	the	dermal-epidermal	junction	to	visualize	capillary	blood	
flow.	RCM	images	were	evaluated	for	 features	of	BCC:	 tumor	nests	surrounded	by	
peritumoral	dark	spaces,	peripheral	palisading,	elongation	of	nuclei	along	the	same	
axis,	 keratinocyte	atypia	with	 spongiosis,	 solar	elastosis,	 increased	vascularization,	
presence	of	 inflammatory	cells	and	 leukocyte	rolling.	 In	addition,	 the	 lesions	were	
evaluated	 for	 RCM	 features	 specific	 for	 BCC	 subtypes.	 After	 RCM	 imaging,	 3	mm	
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punch biopsies of the lesions were obtained for diagnosis by a pathologist. Local 
anesthesia	was	 used	with	 1%	 xylocaine/adrenaline.	 The	 histopathological	 subtype	
was	used	for	correlation	to	the	RCM	images.
RCM imaging
RCM imaging was performed with the commercially available VivaScope 1500 system 
(Lucid Inc.). This system produces en face images of the skin and is able to examine 
the	skin	at	a	depth	of	200	μm.	Images	were	obtained	and	analyzed	using	Vivascan	7.0	
software.	A	more	detailed	description	of	the	system	has	been	published	previously15,28,29.
Histology
The	histopathological	classification	of	BCCs	was	performed	according	to	the	Dutch	
guideline30.	 sBCCs	were	 identified	 by	 nests	 of	 basaloid	 cells	 residing	 highly	 in	 the	
epidermis,	usually	 in	a	multifocal	pattern.	nBCCs	were	characterized	by	large	nests	
with	basaloid	cells,	well	circumscribed	from	the	surroundings.	mnBCCs	were	identified	
by well-circumscribed, small nests of basaloid cells, with a size comparable to the 
bulb	of	a	hair	 follicle.	 The	 skin	 samples	were	embedded	 in	paraffin	after	a	4-hour	
fixation	in	formaldehyde.	Paraffin	sections	(6	μm)	were	processed	side	by	side	and	
dewaxed	with	Histosafe	(Adamas,	Rhenen,	The	Netherlands)	followed	by	rehydration	
in	decreasing	concentrations	of	alcohol	(from	100	to	50%)	and	demineralized	water.	
These	sections	were	hematoxylin-eosin	(HE)	stained	for	assessment	of	histopathological	
features.	 Finally,	 the	 sections	were	 photographed	 at	 a	magnification	 of	 20x	 using	 
a microscope (Axioskop2 MOT; Zeiss), digital camera (Axiocam MRc5; Zeiss) and 
AxioVision	software	(Zeiss).
Results
Diagnosis
All biopsies of the lesions suspect of being BCC were evaluated by a pathologist. 
Forty-three	biopsy	specimens	from	27	patients	contained	histopathological	features	
of	BCC.	The	clinical	characteristics	of	the	study	population	are	summarized	in	Table	1.	
Twenty-three biopsy specimens were characterized as sBCC, 11 as nBCC and 3 as 
mnBCC. Six biopsy specimens showed a mixed-type BCC. Three out of 6 mixed-type 
BCCs	contained	a	superficial	and	nodular	component,	the	other	3	contained	a	nodular	
and	infiltrative	component.	RCM	imaging	was	not	possible	in	2	sBCC	lesions,	due	to	
hyperkeratosis, and these lesions were excluded from analysis. The remaining 14 lesions 
were	diagnosed	as	actinic	keratosis,	unspecific	chronic	 inflammation	or	 sebaceous	
gland hyperplasia. Eleven of these 14 clinically suspicious BCC lesions were not 
suspect of being BCC based on RCM imaging.
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RCM features of BCC
The	images	were	first	evaluated	for	general	RCM	features	of	BCC	(Table	2).	In	40	histo-
pathologically	confirmed	BBC	 lesions,	 tumor	nests	were	found	(97.6%).	Frequently,	
these	nests	were	surrounded	by	peritumoral	dark	spaces	(80.5%).	Further,	keratino-	
cyte atypia was observed in all BCC subtypes. In 92.7% of the BCCs, increased 
Table 1: Clinical	characteristics	of	the	patients	with	a	lesion	diagnosed	as	BCC.
Mean age
± SD, years
Gender 
(M/F)
Skin type 
I II III
All BCCs (n = 27) 65.7 ± 10.0 16/11 4 15 8
sBCC (n = 15) 64.1 ± 11.0 9/6 3 8 4
nBCC (n = 9) 66.1 ± 9.7 6/3 0 6 3
mnBCC (n = 3) 69.7 ± 1.2 2/1 0 2 1
Mixed-type BCC (n = 6) 66.7 ± 9.4 4/2 1 3 2
The	average	number	of	BCCs	per	patient	was	1.6.	 In	some	patients,	BCCs	with	different	subtypes	were	
found,	explaining	the	difference	in	number	of	patients	between	all	BCCs	and	the	subgroups.	BCC	=	basal	
cell	carcinoma;	sBCC	=	superficial	basal	cell	carcinoma;	nBCC	=	nodular	basal	cell	carcinoma;	mnBCC	=	
micronodular basal cell carcinoma.
Table 2: RCM features for subtypes of BCC.
sBCC 
(n = 21)
nBCC 
(n = 11)
mnBCC 
(n = 3)
Mixed-
type BCC 
(n = 6)
BCC
(n = 41)
Mild	keratinocyte	atypiaa 100.0%  
(21/21)
100.0%  
(11/11)
100.0%  
(3/3)
100.0%  
(6/6)
100.0%  
(41/41)
Streamingb 52.4% 
(11/21)
45.5%  
(5/11)
33.3% 
(1/3)
  0.0% 
(0/6)
41.5% 
(17/41)
Nests of basaloid cellsc 100.0%  
(21/21)
100.0%  
(11/11)
100.0%  
(3/3)
83.3% 
(5/6)
97.6% 
(40/41)
Cleftsd 66.7% 
(14/21)
100.0%  
(11/11)
100.0%  
(3/3)
83.3% 
(5/6)
80.5% 
(33/41)
Peripheral palasidinge   9.5%  
(2/21)
81.8%  
(9/11)
66.7% 
(2/3)
50.0% 
(3/6)
39.0% 
(16/41)
Fibrosis surrounding nestsf 42.9% 
(9/21)
100.0%  
(11/11)
66.6% 
(2/3)
66.7% 
(4/6)
63.4% 
(26/41)
Solar elastosisg 95.2% 
(20/21)
18.2% 
(2/11)
33.3% 
(1/3)
66.7% 
(4/6)
65.9% 
(27/41)
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Table 2: Continued.
sBCC 
(n = 21)
nBCC 
(n = 11)
mnBCC 
(n = 3)
Mixed-
type BCC 
(n = 6)
BCC
(n = 41)
Increased vascularityh 90.5% 
(19/21)
100.0%  
(11/11)
100.0%  
(3/3)
83.3% 
(5/6)
92.7% 
(38/41)
Inflammatory	infiltratei 81.0% 
(17/21)
90.9% 
(10/11)
100.0%  
(3/3)
66.7% 
(4/6)
82.9% 
(34/41)
Plumb bright cellsj 42.9%  
(9/21)
36.4%  
(4/11)
66.7% 
(2/3)
50.0% 
(3/6)
43.9% 
(18/41)
Size and shape of the nests
     Round to oval >300 µm
     Round to oval <300 µm
     Bunch of grape shaped
81.0%  
(17/21)
33.3%   
(7/21)
  0.0%   
(0/21)
81.8% 
(9/11)
27.3% 
(3/11)
  0.0% 
(0/11)	
  0.0% 
(0/3)
  0.0% 
(0/3)
100.0% 
(3/3)
83.3% 
(5/6)
33.3% 
(2/6)
  0.0% 
(0/6)
75.6% 
(31/41)
29.3% 
(12/41)
  7.3%  
(3/41)
Location of the nests
    Just below the epidermis
    Dermal 
100.0%  
(21/21)
  4.8%  
(1/21)
  9.1% 
(1/11)
100.0% 
(11/11)
  0.0% 
(0/3)
100.0%  
(3/3)
50.0% 
(3/6)
66.7% 
(4/6)
60.1% 
(25/41)
46.3% 
(19/41)
Branch like structures  
in the nests
  9.5%  
(2/21)
72.7% 
(8/11)
66.7% 
(2/3)
33.3% 
(2/6)
34.2% 
(14/41)
Increased vascular diameter
       +
       ++
       +++
66.7% 
(14/21)
23.8%  
(5/21)
  0.0%  
(0/0)
  0.0% 
(0/11)
54.5% 
(6/11)
45.5% 
(5/11)
  0.0% 
(0/3)
  0.0% 
(0/3)
100.0.% 
(3/3)
50%    
(3/6)
33.3% 
(2/6)
  0.0% 
(0/6)
41.5% 
(17/41)
31.7% 
(13/41)
19.5% 
(8/41)
The	RCM	features	highlighted	in	italics	are	those	that	might	allow	in	vivo	distinction	between	subtypes	
of BCC.
a Cellular	and	nuclear	atypia	is	defined	as	loss	of	the	regular	honeycomb	pattern16,20. b Elongated monomorphic kerat-
inocyte nuclei that are polarized along one axis, which is mostly found above tumor nests3,7,25. c Described 
as	highly	packed	cells	corresponding	to	islands	of	basaloid	tumor	cells	with	high	refractility20,31. d Defined	as	
a	dark	space	surrounding	tumor	nests,	which	correspond	to	peritumoral	mucin	deposition24,31. e Described 
as	polarization	of	nuclei	along	the	same	axis	 in	the	tumor	nests31. f Highly	reflective	bundles	surround-
ing tumor nests. g Defined	as	bright	irregular	bundles	and	lace-like	structures16. h Abundant blood vessels 
are	often	found	juxtaposed	to	BCC	tumor	nests20. Within these vessels, rolling of leukocytes along the 
endo thelial lining is an already described phenomenon26. i Identified	as	bright,	highly	refractile	round	or	
scattered	cells	representing	leukocytes	and	neutrophils,	respectively.	j Described as bright, plump, oval or 
star-shaped	cells	appearing	particularly	in	the	upper	dermis19,32. 
BCC	=	basal	cell	carcinoma;	sBCC	=	superficial	basal	cell	carcinoma;	nBCC	=	nodular	basal	cell	carcinoma;	
mnBCC	=	micronodular	basal	cell	carcinoma;	RCM	=	reflectance	confocal	microscopy.
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	vascularization	was	found	and	these	capillaries	had	mainly	a	horizontal	orientation.	
Other	 general	 RCM	 features	 of	 BCC	were	 solar	 elastosis	 (65.9%),	 fibrosis	 (63.4%),	
presence	of	 inflammatory	 cells	 (82.9%),	peripheral	palisading	 (39%)	and	 streaming	 
of	 keratinocytes	 (41.5%).	 The	 evaluated	 general	 RCM	 features	 of	 BCC	 correlated	 
highly with histopathological features seen in the biopsies. However, streaming of 
keratinocytes	is	a	characteristic	only	seen	with	RCM	and	does	not	correspond	to	any	
known	histopathological	feature.	In	43.9%	of	all	BCCs,	we	found	large	highly	reflective	
cells. These cells were mainly found in the upper dermis surrounding or near BCC 
nests (Figure 1d and 2d).
Figure 1. Micronodular basal cell carcinoma. Clinical, dermatoscopic and RCM images 
with corresponding histology. (a) Micronodular basal cell carcinoma located on the 
left	scapula	clinically	appearing	as	a	pink-colored	papule	with	telangiectasias	and	a	
pearly shine. (b) Corresponding dermatoscopic picture. (c)	Hematoxylin-eosin	tissue	
section	displaying	a	micronodular	basal	cell	carcinoma.	Multiple	tumor	nests	varying	
in size and shape are shown. The black arrow demonstrates a small nest of basaloid 
cells with peripheral palisading. (d) RCM image at the dermal level showing plump 
bright cells (white arrows) near the tumor nests. (e)	Within	 the	nests	 highly	 reflective	
branch-like structures are observed. (f) Tumor nests had a shape similar to a bunch 
of	grapes.	The	tumor	islands	are	separated	by	peritumoral	dark	spaces.	RCM	=	reflectance	
confocal microscopy.
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 Some	RCM	features	were	related	to	a	specific	subtype	(Table	2).	The	presence	of	
peripheral	palisading,	solar	elastosis,	branch-like	structures,	fibrotic	septa,	location,	
size	 and	 shape	 of	 tumor	 nests	might	 be	 important	 to	 distinguish	 between	 nBCC,	
mnBCC and sBCC. Remarkably, peripheral palisading was predominately found in 
nBCC and mnBCC (78.6% of all nBCCs and mnBCCs) opposed to sBCC (9.5% of all sBCC 
lesions).	 Further,	 we	 found	 a	 difference	 in	 the	 size	 and	 shape	 of	 sBCC,	 nBCC	 and	
mnBCC tumor nests. All sBCC and nBCC lesions appeared as round to oval nests 
(Figure	2f	and	3e,	Table	2).	Most	of	these	nests	had	a	diameter	of	>300	μm.	In	contrast,	
Figure 2.	Superficial	basal	cell	carcinoma.	Clinical,	dermatoscopic	and	RCM	images	
with corresponding histology. (a) Clinical picture of an erythematosquamous plaque 
located on the right scapula. (b) Corresponding dermatoscopic picture. (c)	A	superficial	
basal	cell	carcinoma	is	seen	in	the	hematoxylin-eosin-stained	tissue	section.	The	nest	
of basaloid cells is connected with the stratum spinosum (white arrow). (d) 
Corresponding RCM image at the level of the papillary dermis showing plump bright 
cells (white arrows) surrounding basal cell carcinoma nests. (e) Solar elastosis in the 
dermis,	which	appears	as	large	highly	reflective	collagen	bundles.	(f) Nest of basaloid 
cells located just below the epidermis (white arrow) with peritumoral dark spaces. 
The	location	of	this	tumor	nest	corresponds	highly	to	the	location	of	the	tumor	nest	
in	the	conventional	histology	(c).	RCM	=	reflectance	confocal	microscopy.
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mnBCCs showed tumor nests with a shape similar to a bunch of grapes, varying 
between	100	and	300	μm	(Figure.	1e	and	1f,	Table	2).	The	size	and	shape	of	the	tumor	
nests corresponded highly to the nests seen in histology (Figure 1c, 2c and 3c). Fibrosis 
was	found	in	all	subtypes	of	BCC.	However,	nBCC	and	mnBCC	showed	fibrotic	septa	
surrounding	nests	of	basaloid	 cells,	which	were	hardly	 found	 in	 sBCC.	 In	 addition,	
RCM	imaging	showed	highly	reflective	branchlike	structures	within	the	tumor	nests	in	
71.4%	of	all	nBCC	and	mnBCC	lesions.	These	branches	appeared	as	highly	reflective	
bands	within	 the	 tumor	 nests	 (Figure	 1e).	 The	 reflectivity	 of	 these	 structures	was	
Figure 3. Nodular basal cell carcinoma. Clinical, dermatoscopic and RCM images with 
corresponding histology. (a) Clinical picture of a pink-colored papule with a pearly 
shine and telangiectasias on the right scapula. (b) Corresponding dermatoscopic 
image. (c)	Hematoxylin-eosin	tissue	section	displaying	a	nodular	basal	cell	carcinoma.	
A compact oval nest of basaloid cells (white arrow) with peritumoral stroma and 
inflammatory	cells	is	seen	in	the	dermis.	(d) RCM image at the level of the papillary 
dermis showing a cluster of capillaries (arrows). (e) Large oval nest of basaloid cells in 
the dermis (white arrow) with peritumoral dark spaces. A capillary with a large 
diameter	is	seen	adjacent	to	the	nest	(red	arrow).	Within	this	nest	highly	reflective	
branch-like	structures	are	observed.	Further,	 there	are	prominent	highly	reflective	
fibrotic	 septa	 surrounding	 the	 tumor	 nests	 (asterisk).	 RCM	 =	 reflectance	 confocal	
microscopy.
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more prominent in mnBCC compared to nBCC. These branch-like structures were 
rarely found in sBCC lesions (9.5%). Further, the vascular diameter was larger in nBCC 
and	mnBCC	compared	to	sBCC.	In	sBCC,	the	location	of	the	nests	is	important.	Clusters	 
of basaloid cells were visualized just below or connected to the basal cell layer (Figure 2f). 
This is in contrast to nBCC and mnBCC nests, which were found in the papillary dermis. 
More solar elastosis was found in sBCC compared to both nBCC and mnBCC. This solar 
elastosis	was	seen	as	a	highly	reflective	network	of	collagen	fibers	(Figure	2e).	
 For	the	mixed-type	BCCs	containing	a	superficial	and	nodular	component,	RCM	
features of both BCC subtypes were observed. Large round to oval nests were found 
just below the epidermis as well as deeper in the dermis. Further, mild to severe solar 
elastosis was found and in a part there was an increase in vascular diameter. The RCM 
diagnosis	based	on	these	findings	was	in	line	with	the	diagnosis	based	on	the	excision	
specimen.	For	the	mixed-type	BCCs	containing	a	nodular	and	infiltrative	component,	
mainly the nodular component was visualized. Based on the histology of these 
mixed-type	BCCs,	the	infiltrative	component	was	mainly	located	in	the	deeper	dermis,	
which is not possible to visualize by RCM. RCM imaging showed large round to oval 
nests of basaloid cells with peripheral palisading in the upper dermis, referring to the 
nodular component.
Discussion
RCM has proven to be a useful, non-invasive tool for the in vivo diagnosis of skin 
tumors	 and	 inflammatory	 skin	 disorders.	 The	 confocal	 features	 of	melanoma	 and	
non-melanoma skin cancer have been reported previously, including general features 
for BCC7,19,20,32-34.	However,	distinctive	features	for	the	subtypes	of	BCC	have	not	been	
reported. The increasing use of non-invasive therapies, mainly in Europe, is only 
suited	for	certain	subtypes	of	BCC.	For	this	reason	and	the	different	excision	margins,	
correct	 evaluation	 of	 BCC	 subtypes	 is	 becoming	 more	 important	 to	 select	 the	
appropriate treatment1. This will result in direct accurate treatment and therefore 
could reduce the BCC recurrence rate. Therefore, the purpose of this study was to 
define	 confocal	 features	 characteristic	of	 subtypes	of	BCC	 to	 allow	a	non-invasive	
diagnosis.
	 We	evaluated	the	RCM	features	of	41	histopathologically	confirmed	BCCs.	Importantly,	
RCM	 features	 of	 nBCC,	mnBCC	 and	 sBCC	were	 defined.	 It	was	 demonstrated	 that	
tumor	nests	 (aggregations	of	basaloid	cells)	with	peripheral	palisading,	branch-like	
structures,	fibrotic	septa	and	increase	in	vascular	diameter	were	the	main	characteristic	
RCM	features	for	nBCC	and	mnBCC.	The	size,	shape	and	location	of	the	tumor	nests	
allows	further	distinction	between	nBCC	and	mnBCC.	Solar	elastosis	and	the	location	of	
the	tumor	nests	just	below	or	in	connection	with	the	basal	cell	layer	characterize	sBCC.
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 Although this study shows that RCM might allow in vivo diagnosis of nBCC, mnBCC 
and	sBCC,	RCM	features	for	iBCCs	still	need	to	be	defined.	It	was	impossible	to	define	
RCM features for iBCC based on the included mixed-type BCC with an iBCC component 
in the deeper dermis. Unfortunately, we were not able to include single-type iBCCs. 
However,	the	incidence	of	so	few	iBCCs	fits	the	epidemiology	of	BCC	in	general3. 
	 In	addition	 to	 the	described	RCM	 features	 for	 the	 subtypes	of	BCC,	we	 found	
large	highly	reflective	plump	bright	cells	in	a	part	of	the	evaluated	BCCs.	These	plump	
bright	cells	might	be	inflammatory	cells.	However,	these	cells	were	larger	and	different	
in	shape	compared	to	the	already	described	inflammatory	cells	in	BCC	like	lymphocytes	
and	 dendritic	 cells7,19. These cells might be melanophages. With RCM these cells 
appear	as	bright,	plump,	oval	or	star-shaped	cells	with	no	visible	nucleus	and	illdefined	
edges35,36.	 This	 RCM	 description	 corresponds	 highly	 to	 the	 observed	 plump	 bright	
cells	surrounding	the	BCC	nests	but	should	be	confirmed	by	 immunohistochemical	
staining. 
	 RCM	imaging	can	still	be	time	consuming,	a	learning	curve	is	associated	with	it,	
and	the	use	depends	on	the	location	of	the	lesion.	Adequate	protocols	describing	the	
most important RCM features may facilitate and shorten the procedure. Especially, 
RCM	imaging	is	of	additional	value	in	diagnosing	mixed-type	BCC,	previously	treated	
or	other	clinical	indistinctive	lesions37. In contrast to a biopsy, with RCM it is possible 
to	 scan	 the	 complete	 lesion	 non-invasively,	 which	 potentially	 prevents	 missing	 a	
more aggressive part of a tumor in BCCs located in the upper dermis31,37,38.
 In conclusion, this study presents RCM features for BCC, which might allow in vivo 
diagnosis	of	the	nodular,	micronodular	and	superficial	subtype	of	BCC.	This	could	prevent	
a skin biopsy, result in direct proper treatment and establishment of the correct margin 
for excision. Further, it was demonstrated that it is possible to detect mixed-type 
BCCs by RCM.
131
APPLICATION OF RCM IN NONMELANOMA SKIN CANCER
3
 References
1 Ahlgrimm-Siess V, Horn M, Koller S et al. 
Monitoring	efficacy	of	cryotherapy	for	superficial	
basal	 cell	 carcinomas	with	 in	 vivo	 reflectance	
confocal	microscopy:	a	preliminary	study.	Journal	
of	dermatological	science	2009;	53:	60-4.
2	 Crowson	 AN.	 Basal	 cell	 carcinoma:	 biology,	
morphology	and	clinical	 implications.	Modern	
pathology	 :	 an	 official	 journal	 of	 the	 United	
States and Canadian Academy of Pathology, Inc 
2006;	19	Suppl	2:	S127-47.
3	 Nori	S,	Rius-Diaz	F,	Cuevas	J	et	al.	Sensitivity	and	
specificity	 of	 reflectance-mode	 confocal	
microscopy for in vivo diagnosis of basal cell 
carcinoma:	a	multicenter	study.	Journal	of	the	
American	Academy	of	Dermatology	2004;	 51:	
923-30.
4 Ridky TW. Nonmelanoma skin cancer. Journal 
of the American Academy of Dermatology 
2007;	57:	484-501.
5 Lomas A, Leonardi-Bee J, Bath-Hextall F. A 
systematic	 review	 of	 worldwide	 incidence	 of	
nonmelanoma	skin	cancer.	The	British	 journal	
of	dermatology	2012;	166:	1069-80.
6 Madan V, Lear JT, Szeimies RM. Non-melanoma 
skin	cancer.	Lancet	2010;	375:	673-85.
7 Webber SA, Wurm EM, Douglas NC et al. 
Effectiveness	 and	 limitations	 of	 reflectance	
confocal	 microscopy	 in	 detecting	 persistence	
of	 basal	 cell	 carcinomas:	 a	 preliminary	 study.	
The Australasian journal of dermatology 2011; 
52:	179-85.
8 Saldanha G, Fletcher A, Slater DN. Basal cell 
carcinoma:	a	dermatopathological	 and	molecular	
biological	 update.	 The	 British	 journal	 of	
dermatology	2003;	148:	195-202.
9 Christensen E, Mork C, Skogvoll E. High and 
sustained	efficacy	after	two	sessions	of	topical	
5-aminolaevulinic acid photodynamic therapy 
for	basal	cell	carcinoma:	a	prospective,	clinical	
and histological 10-year follow-up study. The 
British	journal	of	dermatology	2012;	166:	1342-8.
10 Geisse JK, Rich P, Pandya A et al. Imiquimod 5% 
cream	for	the	treatment	of	superficial	basal	cell	
carcinoma:	 a	 double-blind,	 randomized,	 vehi-
cle-controlled study. Journal of the American 
Academy	of	Dermatology	2002;	47:	390-8.
11 van der Geer S, Martens J, van Roij J et al. 
Imiquimod 5% cream as pretreatment of Mohs 
micrographic surgery for nodular basal cell 
carcinoma	 in	 the	 face:	a	prospective	randomized	
	 controlled	study.	The	British	journal	of	dermatology	
2012;	167:	110-5.
12 Szeimies RM. Methyl aminolevulinate-photo-
dynamic therapy for basal cell carcinoma. 
Dermatologic	clinics	2007;	25:	89-94.
13	 Rhodes	 LE,	 de	 Rie	 MA,	 Leifsdottir	 R	 et	 al.	
Five-year follow-up of a randomized, 
prospective	trial	of	topical	methyl	aminolevuli-
nate photodynamic therapy vs surgery for 
nodular basal cell carcinoma. Archives of 
dermatology	2007;	143:	1131-6.
14	 Gonzalez	S.	Confocal	reflectance	microscopy	in	
dermatology:	 promise	 and	 reality	 of	
non-invasive diagnosis and monitoring. Actas 
dermo-sifiliograficas	2009;	100	Suppl	2:	59-69.
15 Calzavara-Pinton P, Longo C, Venturini M et al. 
Reflectance	 confocal	 microscopy	 for	 in	 vivo	
skin	 imaging.	Photochem	Photobiol	2008;	84:	
1421-30.
16 Ulrich M, Krueger-Corcoran D, Roewert-Huber 
J	 et	 al.	 Reflectance	 confocal	 microscopy	 for	
noninvasive monitoring of therapy and 
detection	 of	 subclinical	 actinic	 keratoses.	
Dermatology	2010;	220:	15-24.
17	 Richtig	 E,	 Ahlgrimm-Siess	 V,	 Koller	 S	 et	 al.	
Follow-up	of	actinic	keratoses	after	shave	biopsy	
by	 in-vivo	 reflectance	 confocal	microscopy--a	
pilot study. Journal of the European Academy 
of	Dermatology	&	Venereology	2010;	24:	293-8.
18 Scope A, Benvenuto-Andrade C, Agero AL et al. 
Correlation	 of	 dermoscopic	 structures	 of	
melanocytic	 lesions	 to	 reflectance	 confocal	
microscopy. Archives of dermatology 2007; 
143:	176-85.
19 Guitera P, Menzies SW, Longo C et al. In vivo 
confocal microscopy for diagnosis of melanoma 
and basal cell carcinoma using a two-step 
method:	 analysis	 of	 710	 consecutive	 clinically	
equivocal	 cases.	 The	 Journal	 of	 investigative	
dermatology	2012;	132:	2386-94.
20	 Gonzalez	 S,	 Tannous	 Z.	 Real-time,	 in	 vivo	
confocal	 reflectance	 microscopy	 of	 basal	 cell	
carcinoma. Journal of the American Academy 
of	Dermatology	2002;	47:	869-74.
21 Longo C, Soyer HP, Pepe P et al. In vivo confocal 
microscopic	 pattern	 of	 fibroepithelioma	 of	
pinkus.	Archives	of	dermatology	2012;	148:	556.
22 Wolberink EA, van Erp PE, de Boer-van Huizen 
RT	et	al.	Reflectance	 confocal	microscopy:	 an	
effective	 tool	 for	 monitoring	 ultraviolet	 B	
132
CHAPTER 3
phototherapy	in	psoriasis.	The	British	journal	of	
dermatology	2012;	167:	396-403.
23 Longo C, Casari A, Pepe P et al. Confocal 
microscopy insights into the treatment and 
cellular immune response of Basal cell carcinoma 
to photodynamic therapy. Dermatology 2012; 
225:	264-70.
24 Marra DE, Torres A, Schanbacher CF et al. 
Detection	of	residual	basal	cell	carcinoma	by	in	
vivo	confocal	microscopy.	Dermatologic	surgery:	
official	 publication	 for	 American	 Society	 for	
Dermatologic	Surgery	[et	al.]	2005;	31:	538-41.
25 Willard K, Warschaw KE, Swanson DL. Use of 
reflectance	confocal	microscopy	to	differentiate	
hidrocystoma from basal cell carcinoma. 
Dermatologic	 surgery	 :	 official	 publication	 for	
American	Society	for	Dermatologic	Surgery	[et	
al.]	2011;	37:	392-4.
26 Ulrich M, Roewert-Huber J, Gonzalez S et al. 
Peritumoral	 clefting	 in	 basal	 cell	 carcinoma:	
correlation	 of	 in	 vivo	 reflectance	 confocal	
microscopy	 and	 routine	 histology.	 Journal	 of	
cutaneous	pathology	2011;	38:	190-5.
27 Hofmann-Wellenhof R, Wurm EM, Ahlgrimm- 
Siess	V	et	al.	Reflectance	confocal	microscopy--
state-of-art and research overview. Seminars 
in	 cutaneous	medicine	and	 surgery	2009;	28:	
172-9.
28 Rajadhyaksha M, Gonzalez S, Zavislan JM et al. 
In vivo confocal scanning laser microscopy of 
human	skin	II:	advances	in	instrumentation	and	
comparison with histology. The Journal of 
investigative	dermatology	1999;	113:	293-303.
29 Rajadhyaksha M, Grossman M, Esterowitz D et 
al. In vivo confocal scanning laser microscopy of 
human	 skin:	melanin	 provides	 strong	 contrast.	
The	Journal	of	investigative	dermatology	1995;	
104:	946-52.
30 Beljaards R, Bruintjes T, Canninga-van Dijk M. 
Richtlijn Behandeling van het Basaalcelcarci-
noom:	2007.	In.
31 Wolberink EA, Pasch MC, Zeiler M et al. High 
discordance between punch biopsy and 
excision in establishing basal cell carcinoma 
subtype:	analysis	of	500	cases.	 Journal	of	 the	
European Academy of Dermatology and 
Venereology	:	JEADV	2013;	27:	985-9.
32 Aghassi D, Anderson RR, Gonzalez S. Confocal 
laser	microscopic	 imaging	of	actinic	keratoses	
in	 vivo:	 a	 preliminary	 report.	 Journal	 of	 the	
American	Academy	of	Dermatology	2000;	43:	
42-8.
33	 Busam	KJ,	Hester	K,	Charles	C	et	al.	Detection	of	
clinically	amelanotic	malignant	melanoma	and	
assessment of its margins by in vivo confocal 
scanning laser microscopy. Archives of dermatology 
2001;	137:	923-9.
34 Langley RGB, Rajadhyaksha M, Dwyer PJ et al. 
Confocal scanning laser microscopy of benign 
and	malignant	melanocytic	skin	lesions	in	vivo.	
Journal of the American Academy of Dermatology 
2001;	45:	365-76.
35 Bassoli S, Rabinovitz HS, Pellacani G et al. 
Reflectance	 confocal	 microscopy	 criteria	 of	
lichen planus-like keratosis. Journal of the 
European Academy of Dermatology and 
Venereology	:	JEADV	2012;	26:	578-90.
36 Guitera P, Li LX, Scolyer RA et al. Morphologic 
features of melanophages under in vivo 
reflectance	 confocal	 microscopy.	 Archives	 of	
dermatology	2010;	146:	492-8.
37 Peppelman M, Wolberink EA, Koopman RJ et al. 
In	 vivo	 Reflectance	 Confocal	 Microscopy:	 A	
Useful	 Tool	 to	 Select	 the	 Location	of	 a	Punch	
Biopsy	in	a	Large,	Clinically	Indistinctive	Lesion.	
Case	reports	in	dermatology	2013;	5:	129-32.
38 Haws AL, Rojano R, Tahan SR et al. Accuracy of 
biopsy sampling for subtyping basal cell 
carcinoma. Journal of the American Academy 
of	Dermatology	2012;	66:	106-11.
133
APPLICATION OF RCM IN NONMELANOMA SKIN CANCER
3

E.A.W. Wolberink* 
M. Peppelman*
R.J.J Koopman
P.E.J. van Erp
M.J.P. Gerritsen
Case	Reports	in	Dermatology	2013;5(1):129-132
* These authors contributed equally
In vivo reflectance confocal microscopy: 
a useful tool to select the location  
of a punch biopsy in a large, clinically 
indistinctive lesion
Chapter 3.3
CHAPTER 3
Abstract
Reflectance	confocal	microscopy	(RCM)	is	a	noninvasive	technique	for	in vivo imaging 
of	the	skin	that	allows	evaluation	of	the	total	 lesion	area.	This	case	report	about	a	
66-year-old	patient	with	 a	 clinically	 indistinctive,	previously	 treated	erythematous	
lesion on the frontal part of the face demonstrates the use of RCM to select the 
proper	biopsy	location.
137
APPLICATION OF RCM IN NONMELANOMA SKIN CANCER
3
Introduction
Squamous cell carcinoma (SCC) is the second most common non-melanoma skin 
cancer	after	basal	cell	carcinoma	(BCC)1,2. Currently, diagnosis of a clinically suspect 
SCC	or	BCC	is	confirmed	by	histological	evaluation	of	a	skin	biopsy	obtained	from	the	
clinically most suspicious part of the lesion. However, a biopsy only represents a small 
part	 of	 the	 lesion.	 Especially	 in	 large	 lesions,	 this	might	 result	 in	 a	 false-negative	
diagnosis or in missing a more aggressive part of the lesion3,4. Furthermore, clinical 
evaluation	 of	 previously	 treated	 and/or	 large	 lesions	 can	 be	 difficult,	 and	 in	 such	
cases, it is hard to determine the most suspect area for a biopsy. 
	 Reflectance	 confocal	microscopy	 (RCM)	 is	 a	 noninvasive	 technique	 for	 in vivo 
imaging	of	the	skin	that	allows	evaluation	of	the	total	lesion	area5. It is known that 
RCM	 can	 visualize	 non-melanoma	 skin	 cancer,	 melanoma	 and	 inflammatory	 skin	
diseases6,7. However, to the best of our knowledge, it is not described whether RCM 
might	 be	 used	 to	 select	 the	 location	 of	 a	 punch	 biopsy	 in	 a	 large	 and	 clinically	
indistinctive	lesion.
Case Presentation 
A	66-year-old	patient	with	an	erythematous	lesion	on	the	frontal	part	of	the	face	was	
referred from the Department of Dermatology of the Bernhoven Hospital, Oss, The 
Netherlands. At this hospital, the lesion was treated with cryotherapy followed by 
Efudix.	Unfortunately,	both	treatments	were	ineffective.	A	punch	biopsy	after	these	
therapies	revealed	the	presence	of	a	superficial	BCC	and,	therefore,	the	lesion	was	
treated with photodynamic therapy. However, the lesion persisted and increased in 
size.	The	biopsies	obtained	after	photodynamic	therapy	showed	chronic	inflammation	
and	no	residual	tumor	tissue.	For	further	management,	the	patient	was	referred	to	
the	 outpatient	 clinic	 of	 the	 Department	 of	 Dermatology,	 Radboud	 University	
Nijmegen Medical Centre, Nijmegen, The Netherlands. A clinical diagnosis of the 
erythematous	 lesion	with	a	 size	of	2.3	×	2.1	 cm	was	difficult	due	 to	 the	previously	
performed biopsies and treatments (Figure 1). This made it challenging to determine 
the most suspect area for a biopsy. Treatment by surgical excision without prior 
establishment	of	the	diagnosis	was	unfavorable	due	to	the	size	and	the	location	of	the	
lesion.	Therefore,	we	used	RCM	for	a	noninvasive	evaluation	of	the	complete	lesion	
to select the most suspect area for a biopsy. 
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The major part of the lesion showed RCM features corresponding to normal skin or 
actinic	 keratosis.	 More	 importantly,	 one	 small	 part	 showed	 prominent	 aberrant	
features:	 a	 disrupted	 stratum	 corneum,	 keratinocyte	 atypia,	 spongiosis,	 increased	
capillary	blood	flow,	flattening	of	the	dermal	epidermal	junction,	solar	elastosis	and	a	
nest of atypical cells (Figure 2). These features were suspect for either SCC or BCC. A 
3-mm punch biopsy was taken from this part of the lesion. Histopathological 
evaluation	of	the	biopsy	showed	the	presence	of	a	SCC	with	an	invasive	growth	of	0.9	
mm.	 The	 lesion	 was	 excised	 and	 evaluation	 of	 the	 excision	 specimen	 showed	
multifocal	actinic	keratosis	and	two	small	foci	displaying	SCC	with	an	invasive	growth	
of 0.8 and 0.5 mm.
Figure 1: Clinical picture of an erythematous plaque located on the frontal area of the 
face.	The	lesion	showed	a	heterogeneous	appearance	with	erythema,	mild	induration	
and	an	indistinct	margin.	The	lesion	had	a	size	of	2.3	×	2.1	cm	and	had	been	present	
for over 10 years.
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Figure 2. Clinical and RCM images of the squamous cell carcinoma with the corresponding 
histology. (a) Clinically, an erythematosquamous plaque with an irregular border was 
located	 on	 the	 frontal	 area	 of	 the	 face.	 Depigmentation	was	mainly	 found	 in	 the	
cranial part of the lesion. (b)	Corresponding	hematoxylin-eosin	stained	tissue	section	
displaying an invasive squamous cell carcinoma (black arrows). (c) RCM image showing 
flattening	of	the	dermal	epidermal	junction.	Islands	of	dermal	cells	(encircled	area)	
are interspersed between epidermal areas. (d)	 Tumor	 nest	 consisting	 of	 atypical	
epidermal	 cells	 (white	 arrow)	 surrounded	 by	 fibrosis	 (asterisk).	 (e) Spongiosis and 
keratinocyte	atypia,	visualized	as	enlargement	of	the	bright	 intercellular	spaces	and	
loss	of	the	regular	honeycomb	pattern.	(f)	Keratinocyte	atypia	and	streaming	at	the	
stratum spinosum. (g) Severe solar elastosis was seen in the dermis, visualized as 
coarse,	highly	reflective	collagen	bundles.	RCM	=	reflectance	confocal	microscopy.
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Conclusion 
Although it is known that RCM can be helpful for the diagnosis of non-melanoma skin 
cancer,	this	case	demonstrates	the	practical	use	of	RCM	as	a	tool	to	select	the	location	
for	a	punch	biopsy	in	a	large	and	clinically	indistinctive	lesion.	In	this	case,	the	foci	
displaying SCC were only a small part of the total lesion area. Without RCM imaging 
prior to the biopsy, the most aggressive part of the lesion could have been missed. 
RCM	allows	evaluation	of	the	total	lesion	area,	which	might	reduce	sample	errors	and	
delay	in	accurate	diagnosis	and	treatment	of	large	or	clinically	indistinctive	lesions.
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Summary and discussion 
The	overall	objective	of	the	studies	described	in	this	thesis	was	to	explore	the	clinical	
application	 of	 in vivo	 reflectance	 confocal	 microscopy	 (RCM)	 in	 the	 field	 of	
dermatology,	focusing	on	inflammatory	skin	diseases	and	nonmelanoma	skin	cancer	
(NMSC).	 In	 this	 concluding	 chapter	 the	main	findings	of	 the	present	 thesis	will	 be	
summarized	and	discussed.	Subsequently,	recommendations	on	the	applicability	of	
RCM	in	dermatology	and	future	perspectives	will	be	outlined.
Morphological	characterization	of	the	skin	plays	a	key	role	 in	the	establishment	of	
diagnosis of skin lesions and for monitoring of treatment response. When clinical 
diagnosis	of	a	skin	lesion	is	difficult,	histopathological	examination	of	a	biopsy	is	the	
gold	standard	for	further	investigation1.	A	biopsy	results	inherently	in	an	inflammatory	
reaction	 and	 scar	 formation.	 Other	 disadvantages	 of	 a	 biopsy	 are	 the	 inability	 to	
follow-up	dynamic	processes	over	time	and	the	risk	of	sample	error.	Furthermore,	the	
number	of	biopsies	is	limited	due	to	practical	and	cosmetical	reasons.	To	overcome	
these	limitations,	in	recent	years	noninvasive	imaging	tools	have	been	developed	to	
reveal morphological features of the skin that are not visible to the naked eye. These 
skin	 imaging	 devices	 might	 improve	 diagnostic	 accuracy	 without	 the	 need	 for	 a	
biopsy.	Among	novel	noninvasive	skin	imaging	tools	(e.g.	optical	coherent	tomography,	
high frequency ultrasound) RCM stands out because of the high, near-histological 
resolution2-4.	At	the	time	the	research	outlined	in	this	thesis	was	performed,	there	
was an increasing number of studies that showed promising results on the applicability 
of	RCM	to	improve	differentiation	between	benign	and	malignant	melanocytic	skin	
lesions4-9.	 Compared	 to	melanocytic	 skin	 lesions,	 there	was	 less	 known	 about	 the	
value	of	RCM	in	two	other	major	problems	in	dermatology;	NMSC	and	inflammatory	
skin diseases3,10-21.
Aim 1: to investigate the application of RCM in inflammatory skin disease
Since our department has an extensive past performance in psoriasis research, we 
initially	focused	on	this	disorder	as	an	example	of	an	inflammatory	skin	disease.	In	
Chapter 2.1 we described RCM features for psoriasis. The observed features included 
parakeratosis,	presence	of	epidermal	inflammatory	cells,	acanthosis,	papillomatosis	
and	an	increased	number	of	papillary	capillaries.	Furthermore,	in	psoriatic	skin	there	
were non-edged dermal papillae present (no bright rim surrounding the dermal 
papillae), compared to edged papillae in normal skin. This feature can only be seen 
with	RCM,	not	in	conventional	histopathology.	The	presence	of	dermal	inflammatory	
cells	 in	psoriatic	skin	could	not	be	evaluated	with	RCM,	due	to	acanthosis	and	the	
limited	penetration	depth	of	 the	 laser	beam.	Overall,	 there	was	a	high	correlation	
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between	RCM	features	and	conventional	hematoxylin-eosin	stained	tissue	sections.	
These observed features were in line with earlier reports and later performed 
studies11,12,22-28. In a later study performed by Zhong et al. the presence of micro- 
abscesses	of	Munro	was	reported	as	a	highly	specific	RCM	feature	for	psoriasis,	with	
a	specificity	of	96.4%28. 
In Chapter 2.2 a	pilot	study	was	performed	that	evaluated	the	application	of	RCM	as	a	 
tool	to	monitor	microscopic	response	to	ultraviolet	(UV)	B	phototherapy	in	patients	with	
psoriasis	noninvasively.	Based	on	the	defined	psoriasis	RCM	features	in	Chapter 2.1, 
RCM	 imaging	was	performed	before	 the	first	 irradiation	with	UVB	phototherapy,	after	 
nine	 irradiations,	at	 clinical	 clearance	and	 twelve	weeks	after	clearance.	Normalization	 
of	 the	RCM	and	histopathological	 features	after	 treatment	corresponded	highly	 to	
clinical improvement of psoriasis. Moreover, RCM was able to detect persistent 
microscopic	psoriatic	features,	whereas	the	skin	clinically	returned	to	normal	after	
treatment.	Ardigo	et	al.	described	that	RCM	might	detect	treatment	effects	prior	to	
clinical	 observation	 and	 therefore	 could	 be	 used	 to	 identify	 an	 early	 response	 to	
treatment29. In our study we found that the presence of large, clustered, tortuous 
capillaries at baseline might be related to non-responsiveness to UVB phototherapy 
in	patients	with	psoriasis.	A	later	performed	study	by	Basaran	et	al.	suggested	that	
the number of non-edged dermal papilla may be an indicator for treatment response30. 
To	improve	patient	care	for	patients	with	inflammatory	skin	diseases	it	is	important	
to acquire more knowledge about the pathofysiological mechanisms, including 
changes at the cellular level. Therefore, in Chapter 2.3 we used an established model 
to	induce	an	inflammatory	response	to	investigate	if	RCM	is	able	to	assess	dynamic	
inflammatory	processes	in	the	skin	in vivo. RCM	was	able	to	visualize	highly	reflective	
polymorphonuclear	neutrophils	 (PMN)	and	 their	dynamics	over	time,	 representing	
migration,	accumulation	and	degeneration.	Debarbieux	et	al.	stated	that	neutrophils	
appear	morphologically	different	from	lymphocytes31. This could not be observed in 
our study, since lymphocytes in this model are resided too deep in the dermis to 
visualize	with	RCM.	 In	addition,	 the	highly	reflective	degenerating	PMN	at	the	stratum	
corneum	limit	light	penetration	into	the	dermis.	In	future	research,	it	would	be	interesting	
to	investigate	if	RCM	can	distinguish	between	the	various	inflammatory	cells.
The	highly	characteristic	skin	morphology	of	the	accumulation	of	PMN	is	pathognomonic	
for psoriasis and is thought to play a role in the pathophysiology of this skin disease. 
The	dynamics	of	neutrophil	accumulation	in	psoriasis	have	been	described	previously,	
though these dynamics never have been studied in vivo32-35. For these reasons in 
Chapter 2.4 the	dynamics	of	neutrophil	migration	in	psoriasis	was	studied	using	 in 
vivo	RCM.	We	performed	RCM	imaging	in	a	psoriatic	lesion	for	eight	consecutive	days,	
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with	a	 twenty-four	hour	time	 interval.	 In	 all	 lesions,	 a	 cyclic	pattern	of	neutrophil	
migration	was	observed,	consisting	of	squirting	papillae,	transepidermal	migration,	
accumulation	 of	 the	 neutrophils	 in	 the	 stratum	 spinosum,	 accumulation	 in	 the	
stratum	 corneum	 and	 formation	 and	 degeneration	 of	 abscesses. Previous reports 
were	confirmed	by	these	in vivo	data.	In	addition,	we	reported	that	the	duration	of	a	
neutrophil-trafficking	cycle	was	five	to	seven	days	and	showed	a	similar	time-phasing	
in the whole lesion. 
Psoriasis	 is	 a	 heterogeneous	 disease.	 In	 case	 of	 a	 clinical	 exacerbation	 a	 different	
pathophysiological mechanism might be responsible compared to more chronic, 
non-expanding	 psoriasis.	 RCM	 might	 assist	 in	 early	 detection	 of	 expanding	 and	
non-expanding	areas	 in	a	psoriatic	 lesion.	This	distinction	might	contribute	to	new	
insights into the pathogenesis of psoriasis and the development of novel targeted 
therapies. Therefore, in Chapter 2.5	the	distribution	of	histological	features	 in	psoriatic	
patients	with	either	expanding	or	non-expanding	disease	was	studied	by	RCM.	Within	a	
psoriatic	lesion	four	locations	were	imaged:	two	locations	within	the	margin	of	the	lesion	
and	two	locations	in	the	centre	of	the	lesion.	All	locations	predominantly	displayed	similar	
features.	In	contrast,	we	found	significant	differences	between	patients	with	expanding	
and	 non-expanding	 psoriatic	 lesions;	 patients	 with	 an	 exacerbation	 of	 psoriasis	
displayed	 a	 higher	 number	 of	 epidermal	 inflammatory	 cells,	 including	Munro	 and	
Kogoj microabsesses, broader dermal papillae and more tortuous capillaries with a 
high	capillary	blood	flow.	These	results	are	in	line	with	earlier	reports	that	described	
that	the	presence	of	inflammatory	cells	is	related	to	enlarging	and	very	early	lesions	
of psoriasis32,35,36.	Based	on	these	findings,	we	can	question	the	margin	zone	model	
that	is	described	previously	by	others,	which	suggested	that	there	is	more	activity	at	
the	margin	than	within	the	center	of	a	psoriatic	lesion37,38. 
In conclusion, RCM imaging seems to be a useful tool to assess histological features 
of	psoriasis,	monitor	treatment	effects	and	follow-up	dynamic	processes	over	time.	
Additionally,	RCM	might	detect	subclinical	features	of	psoriasis	when	skin	is	clinically	
normal.	 Later	 performed	 studies	 support	 these	 findings23-25,27-31. However, to 
investigate	whether	RCM	is	able	to	distinguish	psoriasis	from	other	skin	diseases	a	
study	is	required	in	which	multiple	skin	disorders	are	included.
Aim 2: to investigate the application of RCM in nonmelanoma skin cancer
NMSC,	 in	particular	basal	cell	 carcinoma	 (BCC),	 is	 the	most	common	cancer	 in	 the	
fair-skinned	population	and	incidence	is	rising	rapidly.	To	reduce	the	burden	on	the	
healthcare	 system	 more	 efficient	 and	 effective	 skin	 cancer	 care	 is	 needed.	 The	
application	of	noninvasive	diagnostic	tools	might	result	in	a	higher	cost-effectiveness.	
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In Chapter 3 we evaluated the applicability of RCM to diagnose NMSC noninvasively, 
focusing on BCC.
In recent years, diagnosis of the subtype of BCC has become more important given 
that	 an	 increasing	 number	 of	 noninvasive	 treatment	 modalities	 have	 become	
available. For this reason, in Chapter 3.1 the accuracy of a punch biopsy, the current 
gold	standard	to	establish	BCC	subtype,	was	investigated.	The	overall	accuracy	of	a	
punch biopsy to determine the BCC subtype was 69%. In 11% of all BCCs an unsuspected 
more aggressive subtype was present. Other studies report similar accuracy rates of 
72.3% and 60.9% and a missed more aggressive BCC subtype component in 14.1% of 
all cases39,40.	 These	 findings	 are	 important,	 since	 the	 presence	 of	 an	 unsuspected	
aggressive	subtype	potentially	results	 in	therapy	failure	of	non-surgical	treatments	
like imiquimod or photodynamic therapy.
The results described in Chapter 3.1 indicate that a punch biopsy is not an ideal tool to 
determine	 the	 BCC	 subtype.	 For	 this	 reason	we	 explored	 the	 utilization	 of	 RCM	 to	
diagnose	the	BCC	subtype.	Previous	studies	showed	that	RCM	was	able	to	identify	a	
BCC13-15,20,21,41,42. However, no studies were performed which evaluated the ability 
of	RCM	to	distinguish	between	different	BCC	subtypes.	In	Chapter 3.2 we described 
features	 for	 superficial,	 nodular	 and	 micronodular	 BCC.	 Superficial	 BCC	 was	
characterized	 by	 the	 presence	 of	 solar	 elastosis	 and	 tumor	 nests,	 consisting	 of	
aggregations	of	basaloid	cells	 located	just	below	or	in	connection	with	the	basal	cell	
layer. The main features for nodular and micronodular BCC were tumor nests with 
peripheral	 palisading,	 branch-like	 structures,	 fibrotic	 septa	 surrounding	 the	 tumor	
nests	and	an	increase	in	vascular	diameter.	The	size,	shape	and	location	of	the	tumor	
nests	 allowed	 further	 distinction	 between	 these	 two	 BCC	 subtypes.	 In	 our	 study	
	characteristics	 for	 infiltrative	BCC	could	not	be	assessed,	since	our	study	 included	only	
three	mixed	type	infiltrative	BCCs	with	the	infiltrative	component	of	the	tumor	deeper	in	
the dermis. Our results are in line with a later study performed by Longo et al, although 
they	did	not	distinguish	between	nodular	BCC	and	micronodular	BCC43.	This	distinction	
is	important	to	determine	the	excision	margin	at	therapeutic	surgical	excision.	Longo	et	al.	
described	RCM	features	for	infiltrative	BCC,	which	was	characterized	by	the	presence	of	
dark	silhouettes,	peripheral	palisading	and	collagen	surrounding	the	tumor	 islands43. 
Other	 characteristics	 such	 as	 shape	 of	 the	 nests	 and	 their	 reflectivity	 could	 be	 of	
importance	in	this	respect.	Infiltrative	BCCs	might	be	more	difficult	to	visualize	due	to	
the	usually	more	deep	location	in	the	dermis	compared	to	the	other	BCC	subtypes.	
In Chapter 3.3 we demonstrated the clinical applicability of RCM in dermatology to 
assist	in	diagnosis.	RCM	imaging	was	performed	in	a	large,	clinically	indistinct	erythe-
matosquamous	 lesion	 located	 on	 the	 forehead	 of	 a	 patient.	 Multiple	 previously	
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performed	 biopsies	were	 inconclusive	 and	 various	 treatments	were	 not	 effective.	
Diagnostic,	and	potentially	therapeutic,	excision	of	the	whole	lesion	was	unfavorable	
due	to	the	size	and	location	of	the	lesion.	Because	of	these	reasons,	the	whole	lesion	
was evaluated using RCM. Guided by the obtained RCM images, the most suspected 
part of the lesion was biopsied. This rendered the diagnosis of a squamous cell 
carcinoma and adequate treatment could be started. The performed study 
demonstrated the major advantage of RCM to evaluate a whole lesion, which 
potentially	reduces	sample	error	and	delay	in	adequate	treatment.	
In summary, we conclude that a punch biopsy is not an ideal tool to determine the 
BCC	subtype	and	RCM	might	be	an	alternative	to	establish	the	diagnosis	of	a	BCC.	In	
addition,	RCM	may	distinguish	between	superficial,	nodular	and	micronodular	BCC	
subtypes.	 Furthermore,	we	 have	 demonstrated	 the	 clinical	 application	 of	 RCM	 to	
establish	diagnosis	in	a	clinically	indistinct	squamous	cell	carcinoma.	These	findings	
are in line with other reports13-15,20,21,41-43. Besides our study, which included a moderate 
number	of	patients,	only	Longo	et	al.	investigated	the	potential	of	RCM	to	determine	
the BCC subtype43.	Prospective	and	large	studies	are	required	to	determine	sensitivity,	
specificity	and	interobserver	variability.	Furthermore,	protocols	need	to	be	developed	
before	this	tool	can	be	implemented	in	routine	patient	care.	
Recommendations and future perspectives
The studies outlined in this thesis show promising results for the clinical applicability 
of	RCM	in	dermatology.	However,	there	are	still	some	drawbacks.	A	major	disadvantage	 
of	RCM	 is	 the	 limited	penetration	depth	of	 the	 laser	 beam.	 In	NMSC,	 or	 other	 skin	
lesions located at the level of the dermis, the lesion might not be visualized completely 
in	 depth.	 In	 addition,	 hyperkeratosis	 or	 acanthosis	 of	 skin	 lesions	 can	 limit	 light	
penetration	into	the	dermis.	
At	the	start	of	the	research	described	in	this	thesis,	we	were	the	first	in	The	Netherlands	 
to	employ	RCM	in	dermatology.	In	the	beginning	it	was	time	consuming	to	get	familiar	 
with	the	device,	to	interpret	RCM	images	and	to	determine	the	possible	applications	
and	limitations.	Over	time,	application	of	RCM	and	interpretation	of	the	RCM	images	
was much faster. 
The	 current	 application	of	 RCM	 in	 inflammatory	 skin	 diseases,	 including	 psoriasis,	
seems	to	be	predominantly	in	a	research	setting.	It	would	be	applicable	in	evaluation	
of	microscopic	 treatment	effects	 (e.g.	 in	 testing	of	 a	new	drug)	or	 to	 increase	 the	
knowledge of pathofysiological mechanisms in order to develop new targeted 
therapies. In future, RCM might be used to adjust the treatment strategy based on 
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certain RCM criteria that detect preclinical microscopic changes. Based on these 
microscopic changes, it may be possible to predict non-responders to expensive 
drugs	(e.g.	the	class	of	biological	drugs)	and	cost-effectiveness	might	be	increased.	
The	application	of	RCM	to	assist	 in	diagnosis	of	a	clinically	 indistinct	 inflammatory	
lesion is less clear, since the majority of diagnosis is made clinically. Furthermore, 
there	is	a	wide	range	of	inflammatory	skin	diseases	and	therefore	many	RCM	features	
need	 to	 be	 determined	 in	 order	 to	 evaluate	 whether	 RCM	 is	 able	 to	 distinguish	
between one and the other.
In	our	opinion,	the	major	clinical	application	of	RCM	in	dermatology	is	in	the	field	of	
skin	malignancies,	in	both	melanoma	and	NMSC.	In	melanoma,	multiple	studies	have	
shown	 the	 applicability	 of	 RCM	 to	 distinguish	malignant	 from	benign	melanocytic	
lesions.	 In	 a	 recently	 published	 study	 the	 benefits	 of	 implementation	 of	 RCM	 in	
standard	medical	care	for	melanoma	was	shown.	In	this	study	there	was	a	significant	
reduction	 in	 the	number	of	benign	 lesions	excised	of	 19.4	 in	conventional	medical	
care	 compared	 to	6.3	when	RCM	was	used	as	a	diagnostic	 tool.	 This	 resulted	 in	a	
reduction	of	the	overall	costs	with	27%44.	In	future	research,	the	cost-effectiveness	of	
RCM	for	diagnosis	of	NMSC	 in	 the	standard	medical	care	needs	to	be	 investigated	
before	RCM	can	be	implemented	on	a	large	scale.	Cooperation	with	other	departments	
might	 help	 to	 achieve	 cost-effectiveness	 of	 RCM	 in	 patient	 care.	 Increasing	 the	
cost-effectiveness	of	medical	care	in	NMSC	is	 important,	because	incidence	is	high	
and	still	increasing.	In	addition,	RCM	is	more	patient	friendly	compared	to	a	biopsy,	
particularly	 in	 patient	 with	 numerous	 (pre)cancerous	 lesions.	 To	 investigate	 the	
cost-effectiveness	of	the	application	of	RCM	in	diagnosis	of	NMSC,	the	sensitivity	and	
specificity	of	RCM	features	of	NMSC	need	to	be	determined	and	protocols	have	to	be	
developed.	Other	clinical	applications	of	RCM	besides	noninvasive	diagnosis	might	
include in vivo and ex vivo	 margin	 determination	 of	 BCC	 preoperatively	 or	
peroperatively,	respectively.
Based	on	the	findings	in	this	thesis,	our	research	group	focused	on	the	implementation	
of	 RCM	 as	 a	 noninvasive	 diagnostic	 tool	 for	 NMSC.	 Currently,	 a	 prospective	 large	
randomized	 controlled	 trial	 is	 enrolled	 in	 collaboration	 with	 two	 non-academic	
hospitals.	The	aim	of	this	trial	is	to	determine	the	sensitivity,	specificity	and	cost-ef-
fectiveness	 of	 RCM	 in	 diagnosis	 of	 BCC.	 This	 kind	 of	 research	 is	 essential	 for	
reimbursement	and	wide	scale	implementation	of	RCM	in	dermatology.
Overall,	in	this	thesis	a	first	step	in	the	exploration	of	the	clinical	application	of	RCM	
in dermatology has been made. The research described in this thesis will be helpful to 
determine	the	future	directions	of	RCM	in	dermatology.	In	addition,	we	have	hopefully	
encouraged	others	to	further	investigate	the	applicability	of	RCM	in	dermatology.	
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Nederlandse samenvatting en discussie
Het	doel	van	de	onderzoeken	gepresenteerd	in	dit	proefschrift	was	om	te	onderzoeken	
of in vivo	reflectie	confocale	microscopie	(RCM)	van	toegevoegde	waarde	is	voor	de	
klinische	dermatologie.	Hierbij	werd	het	accent	gelegd	op	inflammatoire	huidziekten	
en	nonmelanoma	huidkanker.	In	dit	hoofdstuk	worden	de	conclusies	van	het	proefschrift	
samengevat en bediscussieerd. Vervolgens worden aanbevelingen gedaan over de 
huidige	en	mogelijk	toekomstige	toepassingen	van	RCM	binnen	de	dermatologie.	
Het beschrijven van de morfologie van de huid speelt een belangrijke rol in de derma-
tologische	 diagnostiek.	 Deze	 morfologie	 wordt	 mede	 gebruikt	 om	 het	 effect	 van	
behandeling te evalueren. Wanneer het niet mogelijk is om een diagnose te stellen op 
basis van het klinische beeld, wordt meestal een punch biopt afgenomen. Een punch 
biopt	wordt	als	de	‘gouden	standaard’	gezien	voor	aanvullende	diagnostiek1. Echter, 
het	 afnemen	 van	 een	 biopt	 heeft	 diverse	 nadelen.	 Het	 afnemen	 van	 een	 biopt	
veroorzaakt	een	inflammatoire	reactie	in	het	huidweefsel	en	kan	leiden	tot	litteken-
vorming.	 Ook	 is	 een	 punch	 biopt	 niet	 altijd	 representatief	 voor	 de	 gehele	 laesie,	
waardoor een sample error kan optreden. Tevens is het aantal biopten dat afgenomen 
kan	worden	bij	één	patiënt	beperkt.	Daarnaast	is	het	niet	mogelijk	om	histopatholo-
gische	veranderingen	van	exact	dezelfde	huidlaesie	in	de	loop	van	de	tijd	te	volgen.	
Vanwege deze nadelen zijn in de afgelopen jaren nieuwe, niet-invasieve beeldvormende 
technieken ontwikkeld. Deze geven de huidmorfologie op cellulair niveau weer zonder 
dat een punch biopt noodzakelijk is. Van alle nieuwe beeldvormende technieken, 
zoals	optical	coherent	tomography	en	high	frequency	ultrasound,	is	RCM	het	meest	
veelbelovend.	RCM	heeft,	in	tegenstelling	tot	de	overige	technieken,	een	hoge	resolutie,	
waardoor cellulaire en subcellulaire structuren van de huid zichtbaar gemaakt kunnen 
worden2-4. 
Ten	tijde	dat	met	het	onderzoek	beschreven	in	dit	proefschrift	werd	gestart,	kwam	er	
een toenemende hoeveelheid literatuur beschikbaar over melanocytaire huidlaesies 
en RCM. Deze literatuur liet veelbelovende resultaten zien voor het gebruik van RCM 
als	diagnostisch	hulpmiddel	om	benigne	van	maligne	melanocytaire	huidlaesies	 te	
onderscheiden4-9. Op het gebied van twee andere veelvoorkomende problemen in de 
dermatologie,	nonmelanoma	huidkanker	en	inflammatoire	huidaandoeningen,	waren	
destijds	een	beperkt	aantal	studies	beschikbaar	waarin	de	toepassing	van	RCM	werd	
onderzocht3,10-21.
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Doelstelling 1: Het onderzoeken van de toepassing van RCM in inflammatoire 
huidziekten
De	 afdeling	 Dermatologie	 van	 het	 Radboudumc	 Nijmegen	 heeft	 veel	 onderzoeks-
ervaring	 op	 het	 gebied	 van	 psoriasis.	 Om	 deze	 reden	 is	 initieel	 gestart	 met	 het	
onderzoeken	van	psoriasis	als	 inflammatoire	huidaandoening.	 In	Hoofdstuk 2.1 worden 
de RCM kenmerken van psoriasis beschreven. Deze kenmerken bestaan uit parakeratosis, 
de aanwezigheid van ontstekingscellen in de epidermis, acanthosis, papillomatosis en 
een toegenomen aantal capillairen in de papillaire dermis. Daarnaast zijn ‘non-edged’ 
dermale papillen aanwezig in de psoriasis huid en ‘edged’ dermale papillen in normale 
huid.	Dit	is	een	kenmerk	van	psoriasis	welke	niet	beschreven	wordt	in	de	conventionele	
histopathologie. De aanwezigheid van  ontstekingscellen in de dermis kon niet worden 
vastgesteld	met	RCM	vanwege	de	acanthosis	en	beperkte	penetratie	diepte	van	het	laser	
licht.	Alle	psoriasis	kenmerken	in	ogenschouw	genomen,	was	er	een	goede	correlatie	
tussen	de	RCM	kenmerken	en	de	morfologische	kenmerken	in	de	conventionele	hema-
toxyline-eosine gekleurde weefselcoupes. De resultaten in deze studie komen overeen 
met eerder gerapporteerde psoriasis RCM kenmerken en ook met beschreven RCM 
kenmerken in later uitgevoerde studies11,12,22-28. In een studie van Zhong et al. wordt 
daarnaast beschreven dat de aanwezigheid van Munro microabcessen een zeer 
specifiek	RCM	kenmerk	is	voor	psoriasis,	met	een	specificiteit	van	96.4%28. 
In Hoofdstuk 2.2 wordt onderzocht in hoeverre RCM gebruikt kan worden als 
techniek	om	niet-invasief	de	microscopische	effecten	van	behandeling	met	ultraviolet	
B	 (UVB)	 lichttherapie	 bij	 psoriasis	 patiënten	 te	 monitoren.	 Hiervoor	 worden	 de	
psoriasis RCM kenmerken zoals beschreven in Hoofdstuk 2.1 gebruikt. Beeldvorming 
met	RCM	werd	verricht	vóór	de	eerste	belichting	met	UVB,	na	negen	belichtingen,	
wanneer er klinisch geen sprake meer was van zichtbare huidlaesies en twaalf weken 
na het verdwijnen van de huidlaesies. De psoriasis histopathologische kenmerken 
en	psoriasis	RCM	kenmerken	normaliseerden	na	belichting	met	UVB,	waarbij	er	een	
hoge	 correlatie	 was	 met	 de	 klinische	 verbetering.	 Daarnaast	 werden	 met	 RCM	
persisterende kenmerken van psoriasis gezien, terwijl de huid klinisch geheel 
genormaliseerd was. In een studie van Ardigo et al. wordt daarnaast beschreven dat 
RCM	 subklinische	microscopische	 behandeleffecten	 kan	 vaststellen.	 Hierdoor	 kan	
RCM mogelijk gebruikt worden om een vroege behandelrespons vast te stellen29. Op 
basis van de bevindingen in onze studie kan gesuggereerd worden dat de aanwezigheid 
van	 grote,	 geclusterde	 en	 kurkentrekker-achtige	 capillairen	 vóór	 start	 van	 de	
behandeling mogelijk voorspellend is voor therapie falen van UVB fototherapie bij 
psoriasis	patiënten.	In	een	later	uitgevoerde	studie	van	Basaran	et	al.	wordt	geopperd	
dat de hoeveelheid ‘non-edged’ dermale papillen voorspellend zou kunnen zijn voor 
het	effect	van	een	behandeling	bij	psoriasis	patiënten30. 
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Om	de	therapie	voor	patiënten	met	een	inflammatoire	huidaandoening	te	verbeteren,	
is het van belang om de kennis te vergroten over de onderliggende pathofysiologische 
mechanismen. Hierbij zijn ook de histopathologische veranderingen van belang. 
Om deze reden wordt in Hoofdstuk 2.3 onderzocht of RCM gebruikt kan worden om 
in vivo dynamische	 inflammatoire	 processen	 in	 de	 huid	 te	 onderzoeken.	Hierbij	 is	
gebruik gemaakt van een gestandaardiseerd huidmodel waarbij leukotriene B4 (LTB4) 
aangebracht	wordt	op	de	huid	om	een	 inflammatoire	 respons	op	 te	wekken	 in	de	
huid.	 De	 door	 LTB4	 geïnduceerde	 epidermale	 influx	 van	 polymorphonucleaire	
neutrofielen	(PMN)	was	duidelijk	zichtbaar	met	RCM,	vanwege	de	hoge	reflectiviteit	
die deze cellen hebben. De dynamiek van deze cellen kon worden gevolgd in de loop 
van	 de	 tijd.	 Hierbij	 was	 er	 sprake	 van	 migratie	 door	 de	 epidermis,	 gevolgd	 door	
accumulatie	in	het	stratum	corneum	en	stratum	spinosum	en	vervolgens	degeneratie	
van	de	PMN.	De	onderzoeksgroep	van	Debarbieux	heeft	beschreven	dat	met	RCM	
onderscheid	gemaakt	kan	worden	tussen	neutrofielen	en	lymfocyten31. Op basis van 
onze	studie	kon	hierover	geen	uitspraak	worden	gedaan,	omdat	alleen	neutrofielen	
gezien	werden.	Na	applicatie	van	LTB4	treedt	er	wel	een	influx	op	van	lymfocyten	in	
de dermis, echter deze liggen te diep om waargenomen te worden met RCM. 
Daarnaast	 resulteert	 de	 aanwezigheid	 van	 hoog	 reflectieve	 PMN	 in	 het	 stratum	
corneum in een afname van de hoeveelheid laser licht welke tot de dermis kan 
doordringen. Het zou van toegevoegde waarde zijn indien met RCM de verschillende 
typen ontsteking cellen van elkaar onderscheiden kunnen worden. Dit dient nader in 
kaart te worden gebracht. 
De	accumulatie	van	PMN	in	de	huid	is	een	karakteristiek	histopathologisch	kenmerk	
van	psoriasis.	Deze	accumulatie	van	PMN	is	reeds	beschreven	in	eerdere	studies.	Tot	
nu was het echter niet mogelijk om dit dynamische proces in vivo te bestuderen32-35. 
Om deze redenen wordt in Hoofdstuk 2.4	de	dynamiek	van	neutrofielen	in	psoriasis	
in vivo onderzocht door middel van RCM. Op acht opeenvolgende dagen werden RCM 
beelden	gemaakt	op	dezelfde	 locatie	 in	een	psoriasis	 laesie.	De	migratie	van	PMN	
vertoonde	een	cyclisch	patroon,	waarbij	eerst	massale	uittreding	van	neutrofielen	uit	
de top van de dermale papillen plaatvond. Vervolgens migreerden de PMN door de 
epidermis	richting	het	stratum	corneum.	De	PMN	clusterden	samen	ter	hoogte	van	
het stratum spinosum en verplaatsten zich naar het stratum corneum waar de PMN 
abcessen	vormden.	Het	laatste	stadium	van	de	cyclus	bestond	uit	degeneratie	van	de	
gevormde abcessen, waarna de cyclus weer opnieuw begon of uitdoofde. Deze in 
vivo data	 komen	 overeen	 met	 beschrijvingen	 op	 basis	 van	 statische	 data	 in	 de	
literatuur. De uitgevoerde studie met RCM liet daarnaast zien dat de duur van één 
cyclus, zoals hierboven beschreven, vijf tot zeven dagen duurde.
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Psoriasis is klinisch een heterogene huidziekte. Deze huidziekte kan zich presenteren 
variërend	 van	 een	 chronische	 situatie,	 waarbij	 de	 laesies	 langdurig	 onveranderd	
aanwezig	 zijn,	 tot	 een	 snelle	 exacerbatie.	 Mogelijk	 speelt	 in	 een	 actieve,	 snel	
uitbreidende psoriasis een ander pathofysiologisch mechanisme een rol dan in een 
chronische psoriasis en hebben beiden andere histopathologische kenmerken. Indien 
het mogelijk zou zijn op basis van RCM histologische kenmerken het klinische beloop 
te voorspellen, dan zou de behandeling mogelijk beter kunnen worden afgestemd op 
de	 individuele	 patiënt.	 In	Hoofdstuk 2.5 worden om deze reden de histologische 
kenmerken	van	patiënten	met	een	actieve	en	chronische	psoriasis	onderzocht	met	
RCM.	 In	 één	 psoriasis	 laesie	 werden	 vier	 locaties	 gescand;	 twee	 in	 de	 rand	 van	 
de laesie en twee in het centrum. Er was geen verschil in de psoriasis RCM 
kenmerken	 binnen	 één	 psoriasis	 laesie	 in	 een	 patiënt.	 Daarentegen	 waren	 er	
significante	 verschillen	 in	 psoriasis	 RCM	 kenmerken	 tussen	 patiënten	met	 een	 actieve	 
of	 chronische	 psoriasis.	 In	 een	 actieve	 psoriasis	was	 sprake	 van	 een	 groter	 aantal	
epidermale ontstekingscellen (waaronder Munro en Kogoj microabcessen), bredere 
en	 meer	 kurkentrekker-achtige	 capillairen	 en	 een	 prominentere	 capillaire	 bloed-
doorstroming in vergelijking met een chronische psoriasis. De resultaten van deze 
studie zijn in lijn met bevindingen van anderen, welke rapporteerden dat de 
aanwezigheid van ontstekingscellen is gerelateerd aan het ontstaan van nieuwe 
laesies en een uitbreidende psoriasis32,35,36. Op basis van de resultaten in dit onderzoek 
kan het randzone model, welke in het verleden in andere studies is beschreven, in 
twijfel	 worden	 getrokken.	 In	 dit	 model	 zou	 er	 sprake	 zijn	 van	 een	 meer	 actieve	
psoriasis in de rand van een laesie ten opzichte van het centrum37,38. 
Samenvattend	lijkt	RCM	een	geschikte	beeldvormende	techniek	te	zijn	om	histologische	
kenmerken	van	psoriasis	vast	te	stellen,	het	effect	van	een	behandeling	op	cellulair	
niveau te monitoren en om dynamische histopathologische processen in de huid te 
volgen. Daarnaast is het met RCM mogelijk om subklinische kenmerken van psoriasis 
te	detecteren.	Latere	studies	bevestigen	deze	bevindingen23-25,27-31. 
Doelstelling 2: Het onderzoeken van de toepassing van RCM in nonmelanoma 
huidkanker
Nonmelanoma huidkanker (NMSC), en in het bijzonder het basaalcelcarcinoom (BCC), 
is	de	meest	 voorkomende	maligniteit	 in	de	blanke	populatie.	Daarnaast	neemt	de	
incidentie	van	NMSC	nog	steeds	toe.	Deze	grote	aantallen	van	huidkanker	belasten	
de	 gezondheidszorg.	 Hierdoor	 wordt	 het	 steeds	 urgenter	 om	 de	 effectiviteit	 en	
efficiëntie	 van	 de	 huidkanker	 zorg	 te	 vergroten.	 Het	 toepassen	 van	 niet-invasieve	
beeldvormende technieken kan hier mogelijk aan bijdragen. Daarnaast is niet- 
invasieve	diagnostiek	patiëntvriendelijker.	Om	deze	redenen	wordt	 in	Hoofdstuk 3 
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onderzocht	of	RCM	toegepast	kan	worden	om	de	diagnostiek	van	NMSC	te	verbeteren,	
waarbij	gefocust	werd	op	verbetering	van	de	diagnostiek	van	het	BCC.	
In	 de	 afgelopen	 jaren	 zijn	 steeds	 meer	 niet-invasieve	 behandelopties	 voor	 BCCs	
beschikbaar	gekomen.	Omdat	niet-invasieve	 therapieën	 in	principe	alleen	geschikt	
zijn voor minder agressieve BCCs is het vaststellen van het BCC subtype steeds 
belangrijker geworden. In Hoofdstuk 3.1 wordt daarom de nauwkeurigheid van een 
punch biopt voor het vaststellen van het BCC subtype onderzocht. Het punch biopt 
wordt op dit moment als de ‘gouden standaard’ gezien voor het bepalen van het BCC 
subtype. De algehele nauwkeurigheid van een punch biopt voor het vaststellen van 
het BCC subtype was 69%. Daarnaast werd bij excisie in 11% van alle BCCs een meer 
agressief	BCC	subtype	aangetoond,	welke	 initieel	gemist	werd	bij	het	punch	biopt.	
Andere studies laten soortgelijke getallen zien; in twee studies was de nauwkeurigheid 
van een punch biopt voor het vaststellen van het BCC subtype 72,3% en 60,9%. 
Daarnaast werd in 14,1% van alle BCCs een meer agressief subtype gezien in het 
excisie weefsel, welke bij het biopt gemist was39,40. Deze resultaten zijn van belang, 
aangezien het missen van een agressief subtype kan resulteren in therapie falen 
wanneer een andere behandeling dan chirurgische excisie gekozen wordt.  
De resultaten van het onderzoek in Hoofdstuk 3.1 laten zien dat een punch biopt 
geen	 optimale	methode	 is	 om	 het	 BCC	 subtype	 vast	 te	 stellen.	 Daarom	wordt	 in	
Hoofdstuk 3.2 onderzocht of RCM geschikt is om het BCC subtype te bepalen. In eerder 
onderzoek	 is	 reeds	 aangetoond	 dat	 RCM	een	BCC	 kan	 identificeren,	 hierbij	wordt	
echter geen onderscheid gemaakt tussen de verschillende BCC subtypes13-15,20,21,41,42. 
In Hoofdstuk 3.2	beschrijven	we	de	RCM	kenmerken	voor	een	superficieel,	nodulair	
en	micronodulair	BCC.	Het	superficieel	BCC	werd	gekenmerkt	door	de	aanwezigheid	
van solaire elastose en tumor nesten. De tumor nesten bestonden uit een cluster van 
basale cellen die net onder de basale cellaag lagen of hiermee in verbinding waren. 
Het belangrijkste kenmerk voor zowel nodulair als micronodulair BCC was de 
aanwezigheid	 van	 tumor	 nesten	 met	 de	 volgende	 karakteristieken:	 vertakkende	
reflectieve	structuren	in	de	tumor	nesten,	perifere	palissadering,	een	toegenomen	
diameter	 van	 de	 bloedvaten	 en	 fibrotische	 septa.	 Vervolgens	 kon	 onderscheid	
worden	 gemaakt	 tussen	 nodulair	 en	micronodulair	 BCC	 door	 de	 grootte,	 vorm	en	
lokalisatie	van	de	tumor	nesten.	 In	onze	studie	werden	slechts	3	 infiltratieve	BCCs	
geïncludeerd,	welke	bestonden	uit	meerdere	BCC	subtypes.	Hierbij	was	de	 infiltratieve	
component diep in de dermis gelegen, waardoor het niet mogelijk was om kenmerken 
van	het	infiltratieve	BCC	te	bepalen.	De	resultaten	van	deze	studie	komen	overeen	
met bevindingen van Longo et al, hoewel in de studie van Longo et al. geen 
onderscheid wordt gemaakt tussen nodulair en micronodulair BCC43. Het maken van 
dit onderscheid is relevant aangezien het BCC subtype mede bepalend is voor de 
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marge	bij	therapeutische	chirurgische	excisie.	Longo	et	al.	beschrijven	daarentegen	
wel	 RCM	 kenmerken	 van	 een	 infiltratief	 BCC.	 Dit	 BCC	 subtype	wordt	 gekenmerkt	
door	de	aanwezigheid	van	donkere	silhouetten,	perifere	palissadering	en	collageen	
om de tumor nesten43.	 In	vergelijking	met	andere	BCC	subtypes	 liggen	 infiltratieve	
BCCs dikwijls dieper in de dermis, waardoor ze mogelijk moeilijker te zien zijn met 
RCM. 
In Hoofdstuk 3.3 wordt	geïllustreerd	hoe	de	toepassing	van	RCM	de	dermatologische	
diagnostiek	 in	de	dagelijkse	patiëntenzorg	kan	verbeteren.	 In	de	beschreven	casus	
wordt	RCM	toegepast	bij	een	patiënt	met	een	forse	erythematosquameuze	plaque	
op	het	voorhoofd.	Bij	deze	patiënt	waren	reeds	meerdere	punch	biopten	afgenomen	 
en hierna verscheidene behandelingen uitgevoerd zonder resultaat. Gezien de 
grootte	 en	 lokalisatie	 van	 de	 plaque	was	 in toto excisie	 (diagnostisch	 en	mogelijk	
therapeutisch)	niet	wenselijk.	Met	RCM	werd	de	gehele	laesie	afgescand.	Vervolgens	
kon van het meest suspecte deel van de plaque een punch biopt worden afgenomen. 
Op basis van het histopathologische onderzoek werd de diagnose plaveiselcel-
carcinoom gesteld en kon adequate behandeling worden gestart. Deze casus 
illustreert de meerwaarde van RCM om een gehele laesie af te kunnen scannen, 
waardoor de kans op sample error, en hiermee vertraging van adequate behandeling, 
wordt verkleind.
Concluderend	kunnen	we	stellen	dat	een	punch	biopt	geen	optimale	methode	is	om	
het	 BCC	 subtype	 vast	 te	 stellen	 en	 dat	 RCM	 een	 mogelijk	 alternatief	 is	 voor	 het	
vaststellen	van	een	BCC	en	het	bepalen	van	het	BCC	subtype	(superficieel,	nodulair	en	
micronodulair). Daarnaast illustreerden we aan de hand van een casus de toepassing van 
RCM	om	de	 klinische	diagnostiek	 te	 verbeteren.	De	beschreven	 resultaten	 komen	
overeen met bevindingen van andere onderzoeksgroepen13-15,20,21,41-43. Naast onze 
studie werd alleen door Longo et al. onderzocht of met behulp van RCM het BCC 
subtype kan worden vastgesteld43.	Grotere	en	prospectieve	studies	zijn	nodig	om	de	
sensitiviteit,	specificiteit,	interobserver	variabiliteit	en	kosteneffectiviteit	te	bepalen	
van	 RCM	 voor	 diagnostiek	 van	 het	 BCC.	 Ook	 dienen	 RCM	 protocollen	 ontwikkeld	 
te	worden	 vóór	RCM	 toegepast	 en	 geïmplementeerd	 kan	worden	 in	 de	dagelijkse	
dermatologische	praktijk.
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Hedendaagse toepassing van RCM en toekomst perspectief
De	onderzoeken	beschreven	in	dit	proefschrift	laten	veelbelovende	resultaten	zien	
voor de toepassing van RCM in de klinische dermatologie. Er zijn echter enkele 
nadelen.	Het	grootste	nadeel	van	RCM	is	de	beperkte	penetratie	diepte	van	het	laser	
licht. In NMSC, of andere diepliggende huidlaesies, wordt mogelijk niet de gehele 
laesie in beeld gebracht. Daarnaast verminderen hyperkeratosis en acanthosis de 
hoeveelheid laserlicht dat door kan dringen in de dermis. 
Toen	 we	 startten	 met	 de	 onderzoeken	 beschreven	 in	 dit	 proefschrift,	 waren	 
we de eerste onderzoeksgroep in Nederland die RCM toepaste in de klinische 
dermatologie.	 Initieel	 nam	 het	 scannen	 veel	 tijd	 in	 beslag.	 Er	 diende	 te	 worden	
onderzocht hoe het apparaat het best kon worden toegepast, wat de mogelijkheden 
waren en de beperkingen. Tevens nam het interpreteren van de RCM beelden, aan de 
hand	 van	 beschikbare	 literatuur,	 veel	 tijd	 in	 beslag.	 Na	 verloop	 van	 tijd	 ging	 het	
scannen	 van	 de	 huid	 en	 de	 interpretatie	 van	 de	 RCM	 beelden	 aanzienlijk	 sneller.	
Inmiddels	kan	een	huidlaesie	gemiddeld	in	vijf	tot	tien	minuten	beoordeeld	worden	
en	is	er	bij	adequate	instructie	een	snelle	leercurve	bij	nieuwe	gebruikers.	
Op	dit	moment	lijkt	de	toepassing	van	RCM	op	het	gebied	van	inflammatoire	huid-
aandoeningen hoofdzakelijk te zijn op het gebied van onderzoek. RCM kan toegepast 
worden	 om	microscopische	 behandeleffecten	 te	 evalueren	 of	 om	 de	 kennis	 over	
 pathofysiologische mechanismen te vergroten. Hierdoor kunnen nieuwe, gerichte 
behandelingen	 worden	 ontwikkeld	 of	 de	 microscopische	 effecten	 van	 nieuwe	
medicatie	worden	onderzocht.	In	de	toekomst	kan	RCM	mogelijk	toegepast	worden	
om de behandelstrategie aan te passen. In dat geval zouden aan de hand van RCM 
criteria preklinische microscopische veranderingen vastgesteld kunnen worden, 
waarop de behandelstrategie wordt afgestemd. Gebaseerd op deze RCM kenmerken 
zou	het	wellicht	mogelijk	zijn	om	te	voorspellen	welke	patiënten	wel	of	niet	reageren	
op bepaalde dure behandelingen (zoals biologicals). Op deze manier kan RCM 
bijdragen	 aan	 het	 vergroten	 van	 de	 kosteneffectiviteit.	 Er	 dient	 verder	 onderzoek	
gedaan	te	worden	om	te	bepalen	of	RCM	de	diagnostiek	van	inflammatoire	huidziekten	
kan	verbeteren.	Het	overgrote	deel	van	de	dermatologische	diagnostiek	is	gebaseerd	
op het kenmerkende klinische beeld. Bij twijfel over de diagnose zou RCM mogelijk 
toegepast kunnen worden in plaats van een biopt. Hiertoe dient bepaald te worden 
welke	RCM	kenmerken	van	diverse	 inflammatoire	huidziekten	onderscheidend	zijn	
voor een bepaalde diagnose. 
Binnen de klinische dermatologie lijkt RCM de grootste meerwaarde te hebben voor 
verbetering	van	de	diagnostiek	van	zowel	het	melanoom	als	NMSC.	Diverse	onder	-	
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zoeken hebben reeds laten zien dat RCM gebruikt kan worden om klinisch het 
onderscheid te verbeteren tussen benigne en maligne melanocytaire huidlaesies. 
In	 een	 recente	 studie	 werd	 door	 toepassing	 van	 RCM	 een	 significante	 reductie	
aangetoond	 van	het	 aantal	 geëxcideerde	benigne	huidlaesie	 ten	opzichte	 van	één	
melanoom van 19,4 naar 6,3 excisies. Dit resulteerde in een daling van de kosten 
met 27%44. In tegenstelling tot melanoma huidkanker, is tot heden geen onderzoek 
uitgevoerd	 naar	 de	 kosteneffectiviteit	 van	 RCM	 voor	 de	 diagnostiek	 van	 NMSC.	 
Dit	type	onderzoek	 is	noodzakelijk	voordat	RCM	op	grote	schaal	geïmplementeerd	
kan	worden.	 Hiertoe	 dient	 ook	 de	 sensitiviteit	 en	 specificiteit	 van	 RCM	 kenmerken	 
voor de diagnose van NMSC bepaald te worden. Tevens dienen RCM protocollen 
voor	 gebruik	 in	 de	 dagelijkse	 patiëntenzorg	 ontwikkeld	 te	worden.	 Samenwerking	
met	andere	afdelingen	kan	bijdragen	om	RCM	kosteneffectief	 te	maken.	Naast	de	
mogelijke	kostenbesparing,	is	RCM	patiëntvriendelijker	in	vergelijking	met	een	punch	
biopt.	Dit	is	met	name	een	voordeel	voor	patiënten	met	multipele	voor	maligniteit	
suspecte	huidlaesies.	Naast	de	diagnostiek	van	NMSC	kan	RCM	mogelijk	ook	toegepast	
worden	bij	Mohs’	micrografische	chirurgie	om	de	begrenzing	van	een	BCC	te	bepalen	
vóór excisie. Zo kan wellicht het aantal benodigde Mohs’ rondes beperkt worden. 
Ex vivo kan	RCM	mogelijk	gebruikt	worden	tijdens	de	Mohs’	procedure	als	vervanging	
van	de	histopathologische	beoordeling	van	het	geëxcideerde	weefsel.	
De	resultaten	van	de	onderzoeken	beschreven	in	dit	proefschrift	laten	de	potentiële	
waarde zien van toepassing van RCM in de dermatologie. Mede naar aanleiding van 
dit	 proefschrift	 richt	 de	 RCM	 onderzoeksgroep	 van	 de	 afdeling	 Dermatologie	 van	 
het	 Radboudumc	 Nijmegen	 zich	 momenteel	 op	 de	 implementatie	 van	 RCM	 als	
diagnostische	 techniek	 in	de	routine	patiëntenzorg.	 In	 februari	2016	wordt	gestart	
met	 een	 prospectieve	 gerandomiseerde	 studie	 met	 grotere	 patiënten	 aantallen.	
Hierin	 wordt	 de	 sensitiviteit,	 specificiteit	 en	 kosteneffectiviteit	 bepaald	 van	 het	
toepassen	van	RCM	voor	de	diagnostiek	van	het	BCC.	Dit	onderzoek	wordt	uitgevoerd	
in	samenwerking	met	twee	perifere	ziekenhuizen	en	 is	essentieel	voordat	RCM	op	
grote	schaal	geïmplementeerd	kan	worden.	
In	 dit	 proefschrift	 is	 een	 eerste	 stap	 gemaakt	 om	 de	 toepassing	 van	 RCM	 in	 de	
klinische dermatologie te onderzoeken. De beschreven onderzoeken dragen bij aan 
de	toekomstbepaling	van	RCM	in	de	dermatologie.	Hopelijk	moedigt	dit	proefschrift	
andere onderzoeksgroepen aan om de mogelijkheden van RCM voor de klinische 
dermatologie verder te onderzoeken. 
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